INDEX TO PROCEEDINGS SUPPLEMENTS TO VOLUMES 84, 85 and 86

AUTHOR INDEX

ABBIATI, G.A. see IBBA, M., 86, 706P

ABBIATI, G.A., IBBA, M., RESTELLI, G.V. & TESTA, R. Tolerance study on denzimol, a new anticonvulsant agent, compared to phenobarbital and carbamazepine in mice, 86, 659P

ABBRACCHIO, M.P., BERTI, F., CATTABENI, F., DAFFONCHIO, L., FANO, M. & OMINI, C. Role of arachidonic acid metabolites in pulmonary beta-adrenergic desensitization: in vitro and ex vivo studies, 86, 653P

ABBRACCHIO, M.P., LOMBARDELLI, G. & CATTABENI, F. Adenosine modulation of the dopaminergic transmission in striatum, 86, 582P

ABDUL, R., STOLZ, J. & NICHOLLS, P.J. Effects of the anticonvulsant drug beclamide on behavioural models of central monoaminergic systems, 85, 371P

ABEL, M. & HOLLINGSWORTH, M. Tolerance to salbutamol on the rat uterus in vivo compared with nifedipine and diltiazem, 85, 331P

ACCOMAZZO, M.R. see PUGLISI, L., 86, 646P

ADAMI, M. see CORUZZI, G., 86, 639P

ADAMS, A.P., JONES, R.M. & WALI, F.A. Potentiation by verapamil of gallamine and pancuronium-induced blockade at the chick neuromuscular junction, 85, 327P

ADAMS, M. see BOARDER, M.R., 86, 482P

ADDAE, J.I. & STONE, T.W. Apparent desensitisation of excitatory amino acid receptors in rat cortex, 84, 91P

- - - Are there two functionally different NMDLA receptors in rat cortex? 85, 361P

ADEBANJO, A.O. & ONONIWU, I.M. A novel isolated in vitro preparation of the retractor penis from the giant African snail (Archachatina marginata), 85, 355P

- - - Preliminary observation on the excitatory transmission to the retractor penis of the giant snail (Archachatina marginata), 85, 243P

ADHAM, N. & TEMPLETON, D. Enhanced K+ release in rat parotid slices following chronic parasympathetic denervation, 86, 756P

AGBACK, H., BERRY, C.N., HOULT, J.R.S., McCARTHY, T.M. & PHILLIPS, J.A. Ph CL 28A: highly potent inhibitor of prostaglandin 15-hydroxy-dehydrogenase lacking effects on prostaglandin synthetase, 84, 43P

AGOZZINO, S., BELLAVITE, O., CREMONESI, P. & SARRET, M. Cardiac protective activity with L-arginine methyl ester against ischemia and reperfusion-induced arrhythmias in the rat, 86, 716P

AHTEE, L., ATTILA, L.M.J. & ETEMADZADEH, E. Retardation of cerebral dopamine depletion in mice treated repeatedly with morphine, 84, 11P

AIRD, S.A. & NOTARIANNI, L.J. Pharmacokinetics of D-penicillamine and its disulphide in rats, 86, 796P

AKHTAR-KHAVARI, F., KHOYI, M.A. & REZAEI, E. ^{45}Ca uptake in the rat vas deferens: effects of duration of depolarization and chemical denervation, 85, 336P

- - - Effects of KCl, noradrenaline and adenosine triphosphate on ^{45}Ca influx in guinea-pig vas deferens, 85, 334P

AL-ASADY, S.A.H., LENNARD, M.S., SHAW, L., TUCKER, G.T. & WOODS, H.F. Covalent binding of propranolol to rat and human liver microsomes: relation to inhibition of lignocaine metabolism, 85, 306P

AL-DAHAN, M. & THOMAS, P.J. The effects of sex steroids upon muscarinic binding in rat brain, 86, 605P

AL-AHAHIR, H.A.R. & ZEITLIN, I.J. Bile acids activate human colonic tissue kallikrein-like amidase, 86, 481P

AL-KAZWINI, S.J., CRAIG, R.K., HOLMAN, J.J. & MARSHALL, I. Human and rat calcitonin gene related peptides

(CGRP) are vasodilators in coronary and mesenteric vasculature, 86, 544P
AL-KAZWINI, S.J., CRAIG, R.K. & MARSHALL, I. Human and rat calcitonin gene related peptides (CGRP) act post-junctionally in the mouse vas deferens, 86, 679P
ALABASTER, V.A., DAVEY, M.J. & GREENGRASS, P.M. Selectivity of doxazosin for α_1-adrenoceptors, 85, 376P
ALI, H., KICZINSKA, J. & NICHOLLS, P.J. Induction of methaemoglobin by aminoglutethimide in the mouse, 85, 302P
ALI, S.M., LONGSTAFF, A., O'NEIL, G.S. & RAMAN, V. Enhancement by verapamil of presynaptic inhibitory effect of GABA on sympathetic transmission in rat anococcygeus muscle, 86, 470P
ALLCORN, R.J., CUNNANE, T.C., MUIR, T.C. & WARDLE, K.A. α,β meATP does not inhibit [^{3}H]-noradrenaline release in the rabbit ear artery, 85, 263P
ALLAN, G. & HUGHES, B. The effect of graded increases in haemoglobin-oxygen affinity on myocardial function in isolated rabbit hearts, 86, 616P
ALLAN, G., CAMBRIDGE, D., LEE-TSANG-TAN, L., VAN WAY, C. & WHITING, M.V. Protective action of allopurinol in an experimental model of haemorrhagic shock with reperfusion, 86, 439P
ALLEN, E.M. & NICHOLLS, P.J. Tissue distribution of [^{14}C]-pentobarbitone in rats with experimental chronic renal failure, 85, 303P
ALPS, B.J., BROWN, C.M., CALDER, C. & KILPATRICK, A.T. Nicardipine, a calcium entry blocker, protects striatal dopamine in periods of cerebral ischaemia, 85, 329P
- - - The effect of unilateral occlusion on the electroencephalograph of the mongolian gerbil, 86, 669P
AMMENDOLA, D., DE SARRO, A., NACCARI, F., GERMANA, G., ROTIROTI, D. & NISTICO, G. Crop-sac stimulatory effects of cholinergic mechanisms in pigeons, 86, 660P
ANAND, H., COLLINS, J.F. & ROBERTS, P.J. Kainic acid binding in the rat cerebellum: effects of novel kainate analogues, 86, 473P
ANAND, H., LOPEZ-COLOME, A. & ROBERTS, P. J. Excitatory amino acid induced changes in chick retinal cyclic GMP levels, 84, 184P
ANDERSON, A.J. & HARVEY, A.L. Electrophysiological actions of facilitatory toxins from mamba venoms on mammalian neuromuscular junctions, 86, 588P
ANDERSON, R.A. & MITCHELL, R. Uptake and release of [^{3}H] GABA from nerve terminals in neurointermediate pituitary gland, 84, 5P
ANDREANI, A., RAMBALDI, M., LELLI, G., BOSSA, R. & GALATULAS, I. Synthesis and antitumour activity of alkylating agents related to a local anaesthetic (1), 86, 771P
ANDREWS, M., HEWICK, D.S. & STEVENSON, I.H. The redistribution of digoxin after treatment with digoxin-specific Fab fragments in guinea pigs, 84, 125P
ANGELO-KHATTAR, M. & THULESIUS, O. The effect of indomethacin and diclofenac sodium on ureteral contraction in vivo and in vitro, 85, 325P
ANGELICI, O. see SCHIAVONE, A., 86, 798P
ANGELICO, P. see IBBA, M., 86, 706P
ANGELUCCI, L. see GHIRARDI, O., 86, 683P
- - - see MACCARI, F., 86, 800P
ANTONELLI, T., BEANI, L., BIANCHI, C., RANDO, S., SIMONATO, M. & TANGANELLI, S. The cortical acetylcholine release is increased and the GABA out-flow is reduced during morphine withdrawal, 86, 535P
ANTONETTI, F., MARTELLI, F. & BORRELLI, F. Orgotein effect on doxorubicin-induced cardiac lipid peroxidation in mice, 86, 714P
- - - Restoration by orgotein of rat cardiac cell beating inhibited by doxorubicin, 86, 715P
ARAM, J.A. & LODGE, D. N-methylaspartate antagonists block epileptiform discharges in rat cortical slices maintained in magnesium-free medium, 86, 538P
ARBILLA, S., BENKIRANE, S. & LANGER, S. Z. α_2-adrenoceptor mediated inhibition by β-phenylethylamine of [^{3}H]-5-HT release from rat hippocampal slices, 86, 413P
ARBILLA, S., DEPOORTERE, H., GEORGE, P. & LANGER, S.Z. Pharmacological profile of zolpidem: a novel hypnotic agent, 86, 432P
ARBUTHNOTT, G., UNGERSTEDT, U. & WALKER, R. The effects of nomifensine on dopamine release into a dialysis fibre implanted in the neostriatum of anaesthetised rat, 84, 10P

ARKLE, S., IVERSEN, L.L., MICHALEK, R., POAT, J.A. & TEMPLETON, D. The effect of isoprenaline on the secretory response to substance P in the rat parotid salivary gland, 86, 701P

ARMSTRONG, J.M. & DUMEZ, D. Nicardipine lowers coronary and total peripheral vascular resistance in anaesthetised dogs, 84, 174P

ARMSTRONG, J.M. & FERRANDON, P. Biphasic effect of Bayer k 8644 (calcium entry facilitator) on the efficiency of the rat working heart in vitro, 86, 718P

- - - Nicardipine: beneficial effect on cardiac function and energy conservation during coronary reperfusion of the rat working heart, 86, 503P

- - - The effect of nicardipine on cardiac function and high energy phosphate metabolism in the rat working heart, in vitro, 85, 328P

ARMSTRONG, J.M. & LEFOURNIER, C. Calcium entry blocking agents: comparative potency using rat aorta and taenia caecum preparation in vitro, 84, 173P

ARMSTRONG, R., JONES, R.L. & TYMKEWYCZ, P. M. The nature of arachidonic acid-induced aggregation of rat platelets, 84, 147P

ARSENI, A. see MACCARI, F., 86, 800P

ASCIOTI, C. see DE SARRO, G.B., 86, 676P

ASKAM, V., SMITH, J.A. & WILSON, J.F. In vitro and in vivo activity of a novel melatonin analogue, 85, 313P

ATKINSON, D.J. & ATTERWILL, C.K. Effect of serum factors on sodium-pump activity and DNA synthesis in cultured cerebellar neural cells, 85, 351P

ATTERWILL, C.K. see ATKINSON, D.J., 85, 351P

ATTERWILL, C.K. & GALLO, V. Effects of serum and thyroid hormone on the voltage-dependent Na^+ uptake of cultured cerebellar neural cells, 84, 149P

ATTERWILL, C.K., CONYBEARE, G., HARLAND, R. & LESLIE, G.B. Toxicity of orally administered tri-iodothronine (T_3) in rats, 84, 124P

ATTILA, L.M.J. see AHTEE, L., 84, 11P

AVKIRAN, M. & WOODWARD, B. Effects of desipramine and yohimbine on plasma catecholamines and coronary ligation induced arrhythmias in the anaesthetised rat, 86, 615P

AWARA, W., HILLIER, K. & JONES, D. Do endogenous prostaglandin E_2 and thromboxane A_2 modulate the mitogen-induced proliferation of peripheral blood lymphocytes? 86, 429P

BABBINI, M., BARTOLETTI, M., GAIARDI, M., BACCHI, A. & GUBELLINI, C. Effects of feeding conditions on the cueing properties of morphine, 86, 707P

BACCARO, C., FAILLI, P., FRANCONI, F., GIOTTI, A. & MONTORSI, L. Cardio-protective activity in vitro of L-arginine methylester during cardiac hypoxia and reoxygenation, 86, 621P

BACCHI, A. see BABBINI, M., 86, 707P

BACK, D.J. & RIVIERE, J.H. Inhibition of hepatic drug metabolism by quinoline derivatives in vitro, 86, 801P

BADAWY, A.A.-B & NORMAN, S. The mechanism of enhancement of rat liver tryptophan pyrrolase activity by acute morphine administration, 85, 298P

BAGUST, J. see IBRAHIM, N., 86, 471P

BAILEY, C.C. & KITCHEN, I. Development of proenkephalin products in rat striatum and the inhibitory effects of lead exposure, 85, 291P

BAILEY, S.J. & HOLZER, P. A tachykinin antagonist inhibits the substance P-induced accumulation of inositol bisphosphate in guinea-pig small intestine, 86, 410P

BAKER, M.K., JENNER, P. & MARSDEN, C. D. Excitatory amino acid agonists and antagonists alter K^+-evoked, but not basal, release of [^{3}H]-dopamine from rat striatal slices, 84, 181P

BAKHLE, Y.S. & GRANTHAM, C.J. Pulmonary pharmacokinetics of prostaglandin E_2: a selective biochemical marker of pulmonary oedema? 84, 203P

BAKHLE, Y.S. & PANKHANIA, J.J. Effects of inhibitors of prostaglandin (PG) inactivation on PG synthesis from exogenous and endogenous arachidonate in lung, 85, 275P

BAKHLE, Y.S., MONCADA, S., DE NUCCI, G. & SALMON, J.A. Differential release of eicosanoids by various stimuli in guinea pig isolated lung, 84, 38P

- - - Ovalbumin-induced eicosanoid release in guinea-pig isolated lungs perfused via the pulmonary artery and via the trachea, 86, 423P

BALDINI, L. see DECORTI, G., 86, 794P

BALDUINI, W. see CANTONI, O., 86, 563P
BALFOUR, D.J.K. & BENWELL, M.E.M. Stereospecific binding of L-tryptophan to rat cortex - a ligand for tryptophan uptake sites? 84, 94P
BALFOUR, D.J.K. & COPLAND, A.M. Behavioural and adrenocortical responses to diazepam in two designs of elevated x-maze apparatus, 86, 711P
- - - The role of chronic stress in the development of diazepam dependence, 84, 72P
BALFOUR, D.J.K. & GRAHAM, C.A. A comparison of the effects of nicotine and diazepam of rat behaviour in an elevated x-maze, 86, 591P
BALLS, M., FRY, J.R. & WARREN, M. Effect of dexamethasone on 7-alkoxycoumarin-O-dealkylase activity of rat hepatocytes in primary culture, 85, 387P
BARASI, S., BENSRETI, M.M., DUGGAL, K.N., GONZALEZ, J.P. & SEWELL, R.D.E. Antinociceptive activity of intravenous and intrathecal dopamine agonists in naive and supersensitive rats, 84, 166P
BARASI, S., CLATWORTHY, A., DUGGAL, K.N., GONZALEZ, J.P. & SEWELL, R.D.E. Blockade of the antinociceptive effect of intrathecal dopamine agonists in naive and supersensitive rats, 85, 352P
BARBARO, A.M. see CANTELLI FORTI, G., 86, 554P
BARBER, H.E., HAWKSWORTH, G.M. & WALKER, K.A. Theophylline disposition in rats with adjuvant-induced arthritis, 84, 120P
BARLOW, R.B. A poor man's molecular graphics, 86, 819P
BARNES, A. & GOADBY, P. The use of thromboxane receptor antagonists to determine the involvement of TxA_2 in guinea-pig anaphylaxis, 86, 804P
BARNES, J.C., COSTALL, B. & NAYLOR, R.J. Hyperactivity induced by dopamine from rat nucleus accumbens can be modulated by glycine, 86, 695P
BARNES, N.J.G. & SENIOR, J. The response of rat uterine tissue to oxytocin and prostaglandin $F_{2\alpha}$ in the presence of calcium channel antagonists, 85, 289P
BARNES, N.J.G., COSTALL, B. & NAYLOR, R. J. Infusion of MPTP into cell body and terminal areas of the nigrostriatal pathway in primate brain, 86, 708P
BARNES, N.J.G., COSTALL, B., DOMENEY, M. & NAYLOR, R.J. Increased locomotor activity caused by dopamine infused into the nucleus accumbens of primate brain, 86, 468P
BARNETT, D.B. see SWART, S.S., 84, 63P
BARNETT, K. & PIPER, P.J. The release of leukotrienes from large and small airways of guinea-pig and man, 86, 642P
BARTOLETTI, M. see BABBINI, M., 86, 707P
BARTOLI KLUGMANN, F. see DECORTI, G., 86, 794P
BARTOLINI, A., GALLI, A., GIOTTI, A., GIULIANI, S., MALMBERG-AIELLO, P., PATACCHINI, R. & RENZI, G. Bicuculline: a $GABA_A$ antagonist with other pharmacological actions, 86, 547P
BARTOLINI, D. see SOLDANI, G., 86, 640P
BARTOLINI, L. see VANNUCCHI, M.G., 86, 606P
BASA, M. see DECORTI, G., 86, 794P
BARWELL, C.J. Hordenine (N,N-dimethyl tyramine) is a selective substrate for monoamine oxidase B from rat liver, 86, 476P
BARWELL. C.J. & HEIKKILA, R.E. MPTP demethylation by microsomes from mice and guinea-pig liver, 86, 477P
BARZAGHI, F. & GALLIANI, G. Effect of scopolamine on a one-trial passive avoidance task in the mouse, 86, 661P
BATES, R.F.L., BROWN, J.F., BUCKLEY, G. A., McARDLE, C.A., STRETTLE, R.J. & WOOD, D.A.R. Inhibition of indomethacin-induced gastric erosions in the mouse by intracerebroventricularly administered salmon calcitonin, 86, 809P
BATTY, I., KENDALL, D.A. & NAHORSKI, S. R. Endogenous acetylcholine mediates inositol phospholipid hydrolysis induced by depolarizing stimuli in cerebral cortex slices, 84, 108P
BATY, J.D. see LINSDAY, R.M., 85, 378P
- - - see LINDSAY, R.M., 86, 797P
BAX, N.D.S., TUCKER, G.T., LENNARD, M. S. & WOODS, H.F. Impairment of lignocaine clearance by propranolol - major contribution of enzyme inhibition, 84, 137P
BEAHON, S.J., CASSON, I.F. & McLEAN, W. G. The effects of diabetic rat and human serum on the polymerisation of brain tubulin, 84, 81P
BEALES, D. see HUE, D.P., 84, 121P

BEANI, L. see ANTONELLI, T., 86, 535P
BEANI, L., BIANCHI, C. & SINISCALCHI, A. Opposite effects of 5-HT on the ^{3}H CH efflux from guinea-pig striatal slices, 86 664
BEATTIE, D.T., CUNNANE, T.C. & MUIR, T.C. Effects of Ca^{2+}-entry blockers on spontaneous and electrically-evoked release of transmitter from guinea pig vas deferens nerves, 84, 29P
BECKERINGH, J.J., THOOLEN, M.J.M.C., TIMMERMANS, P.B.M.W.M. & VAN ZWIETEN, P.A. Influence of phenoxybenzamine, nifedipine and D 600 on vasoconstriction elicited by enantiomers of SK&F 89748A, 84, 177P
BELLAVITE, O. see AGOZZINO, S., 86, 716P
BENAVIDES, J., BURGEVIN, M.C., DOBLE, A., LE FUR, G. & UZAN, A. A role for peripheral-type benzodiazepine binding sites in regulatine K^{+}-evoked $^{45}Ca^{++}$ uptake in a rat pituitary cell line, 86, 440P
BENKELFAT, C., GALZIN, A.M. LANGER, S.Z., LOO, H., POIRIER, M.F., SECHTER, D. & ZARIFIAN, E. Reduced Bmax of [^{3}H]-imipramine binding to platelets of depressed patients free of previous medication with 5-HT uptake inhibitors, 85, 215P
BENKIRANE, S. see ARBILLA, S., 86, 413P
BENNARDINI, F., FRANCONI, F., GIOTTI, A., MATUCCI, R. & STENDARDI, I. Binding of ^{3}H nitrendipine during hypoxia and subsequent re-oxygenation, 86, 623P
BENNETT, A. see CAPASSO, F., 86, 650P
BENNETT, G.W., GREEN, A.R., LIGHTON, C. & MARSDEN, C.A. The effect of repeated electroconvulsive shock on the behavioural response to a TRH analogue (CG 3509), 86, 455P
BENNETT, G.W., LIGHTON, C. & MARSDEN, C.A. The effect of chronic antidepressant treatment on the behavioural response to a TRH analogue (CG 3509), 85, 244P
- - - The effect of 5,7-dihydroxytryptamine on amitriptyline-induced increases in brain and spinal cord levels of TRH, 86, 673P
BENNETT, T., FOULKES, R. & GARDINER, S.M. Inhibition of ganglionic transmission reveals a pressor effect of exogenous corticosterone acetate in conscious Long Evans rats, 85, 209P
BENOIT, E., CARRATU, M.R., DUBOIS, J.M. & MITOLO-CHIEPPA, D. Effects of ketamine on the frog node of ranvier, 86, 665P
BENOIT, E., CARRATU, M.R., DUBOIS, J.M., MITOLO-CHIEPPA, D. & PREZIOSI, P. Block of nerve activity by etomidate, 86, 549P
BENSRETI, M.M., GONZALEZ, J.P., MCCLEARY, W.L. & SEWELL, R.D.E. An examination of the thermoregulatory effects of meptazinol and its quaternarized derivative, 85, 296P
BENTHAM, J.M., HIGGINS, A.J. & WOODWARD, B. Changes in lysophospholipids and phospholipase A_2 activity during ischaemia in the isolated rat heart, 86, 810P
BENWELL, M.E.M. see BALFOUR, D.J.K., 84, 94P
BENYON, R.C., CHURCH, M.K., HOLGATE, S.T. & HUGHES, P.J. Methyltransferase inhibitors may inhibit histamine release by elevating cyclic AMP in mast cells and basophils, 86, 407P
BERESFORD, A.P., HUMPHREY, M.J. & STOPHER, D.A. Amlodipine, a calcium channel blocker with pharmacokinetic properties novel to dihydropyridines, 85, 333P
BERETTERA, C. see ESPOSITO, E., 86, 677P
BERNARDINI, C. see DEL TACCA, M., 86, 638P
- - - see SOLDANI, G., 86, 640P
BERNARDINI, C., CORSANO, E., DEL TACCA, M. & SOLDANI, G. Alpha-2 agonists and antagonists and gastric acid secretion, 86, 781P
BERRIDGE, T.L., GADIE, B., LANE, A.C., ROACH, A.G., STRACHAN, D.A., TULLOCH, I.F. & WELBOURN, A.P. Antagonist potency of RX 821001 and its enantiomers at α_1- and α_2-adrenoceptors in rats, 84, 193P
BERRIE, C.P., BIRDSALL, N.J.M., HULME, E.C., KEEN, M. & STOCKTON, J.M. pirenzepine binding to solubilized muscarinic receptors from rat cerebral cortex and myocardium, 84, 4P
BERRINO, L. see MARMO, E., 86, 626P
BERRY, C.N. see AGBACK, H., 84, 43P
BETTONI, G., BRYANT, S.H., CONTE-CAMERINO, D., FERRANNINI, E., PERSICHELLA, M. & TORTORELLA, V. Stereoselectivity of chloride channel studied in rat skeletal muscle by chiral analogues of myotonya inducers, 86, 774P
BERTACCINI, G. see CORUZZI, G., 86, 639P
BERTACCINI, G., CORUZZI, G. & POLI, E. Effect of calcium antagonists with different site of action on the

duodenal muscle, 86, 641P
BERTELLI, A. see SCHINETTI, M.L., 86, 562P
BERTI, C., KHAN, G. & NISTRI, A. Effects of acetylcholine on synaptic transmission in the frog optic tectum, 86, 668P
BERTI, F. see ABBRACCHIO, M.P., 86, 653P
- - - see FOLCO, G.C., 86, 645P
BERTI, F., BORSA, L., BRUNELLI, G., DAFFONCHIO, L., FABBRI, L., HERNANDEZ, A. & OMINI, C. Relationship between prostaglandin D_2 and cholinergic system on tracheal smooth muscle, 86, 773P
BERTOLASI, V. see BOREA, P.A., 86, 666P
BEST, R., LEWIS, D.A. & PATEL, R. The effect of some non-steroidal anti-inflammatory drugs on leucocyte function, 86, 520P
BHALLA, P., GURDEN, M.F. & KENNEDY, I. Studies on the adenosine receptors in dog coronary artery, 86, 438P
BHASKAR, N.K., FILIPOWICZ, B. & HAWKEY, C. J. Inhibition of human gastric mucosal thromboxane synthesis by WHR2348A, 85, 268P
BIAGI, G.L. see CANTELLI FORTI, G., 86, 554P
BIANCHETTI, A. see CROCI, T., 86, 782P
- - - see MIRANDA, G.F., 86, 689P
BIANCHETTI, A., LAVEZZO, A., PICERNO, N., MANZONI, L. & MANARA, L. Effects of cimetidine, ranitidine and the new H_2 receptor antagonist CM 57755 on drug metabolism in rats, 86, 790P
BIANCHI, C. see ANTONELLI, T., 86, 535P
- - - see BEANI, L., 86, 664P
BIELLA, G., BRAGA, P.C., GROPPETTI, A. & PARENTI, M. Effects of acetylsalicylate on serotonin and opiates in rat CNS: correlation to drugs' antinociception, 86, 531P
BILLINGHAM, M.E.J., CAREY, F., GROWCOTT, J. W. & HUGHES, C.L. Indomethacin-induced gastro-intestinal lesions: protection by salicylate and relationship to plasma acute phase proteins, 85, 272P
BIRCH, N.J., COLEMAN, I.P.L. & KARIM, A.R. Bidirectional fluxes and factors affecting the movement of lithium in isolated jejunal mucosa of guinea pig, 84, 23P
- - - Lithium distribution in a three compartment system of guinea pig gastrointestinal tract: effects of drugs, 85, 304P
- - - Lithium transport in guinea-pig isolated jejunal mucosa, 84, 78P
BIRDSALL, N.J.M. see BERRIE, C.P., 84, 4P
BIRY, P. see PIERI, L., 86, 592P
BIZIERE, K., BOUGAULT, I., KAN, J.P., MOUGET-GONIOT, C., MONS, G. & WORMS, P. Effect of two amino-pyridazine derivates on both forms of monoamine oxidase in rat brain, 86, 417P
BIZIERE, K., BROCHARD, J., CHAMBON, J.P., HALLOT, A. & RODIER, D. CM 40907, a new potential anti-epileptic drug with a broad spectrum of anticonvulsant activities, 85, 384P
BIZIERE, K., CALASSI, R., CHAMBON, J. P., HALLOT, A. & MICHAUD, J.C. SR 41378, a new potential hypnotic drug with anticonvulsant properties, 84, 198P
BIZIERE, K., CALASSI, R., PERIO, A. & TERRANOVA, J.P. Anti-anxiety activity of SR 41378 a new non-benzodiazepine hypnotic, 84, 146P
BIZIERE, K., CHEVALLIER, E., KAN, J. P., WERMUTH, C.G. & WORMS, P. Neuropharmacological profile of SR 95191, a new atypical anti-depressant drug with MAOI and dopaminomimetic activities, 86, 404P
BIZIERE, K., GUEUDET, C. & WORMS, P. Turning induced by intrastriatal injections in conscious mice: a useful screening model for dopaminomimetic drugs, 85, 385P
- - - Turning induced by intrastriatal injection of GABA-mediated inhibition of dopaminergic function, 84, 55P
BOARDER, M.R., MARRIOTT, D.B. & ADAMS, M. Response of neuroblastoma hybrid cells to phosphodiesterase inhibitors and PGE_1: changes in cyclic AMP and opioid peptides, 86, 482P
BOFFA, G. see GIAMMATTEO, D., 86, 727P
BÖHM, E., MUSCHOLL, E., & RACKE, K. Naloxone increases electrically evoked dopamine release preferentially in the neural lobe of the rat neurointermediate lobe (nil), 86, 534P
BONANNO, G., GEMIGNANI, A., MAURA, G. & RAITERI, M. Changes of sensitivity of presynsptic alpha-2 adrenoceptors in rat brain after long-term clonidine administration, 86, 548P
BONANNO, G., MARCHI, M. & RAITERI, M. The release of endogenous dopamine from superfused rat striatal synaptosomes is potentiated by acetylcholine, 84, 190P

BOND, R.A. see CHARLTON, K.G., 84, 57P
BOND, R.A., CHARLTON, K.G., & CLARKE, D.E. Further characterization of the pre-junctional inhibitory 5-HT_1 receptor in rat kidney, 86, 401P
- - - Inhibition of the cholinergic twitch response in guinea pig ileum: evidence for a receptor to clonidine distinct from 2 sites, 84, 14P
BONETTI, E.P., BURKARD, W.P., GABL, M. & MOHLER, H. The partial inverse benzodiazepine agonist Ro 15-4513 antagonizes acute ethanol effects in mice and rats, 86, 463P
BONGIANNI, F., CARLA, V., MORONI, F. & PELLEGRINI, D. Ca^{++}-channel inhibitors prevent morphine withdrawal syndrome in rats, 86, 529P
BONGRANI, S. see FERRARI, R., 86, 722P
- - - see SCHIANTARELLI, P., 86, 732P
BONIFAZI, V. see DEL TACCA, M., 86, 638P
BOOBIS, A.R., DAVIES, D.S., MCQUADE, J. & SESARDIC, D. Specificity of isozymes of cytochrome P-450 determined by inhibitory monoclonal antibodies, 86, 511P
BOOBIS, A.R., TEE, L.B.G., HAMPDEN, C.E., HUGGETT, A.C. & DAVIES, D.S. Comparative ability of man to activate paracetamol to its hepatotoxic metabolite, 84, 138P
BORGHI-CIRRI, M.B., GIANNELLA, E., MANNAIONI, P.F., MASINI, E. & RUCCI, L. Effects of vidian nerve stimulation and resection on histamine content in human nasal sinus mucosa, 86, 775P
BOREA, P.A. see CANTELLI FORTI, G., 86, 554P
BOREA, P.A., GILLI, G., BERTOLASI, V. & FERRETTI, V. A stereochemical model accounting for receptor binding affinity and intrinsic activity of β-carbolines, 86, 666P
BORELLA, F. see DI GIULIO, A.M., 86, 527P
BORKOWSKI, K.R. see BLACKBURN, T.P., 85, 382P
BORKOWSKI, K.R. & PORTER, M. Reduced β-adrenoceptor-mediated vasodilation in spontaneously hypertensive rats, 84, 158P
BORNSTEIN, J.C., LEES, G.M. & MCBAIN, C. J. Comparative effects of "calcium antagonists" on inhibitory junction potentials of circular muscle of guinea-pig ileum, 86, 724P
BORRELLI, F. see ANTONETTI, F., 86, 714P, 715P
BORSA, L. see BERTI, F., 86, 773P
BOSSA, R. see ANDREANI, A., 86, 771P
BOSSA, R., DASDIA, T., GALATULAS, I. & ZUNINO, F. Calcium antagonists and sensitivity to anthracyclines in resistant P388 leukaemia, 86, 772P
BOTARELLI, M. see PACIFICI, L., 86, 728P
BOTTOMLEY, K.M.K., RISING, T.J. & STEWARD, A. Relative efficacies of histamine H_2-receptor agonists in the guinea pig right atrium, 84, 47P
BOU, J., FERNANDEZ, A.G., JAUREGUI, J. M. & MASSINGHAM, R. Lack of response of guinea-pig ileum preparations to metaclopramide following ablation of enteric neurones with Triton X-100, 85, 210P
BOUCHENAFA, O. & LIVINGSTON, A. Autoradiographic localisation of [^{3}H]-clonidine and [^{3}H]-prazosin in the spinal cord of the sheep, 86, 518P
BOUGAULT, I. see BIZIERE, K., 86, 417P
BOUTAL, L.E., FOSTER, M.R., GEISOW, H.P. & SKIDMORE, I.F. Inhibition of ^{111}indium labelled platelet deposition by aspirin, prostacyclin and the thromboxane antagonist, AH23848, 86, 802P
BOVA, S., DEVETTO, P., CARGNELLI, G. & LUCIANI, S. Effect of amiloride on vascular smooth muscle contraction and inhibition of sodium calcium exchange, 86, 624P
BOVA, S., FERRARI, M., PADRINI, R., PIOVAN, D. & CARGNELLI, G. Has the inhibition of Na^+/Ca^{++} exchanges by amrinoine relevance in the vascular effect of the drug? 86, 720P
BOWERY, N.G., GILL, R., HUDSON, A.L., IVERSEN, S.D., PRICE, G.W. & THOMAS, S. The location of $GABA_B$ binding sites in the rat hippocampus, 85, 238P
BOWERY, N.G., HUDSON, A.L. & PRICE, G. W. Comparative autoradiographic studies with [^{3}H]-GABA and [^{3}H]-(-)-baclofen in rat brain in vitro, 85, 234P
BOWMAN, A., GILLESPIE, J.S. & SOARES-DA-SILVA, P. The relaxant effect on the rabbit aorta of the inhibitory factor from the bovine retractor penis is not endothelium dependent, 84, 19P

BOWMER, C.J., COLLIS, M.G. & YATES, M.S. Effect of 8-phenyltheophylline on glycerol-induced acute renal failure in the rat, 84, 131P

BOWMER, C.J., DEAN, H.G., SILBERSTEIN, D.J. & YATES, M.S. Effect of acute renal failure on the pharmacokinetics and biliary excretion of [^{3}H]-N-acetylprocainamide ethobromide in the rat, 84, 132P

BOYCE, S., JENNER, P. & MARSDEN, C.D. Alterations in brain dopamine receptor function following chronic administration of L-dopa, bromocriptine or pergolide to rats, 86, 632P

BOYLE, F.C. & OHIA, S.E. Changes in catecholamine inhibitory effects in the rat isolated uterus induced by ovariectomy and cyclo-oxygenase inhibition, 84, 42P

- - - Specificity of enhancement of β-adrenergic responses by cyclo-oxygenase inhibition in the rat isolated uterus, 86, 648P

BLABER, L.C., FRYER, A.D. & MACLAGAN, J. Neuronal muscarinic receptors attenuate vagally-induced constriction of feline bronchial smooth muscle, 85, 393P

BLACK, J.W., GERSKOWITCH, V.P., HULL, R.A. D. & LEFF, P. Concentration-ratio analysis of the inotropic effects of phenylephrine in guinea-pig left atrial muscle, 85, 258P

BLACK, J.W., LEFF, P. & SHANKLEY, N.P. Further analysis of anomalous pK_B values for muscarinic antagonists on the mouse stomach assay, 85, 212P

BLACKBURN, T.P., BORKOWSKI, K.R. & FRIEND, J. κ-opioid diuretic effects of tifluadom mediated in the periphery? 85, 382P

BLACKBURN, T.P., COX, B. & HEYWOOD, B. Fenfluramine-induced hyperthermia - an in vivo model for the evaluation of drugs active at 5-HT_2 receptors, 85, 381P

BLACKBURN, T.P., GLEN, J.B., HUNTER, S.C. & WOOD, P. Adrenocortical function in rats during anaesthesia with etomidate, methohexitone or propofol, 86, 497P

BLACKHAM, A., NORRIS, A.A. & WOOD, B.E. Role of neutrophils and arachidonic acid metabolites in experimental models of ear inflammation in mice, 86, 786P

BLACKMAN, D.E., MCCARTHY, P.S. & NAYLOR, V.J.H. Buprenorphine: demonstration of morphine-like but not of N-allylnormetazocine-like stimulus generalization, 85, 295P

BLAKE, J., EVANS, R.H. & SMITH, D.A.S. Effect of nicotine on motoneurones in the rat hemisected spinal cord preparation, 86, 396P

BLAKEMORE, R.C., BROWN, T.H., CHENERY, R.J., DURANT, G.J., GANELLIN, C.R., PARSONS, M.E., RASMUSSEN, A.C. & RAWLINGS, D.A. SK&F 93574 a potent and long acting histamine H_2-receptor antagonist for intravenous administration, 86, 570P

BLAKEMORE, R.C., GRISTWOOD, R.W., OWEN, D.A.A. & PARSONS, M.E. SK&F 94120 a selective PDE III inhibitor potentiates isoprenaline inotropic but not chronotropic responses in the guinea-pig heart, 86, 630P

BLOOMFIELD, J.G., ELLIOTT, J.M. & EVANS, D.J. Platelet [^{3}H]-imipramine and [^{3}H]-yohimbine binding are reduced in Cushing's disease, 86, 402P

BLOOMFIELD, J.G., ELLIOTT, J.M. & RUTTERFORD, M.G. Changes in [^{3}H]-imipramine binding in rabbits associated with pregnancy and oestrogen/progesterone treatment, 85, 217P

- - - Changes in [^{3}H]-yohimbine binding in rabbits associated with oestrogen/progesterone treatment and pregnancy, 85, 323P

BLOXHAM, C.A., BRUNDISH, D.E., CANDY, J.M., HIRST, B.H., SNELL, C.R., WEIGHTMAN, D.R. & WHITFORD, C.A. Distribution of tritiated somatostatin binding sites in the human brain, 85, 232P

BLURTON, P.A. & WOOD, M.D. Complex inhibition of [^{3}H]-5-HT binding by spiperone and mianserin, 84, 98P

BRADBURY, A.J., COSTALL, B., DOMENEY, A.M., JENNER, P., MARSDEN, C.D. & NAYLOR, R.J. The neurotoxic action of 1-methyl-4-phenylpyridine (MPP+) on the nigrostriatal dopamine system of the rat, 85, 350P

BRADBURY, A.J., COSTALL, B., DOMENEY, A.M., JENNER, P., MARSDEN, C.D., NAYLOR, R.J. & TAN, C.C.W. The neurotoxic actions of MPP^+ in the rat are not confined to dopamine and the substantia nigra, 86, 691P

BRADBURY, A.J., COSTALL, B., JENNER, P. G., KELLY, M.E., MARSDEN, C.D. & NAYLOR, R.J. Benztropine antagonises the neurotoxic actions of MPTP in the mouse, 86, 526P

- - - Loss of striatal and limbic dopamine after a single treatment of

mice with MPTP, 86, 685P
- - - Neurotoxic actions of MPTP in the mouse: modification by monoamine oxidase inhibitors, 85, 348P
BRADBURY, A.J., GUNNING, S.J., NAYLOR, R. J. & TAN, C.C.W. Drug action on serotonin mechanisms can enhance field stimulation-induced contraction of stomach smooth muscle, 86, 738P
BRADLEY, H.A., SCOTT, N.C. & WOODBURN, M. M.P. Chlordiazepoxide increases tolerance to the respiratory depressant effects of morphine in the mouse, 86, 767P
BRADSHAW, C.M., MORLEY, M.J. & SZABADI, E. Failure of N-2-chlorethyl-N-ethyl-2-bromobenzylamine (DSP4) to affect positively reinforced operant behaviour, 85, 356P
- - - Lack of effect of N-2-chloroethyl-N-2-bromo-benzylamine (DSP4) on performance in an operant discrimination procedure, 86, 419P
- - - Neuronal responses to acetylcholine and carbachol in the cerebral cortex: involvement of M_1 muscarinic receptors, 86, 395P
BRADSHAW, C.M., SHERIDAN, R.D. & SZABADI, E. Is the excitatory neuronal response to dopamine mediated by D_1 or D_2 dopamine receptors in the cerebral cortex? 84, 1P
BRAGA, P.C. see BIELLA, G., 86, 531P
BRAIN, S.D., GIRGIS, S., MACINTYRE, I., MORRIS, H.R., TIPPINS, J.R. & WILLIAMS, T.J. Local oedema induced by synergism between calcitonin gene-related peptide and mediators of increased vascular permeability, 85, 233P
BRECKENRIDGE, A.M., COLEMAN, M.D., EDWARDS, G., HOWELLS, R.E., MIHALY, G.W. & WARD, S.A. The sustained release of pyrimethamine base and pyrimethamine pamoate from a biodegradable injectable drug preparation, 86, 405P
BREWSTER, M. see NATOFF, I.L., 85, 337P
BREWSTER, M., GEROLD, M., KLEVANS, L.R., NATOFF, I.L., PATEL, A.T. & WENGER, J.J. The antihypertensive activity of the angiotensin 1-converting enzyme inhibitor cilazapril (Ro 31-2848), 85, 393P
BREZENOFF, H.E. see SQUADRITO, F., 86, 629P
BRIET, C., CASTRO, B., GUEUDET, C., MARTINEZ, J. & WORMS, P. Contralateral turning induced by intrastriatal injection of sulphated CCK-8: antagonism by CCK-27-32NH_2, 85, 383P
BRIGGS, I. & FITTON, J.C. Opioids act on μ receptors to reduce dorsal root potential amplitude in rat isolated spinal cord, 85, 380P
BRIGGS, I., GROWCOTT, J.W. & JAMIESON, A. Selective actions of substance P 6-11 on tachykinin 'E' receptors, 85, 287P
BRIGHT, J.E. & MARRS, T.C. Methaemoglobinaemia produced by p-aminopropiophenone and p-aminooctanoylphenone, 86, 740P
- - - The treatment of experimental cyanide poisoning, 85, 301P
BRILEY, M. & MORET, C. Allosterism is not needed to explain complex binding of [^{3}H]-imipramine in rat hypothalamus, 85, 220P
BRILEY, M., CARILLA, E. & FABRE, M. Comparative binding studies with [^{3}H]-methyltrienolone and [^{3}H]-mibolerone, two synthetic ligands for the androgen receptor, 84, 127P
BRILEY, M., CHOPIN, P., FILE, S.E. & PELLOW, S. Validation of a test of anxiety in the rat based on exploratory activity in a plus-maze, 86, 456P
BRISTOW, D.R., CAMPBELL, M.M., IVERSEN, L.L., KEMP, J.A., MARSHALL, G.R., WATLING, K.J. & WONG, E.H.F. 2-amino-thiazoline-4-acetic acid - a novel, specific $GABA_A$ receptor agonist, 86, 430P
BROADLEY, K.J. & WILLIAMSON, K.L. Examination of α-adrenoceptors of rat isolated atria, 84, 160P
BROADLEY, K.J. & WILSON, A.N.A. Comparison of the effects of adenosine on atrial and ventricular cardiac preparations, 85, 227P
- - - Effects of dipyridamole and deoxycoformycin on the action of adenosine in guinea-pig cardiac tissues, 86, 441P
- - - Is the antagonism by adenosine of responses to both isoprenaline and histamine in guinea-pig isolated atria mediated through cAMP? 84, 176P
- - - The response of the guinea-pig heart to isoprenaline and its proposed modulation by endogenous adenosine, 86, 721P
BROADLEY, K.J., CHESS-WILLIAMS, R.G. & SHERIDAN, D.J. Can supersensitivity following chronic catecholamine depletion be fully explained by an increase in β-adrenoceptor number? 84, 194P

- - - ^{3}H prazosin binding during ischaemia and reperfusion in the guinea-pig langendorff heart, 86, 759P
BROADLEY, K.J., CHESS-WILLIAMS, R.G., ROBERTS, L. & SHERIDAN, D.J. The α-adrenoceptor mediated responses of the guinea-pig aorta and ileum: effect of temperature, 85, 320P
BROADLEY, K.J., CHESS-WILLIAMS, R.G., SHERIDAN, D.J. & WILLIAMSON, K.L. Relative α- and β-adrenoceptor density determines which receptor mediates the cardiac response to phenylephrine, 85, 261P
BROADLEY, K.J., ROACH, A.G. & WILLIAMSON, K.L. Positive inotropic and chronotropic effects of noradrenaline which cannot be explained by α- or β-adrenoceptor stimulation, 86, 699P
- - - The α-adrenoceptor-mediated components of the responses to adrenaline and phenylephrine of rat isolated atria, 85, 324P
BROADHURST, A.M. & WYLLIE, M.G. Different displacement profiles of alpha-adrenoceptor agonists and antagonists versus ^{3}H-rauwolscine binding in rat cerebral cortex, 86, 614P
BROCHARD, J. see BIZIERE, K., 85, 384P
BROCK, J.A.C. see MCKILLOP, C.M., 84, 123P
BROSTOFF, J., FLINT, K.C., HUDSPITH, B., JOHNSON, N. MCl., LEUNG, K.B.P. & PEARCE, F.L. Some properties of mast cells obtained by human bronchoalveolar lavage, 85, 205P
BROWN, C.M. see ALPS, B.J., 85, 329P; 86, 669P
BROWN, C.M., DUNCAN, G.P., MCKENNIFF, M.G., PATMORE, L. & WHITING, R.L. Characterisation of β-adrenoceptors on cultured human embryonic lung cells, 86, 766P
BROWN, C.M., DYE, A.D., GOODWIN, K., KILPATRICK, A.T. & WHITING, R.L. Sodium alters the kinetics associated with neuronal uptake of 5-hydroxytryptamine, 86, 600P
BROWN, F. & MITCHELL, P. B-HT 920 is a dopamine agonist causing little or no motor hyper-activity, but is it a selective autoreceptor agonist? 84, 185P
BROWN, J.F. see BATES, R.F.L., 86, 809P
BROWN, J.R., HUNTER, J.C. & JORDAN, C.C. Characterisation of tachykinin receptors in the marmoset ileum and colon, 86, 696P
BROWN, K.A., WILBOURN, B., FERRIE, J. & DUMONDE, D.C. Effect of non-steroidal anti-inflammatory drugs (NSAID) on the adhesion of human leucocytes to cultured endothelium, 86, 425P
BROWN, M.J. & HARLAND, D. Involvement of dopamine receptors and α_2-adrenoceptors in the hypotensive effect of B-HT 958 in the rat, 84, 64P
BROWN, R.F.R., DRAWBAUGH, R.B. & MARRS, T.C. Effects of repeated subcutaneous administration of paraquat, 86, 729P
BROWN, T.H. see BLAKEMORE, R.C., 86, 570P
BROWNE, J.L. & PILCHER, C.W.T. Nociceptive effects of GABA-ergic agents in socially crowded rats, 86, 483P
BRUNDISH, D.E. see BLOXHAM, C.A., 85, 232P
BRUNELLI, G. see BERTI, F., 86, 773P
BRUNELLESCHI, S., CONTI, A., FANTOZZI, R., LODOVICI, M., MANNAIONI, P.F. & MASINI, E. Paracetamol-induced histamine release from rat peritoneal mast cells after in vitro activation by monooxygenases, 86, 574P
BRUNELLESCHI, S., FANTOZZI, R., GIOTTI, A., LEDDA, F. & MIAN, M. Inhibition of human neutrophil activity by calcium entry blockers, 86, 575P
BRUNELLESCHI, S., FANTOZZI, R., MANNAIONI, P.F. & MASINI, E. Neutrophil-mediated histamine release from mast cells: a role for oxygen radicals, 86, 576P
BRYANT, S.H. see BETTONI, G., 86, 774P
BRYANT, S.H., CONTE-CAMERINO, D., FRANCONI, F., GIOTTI, A. & MAMBRINI, M. Lack of antagonism by taurine on chloride channel block by anthracene-9-carboxylic acid in rat skeletal muscle, 86, 586P
BUCKETT, W.R. & DIGGORY, G.L. Noradrenaline turnover: drug-induced changes evaluated using a new HPLC-ECD assay for free MHPG in mouse brain, 86, 414P
BUCKETT, W.R. & LUSCOMBE, G.P. Anomalous "depressant" activity of trazodone and related halogenated phenylpiperazines in a putative model of depression, 86, 590P
- - - Effect of selective and non-selective monoamine oxidase inhibitors on the P,P'-DDT-induced behavioural response in mice, 86, 478P

- - - Turn preference does not influence the response of mice in putative models of depression and anxiety, 86, 713P
BUCKETT, W.R., FLETCHER, C., HINDS, M. & MASON, R. Subsensitivity of cerebellar Purkinje cells to ionophoresed noradrenaline induced by chronic administration of dothiepin, 86, 466P
BUCKLEY, G.A. see BATES, R.F.L., 86, 809P
BULLOCH, J.M., MCGRATH, J.C. & MCKEAN, C. E. Comparison of α_2-adrenoceptor-mediated pressor responses in pithed rats and rabbits, 86, 745P
BULLOCK, G.R., TAYLOR, S.G. & WESTON, A. H. No evidence for an endothelial component in the relaxant effect of hydralazine on rat aorta, 85, 269P
BUNCE, K.T. Stimulation of gastric non-parietal secretion by prostaglandin F_2 in the rat and cat, 86, 815P
BUNCE, K.T. & CLAYTON, N.M. The effect of the prostaglandin endoperoxide analogue, U46619, on gastric mucosal ulceration and non-parietal secretion in the rat, 86, 421P
BUNCE, K.T. & SPRAGGS, C.F. Neurogenic anion secretion by guinea-pig isolated duodenal mucosa, 85, 204P
BURGES, R.A., CARTER, A.J., GARDINER, D.G. & HIGGINS, A.J. Amlodipine, a new dihydropyridine calcium channel blocker with slow onset and long duration of action, 85, 281P
BURGEVIN, M.C. see BENAVIDES, J., 86, 440P
BURKARD, W.P. see BONETTI, E.P., 86, 463P
BURLEIGH, D.E. & TROUT, S.J. Substance P contractions of guinea pig taenia caeci by a direct action on smooth muscle, 84, 165P
BUSHFIELD, M., DRUMMOND, A.H. & MACINTYRE, A.E. Direct and indirect effects of ADP on platelet cytosolic free calcium, 84, 28P
BUSHFIELD, M., MCNICOL, A. & MACINTYRE, D. E. Differential inhibition of platelet receptor-activated functional responses and transduction processes by cAMP, 86, 577P
BUSS, D.C. see WATT, A.H., 84, 140P
BUTLER, K.D., DAVIES, J.A., MENYS, V.C., SHAND, R.A. & WALLIS, R.B. The kinetics of platelet and fibrin (ogen) deposition on to damaged rabbit carotid arteries in vivo, 86, 556P
BYFORD, A.J., DAVIDSON, J., FOSTER, D. & GOADBY, P. Effects of changes in calcium and phosphate concentrations on the responses of isolated cardiac muscle to inotropic drugs, 86, 725P

CACIAGLI, F. see CICCARELLI, R., 86, 672P
- - - see DI IORIO, P., 86, 583P
CAGIANO, R., SALES, G.D. RENNA, G., MARTELLI, C., RACAGNI, G. & CUOMO, V. Ultrasonic vocalization in rat pups: effects of early postnatal exposure to haloperidol, 86, 789P
CAIRNDUFF, B., GRAHAM, W.C., JOHNSON, M.A., MEECHAM, K.G. & SMITH, G. The use of software for the BBC microcomputer to facilitate behavioural screening tests, 86, 525P
CALABRESE, S. see CICCARELLI, R., 86, 672P
CALASSI, R. see BIZIERE, K., 84, 146P, 198P
CALDER, C. see ALPS, B.J., 85, 329P; 86, 669P
CALDWELL, J. & CHIDGEY, M.A.J. Dose- and vehicle-related variation in the disposition of benzyl acetate in the rat, 85, 207P
CALDWELL, J., FARMER, P.B., SANGSTER, S.A. & SUTTON, J.D. The fate of eugenol in the rat and its variation with dose, 84, 24P
CALDWELL, J., CHIDGEY, M.A.J. & KENNEDY, J.F. The absorption and disposition of topically-applied benzyl acetate in the rat, 86, 512P
CALDWELL, J., DOLPHIN, C.T. & SMITH, R. L. The influence of the immune modulator, polyrI.rC upon the metabolism of aspirin in mice, 85, 208P
CALLEJA, C., DELGADO, C. & TAMARGO, J. Effect of propafenone on the electro-physiological properties of sheep ventricular muscle and purkinje fibres, 84, 172P
CALLEN, T.S. see RUSSELL, N.J.W., 86, 788P
CALLEN, T.S., COX, B., JAMIESON, A., MAJOR, J.S., OLDHAM, A.A. RUSSELL, N.J.W., SCOTCHER, K.P. Effects of inhibitors of the renin-angiotensin system on carrageenin-induced oedema in rats, 86, 750P
CALLINGHAM, B.A. MAZEL, P. & PORTER, J.C. Some properties of amine oxidase activities in the rat intestine, 86, 553P
CAMBRIDGE, D. see ALLAN, G., 86, 439P

CAMERON, D., ENGLISH, T.A.H., GRISTWOOD, R. W., MORL, C.J., OWEN, D.A.A. & WALLWORK, J. Positive inotropic actions of SK&F 94120 on human isolated ventricular myocardium, 85, 226P
CAMPBELL, M.M. see BRISTOW, D.R., 86, 430P
CANDELETTI, S. see SPAMPINATO, S., 86 528P
CANDUSSIO, L. see DECORTI, G., 86, 794P
CANDY, J.M. see BLOXHAM, C.A., 85, 232P
CANDY, J.M., COURT, J.A. & HOBAN, R.P. Role of M_1 muscarinic receptors in K^+ facilitation of phoshatidylinositol hydrolysis, 86, 607P
CANDY, J.M., COURT, J.A. & SMITH, C.J. Enhancement of the phosphotidylinositol response by raised extracellular potassium in rat cerebral cortex, 84, 61P
CANDY, J.M., PERRY, R.H. & YATES, M. Autoradiographic localisation of 5-HT and imipramine binding sites in the raphe nuclei of the human brain, 84, 90P
CANDY, J.M. SNELL, C.R. & WHITFORD, C.A. Distribution of high affinity ^3H-somatostatin binding sites in the rat brain, 86, 551P
CANEVARI, A., PACIFICO, P., DI ROCCO, A., CUGURRA, F., GIGLIO, C. & NADALINI, V.F. Human vas deferens motility following in vitro and in vivo administration of atropine and diazepam, 86, 776P
CANFIELD, S.P. & WHITE, J.P.N. Contribution of mucus to luminal alkalinisation in an isolated rat duodenum preparation, 84, 80P
CANTELLI FORTI, G., GUERRA, M.C., BARBARO, A.M., HRELIA, P., BIAGI, G.L. & BOREA, P. A. Relationship between lipophilic character and urinary excretion in rats of a series of nitroheterocyclic compounds, 86, 554P
CANTONI, O., SESTILI, P., PIEDIMONTE, G., BALDUINI, W., CRISTALLI, G., GRIFANTINI, M. & CATTABENI, F. The effect of deazaadenosine derivatives on cell growth, nucleic acids and protein synthesis in cultured cells, 86, 563P
CAPARROTTA, L. see FASSINA, G., 86, 584P
CAPASSO, F., TAVARES, I.A., TSANG, R., RENNIE, J.A. & BENNETT, A. Synthesis of arachidonate products by rat and human colon. Effects of intestinal secretagogues, 86, 650P
CAPUTI, A.P. see SQUADRITO, F., 86, 629P
CARENZI, A. see SALA, R., 86, 603P
CAREY, F. see BILLINGHAM, M.E.J., 85, 272P
CAREY, F. & FORDER, R.A. Development and characterisation of a radioimmunoassay for leukotriene B_4, 84, 34P
CAREY, F. & HAWORTH, D. Effect of the EP1 receptor antagonist SC-19220 in a model of yeast and PGE_2 induced hyperalgesia and oedema, 86, 656P
- - - Effect of the mixed cyclo-oxygenase/5-lipoxygenase inhibitor, BW755C in a model of yeast-induced inflammation, 86, 652P
- - - Temporal studies of the formation of cyclo-oxygenase and lipoxygenase metabolites in yeast-induced inflammation, 85, 271P
CARFAGNA, N. & MORETTI, A. Effect of ergoline derivatives on dopamine turnover in rat brain, 86, 670P
CARGNELLI, G. see BOVA, S., 86, 624P, 720P
CARGNONI, A. see GIAMMATTEO, D., 86, 727P
CARILLA, E. see BRILEY, M., 84, 127P
CARLA, V. see BONGIANNI, F., 86, 529P
CARLSON, R.P., CHANG, J. & LEWIS, A.J. Does leukotriene B_4 play a role in urate-induced synovitis in dogs? 86, 521P
CARMIGNANI, M. see PREZIOSI, P., 86, 542P
CARON, M.G., DICKINSON, K.E.J., LEEB-LUNDBERG, L.M.F., LEFKOWITZ, R.J., PETERS, J.R. & STRASSER, R.H. Desensitisation of rat pineal β-adrenoceptors, 85, 326P
CARPENEDO, F. see FLOREANI, M., 86, 726P
CARPENTER, J.R. Intrinsic activity and potency of guinea-pig tracheal relaxants after different spasmogens in vitro, 85, 257P
CARRARA, M.C., CARROLL, M.A. MCGIFF, J.C. & SCHWARTZMAN, M. Cytochrome P450-dependent arachidonate metabolites in renomedullary cells from the thick ascending limb of hypertensive rabbits, 84, 39P
CARRATU, M.R. see BENOIT, E., 86, 549P, 665P
CARROLL, M.A. see CARRARA, M.C., 84, 39P
CARTER, A.J. see BURGES, R.A., 85, 281P

CASSISI, M. see MIRANDA, G.F., 86, 689P
CASSON, I.F. see BEAHON, S.J., 84, 81P
CASTELLETTI, L. see MEMO, M., 86, 543P
CASTELLO, R. see CESERANI, R., 86, 780P
CASTRO, B. see BRIET, C., 85, 383P
CATTABENI, F. see ABBRACCHIO, M.P., 86, 582P, 653P
- - - see CANTONI, O., 86, 563P
CATTANEO, C. see CROCI, T., 86, 782P
CAVALHEIRO, E.A., MELDRUM, B.S. & TURSKI, L. Effect of intranigral 2-amino-7-phosphonoheptanoate and N-methyl-D-aspartate on seizures produced by pilocarpine in rats, 85, 367P
CAVERO, I. & HICKS, P.E. Effects of alfuzosin and idazoxan on nerve mediated contractions in the rabbit isolated urethra, 86, 612P
- - - Studies on the transient hypotensive effects of fenoldopam, a DA_1 dopamine receptor agonist, in rats, 86, 436P
CAVERO, I. & THIRY, C. Method for the electrical stimulation of postganglionic cardioaccellerator sympathetic nerve fibres in pithed rats, 84, 182P
CAVERO, I., HICKS, P.E. & LEFEVRE-BORG, F. α_1-adrenoceptor antagonist effects on alfuzosin in rabbit and dog lower urinary tract, 86, 416P
- - - Cardiovascular profile of quinpirole, a selective and specific DA_2-dopamine receptor agonist, in rats, 86, 618P
CAVERO, I., HICKS, P.E., LANGER, S.Z. & LEFEVRE-BORG, F. Cardiovascular synergistic action between diltiazem and alfuzosin under in vivo and in vitro conditions, 84, 16P
CAVERO, I., LEFEVRE-BORG, F. & MANOURY, Ph. Pharmacological profile of cicloprolol, a compound which behaves as an agonist and an antagonist at β_1-adrenoceptors, 84, 31P
CAVICCHINI, E., see SPAMPINATO, S., 86, 528P
CAVICCHIOLI, L., CONSOLAZIONE, A. & LEON, A. Dopamine receptor neuroplasticity can be affected by GM_1 ganglioside treatment, 86, 671P
CECONI, C. see GIAMMATTEO, D., 86, 727P
CERRITO, F. see PREZIOSI, P., 86, 542P
CESERANI, R. see GROSSONI, M., 86, 628P
CESERANI, R., VAGHI, F., CASTELLO, R., TOTI, D., LAZZARINI, A.M., SCARPONI, U. & deCASTIGLIONE, R. Antisecretory and antiulcer effect of a potent H_2-antagonist: FCE 23067, 86, 780P
CHAMBERS, S.D., CHURCH, M.K. & HUGHES, P.J. Adenosine enhancement of A23187 induced 5-hydroxytryptamine release from rat mast cells is not P_1- or P_2-purinoceptor mediated, 86, 400P
CHAMBON, J.P. see BIZIERE, K., 84, 198P; 85, 384P
CHANG, J. see CARLSON, R.P., 86, 521P
CHAPMAN, A.G., FAINGOLD, C.L. & HART, G.P. Regional amino acid levels in audiogenic seizure susceptible rats during control and seizure conditions, 85, 368P
CHAPMAN, J.B. & CUTLER, M.G. Sodium valproate: effects on development. social behaviour and seizure susceptibility in the offspring of gerbils, 86, 540P
CHAPPELL, S.P., GRIFFITH, T.M., HENDERSON, A.H. & LEWIS, M.J. Influence of cholesterol feeding on endothelium-dependent vasomotor response in rabbit aortic strips, 85, 266P
CHAPPELL, S.P., HENDERSON, A.H. & LEWIS, M.J. Myocardial reoxygenation damage can be circumvented, 85, 332P
CHAPPLE, D.J. & DONOGHUE, S. On-line analysis of cardiovascular data using a mini-computer system, 85, 308P
CHARLTON, K.G. see BOND, R.A., 84, 14P; 86, 401P
CHARLTON, K.G., BOND, R.A. & CLARKE, D.E. Evidence for a prejunctional inhibitory $5\text{-}HT_1$ receptor in rat kidney, 84, 57P
CHEETHAM, S.C., CROMPTON, M.R., KATONA, C.L.E., HORTON, R.W., PARKER, S.J. & REYNOLDS, G.P. $GABA_A$ and benzodiazepine binding sites in the cortex of depressed suicide victims, 86, 593P
CHENERY, R.J. see BLAKEMORE, R.C., 86, 570P
CHENERY, R.J., EMERY, S., NORMAN, S. J. & OLDHAM, H.G. The effect of cimetidine and ranitidine on paracetamol glucuronidation and sulphation in cultured rat hepatocytes, 84, 164P
CHESS-WILLIAMS, R.G. see BROADLEY, K.J., 84, 194P; 85, 261P, 320P; 86, 759P
CHEVALLIER, E. see BIZIERE, K., 86, 404P
CHIDGEY, M.A.J. see CALDWELL, J., 85, 207P; 86, 512P
CHINETTI, L. see PUGLISI, L., 86, 646P

CHITRANUKROH, A., COOK, P. & JAMES, I. The effect of nicardipine, a calcium entry blocker, on paracetamol induced injury in mice, 86, 602P
CHOLERTON, S. & PARK, B.K. The pharmacological response to vitamin K_1 in the anticoagulated rat, 86, 406P
CHOPIN, P. see BRILEY, M., 86, 456P
CHRISTIE, G., KITTERINGHAM, N.R., MAGGS, J.L. & PARK, B.K. The role of glutathione in the disposition of 2,4-dinitro-fluorobenzene in the rat, 86, 799P
CHURCH, M.K. see BENYON, R.C., 86, 407P
- - - see CHAMBERS, S.D., 86, 400P
CHURCH, M.K. & FEATHERSTONE, R.L. An examination of interactions between substance P and other agonists in airway smooth muscle, 86, 484P
CHURCH, M.K., HOLGATE, S.T., NORN, S. & PAO, G.J-K. Bacteria-induced histamine release from human dispersed lung and tonsillar mast cells, 86, 509P
CIABATTONI, G. see PREZIOSI, P., 86, 649P
CICCARELLI, R. see DI IORIO, P., 86, 583P
CICCARELLI, R., DI IORIO, P., LONGHI, O. N., CALABRESE, S. & CACIAGLI, F. Relationship between electrically-induced adenosine release and cAMP levels in rat striatal primary cultures, 86, 672P
CIUFFI, M., FRANCHI-MICHELI, S., LUZZI, S. & ZILLETTI, L. Functional activity of GABA receptors in myenteric plexus from morphine tolerant guinea-pigs, 86, 637P
CIVELLI, M. see NICOSIA, S., 86, 647P
CLAGUE, R.U., EGLEN, R.M., STRACHAN, A.C. & WHITING, R.L. Comparison of cholinergic activity of suberyldicholine with that of carbachol in vitro, 84, 155P
CLAGUE, R.U., FINLAYSON, J.R. & WHITING, R.L. Central α_2-adrenoceptor function following acute and chronic dosing with imiloxan, 84, 154P
CLARK, B.F., COLLIER, A., MATTHEWS, D.M. & TYMKEWYCZ, P.M. Changes in platelet function in diabetes mellitus with improvement of glycaemic control, 86, 795P
CLARK, C.R. see LINGFORD-HUGHES, A.R., 85, 290P
CLARKE, B., PATMORE, L. & WHITING, R.L. Comparative inotropic effects of calcium modulators on guinea-pig and rat myocardium, 85, 330P
- - - Mechanism of positive inotropic action of trifluoperazine in guinea-pig ventricular muscle, 86, 760P
CLARKE, D.E. see BOND, R.A., 84, 14P; 86, 401P
- - - see CHARLTON, K.G., 84, 57P
CLATWORTHY, A. see BARASI, S., 85, 352P
CLAYTON, N.M. see BUNCE, K.T., 86, 421P
COATES, W.J., EDEN, R.J., EMMETT, J. C., GRISTWOOD, R.W., OWEN, D.A.A., SLATER, R.A., TAYLOR, E.M. & WARRINGTON, B.H. SK&F 94120, a novel agent with positive inotropic and vasodilator activity, 84, 22P
COENE, M.-C., HERMAN, A.G., JORDAENS, F., VAN HOVE, C., VERBEUREN, T.J. & ZONNEKEYN, L. Endothelium-dependent relaxations in isolated arteries of control and hypercholesterolaemic rabbits, 85, 267P
COKER, S.J., KANE, K.A., PARRATT, J. R. & WILLIAMS, F.M. The effects of nicergoline an α-adrenoceptor blocking drug on ischaemia and reperfusion-induced arrhythmias in anaesthetised dogs, 84, 30P
COLEMAN, I.P.L. see BIRCH, N.J., 84, 23P, 78P; 85, 304P
COLEMAN, M.D. see BRECKENRIDGE, A. M., 86, 405P
COLEMAN, R.A., DENYER, L.H. & SHELDRICK, R.L.G. The influence of protein binding on the potency of the prostanoid EP_1-receptor blocking drug, AH6809, 86, 803P
COLEMAN, R.A., KENNEDY, I. & SHELDRICK, R.L.G. AH6809, a prostanoid EP_1-receptor blocking drug, 85, 273P
COLES, D.J., ELLIS, C.E., HOLMES, S. W., TRIM, J.L. & WILSON, K.L. The effects of angiotensin converting enzyme inhibitors on the action of diuretics in the rat, 86, 748P
COLLIER, A. see CLARK, B.F., 86, 795P
COLLINGRIDGE, G.L., HERRON, C.E. & WILLIAMSON, R. A selective N-methyl-D-aspartate antagonist reduces convulsant-induced epileptiform activity in rat hippocampal slices, 86, 474P
COLLINS, G.G.S. see DEWHURST, D.G., 85, 360P; 86, 663P
COLLINS, J.F. see ANAND, H., 86, 473P
COLLINS, J.F., CONNICK, J.H. & STONE, T.W. Absence of uptake and binding of radiolabelled quinolinic acid in rat brain, 85, 373P

COLLINS, P., GRIFFITH, T.M., HENDERSON, A.H. & LEWIS, M.J. 8-Bromo-cGMP and calcium flux in arterial smooth muscle, 85, 279P
- - - Endothelium and calcium flux in rabbit aortic preparations, 85, 342P
COLLIS, M.G. see BOWMER, C.J., 84, 131P
CONNICK, J.H. see COLLINS, J.F., 85, 373P
CONNICK, J.H. & STONE, T.W. The effect of quinolinic acid and the kynurenines on the uptake of [^{3}H]-D-aspartic acid in rat brain, 84, 92P
CONNOR, H.E., FENIUK, W., HUMPHREY, P.P. A. & PERREN, M.J. 5-carboxamido-tryptamine is a selective agonist at 5-HT receptors mediating vasodilation and tachycardia in the anaesthetised cat, 85, 222P
CONOLAN, S., QUINN, M.J. & TAYLOR, D.A. Peripheral 5-HT$_2$ receptor activation following administration of tryptamine derivatives in rats, 86, 399P
CONSOLAZIONE, A. see CAVICCHIOLI, L., 86, 671P
CONSTANTI, A. & WILLIAMS, S.H. Pharmacological determination of the pA$_2$ for pirenzepine using a mammalian in vitro brain slice preparation, 86, 394P
CONTE-CAMERINO, D. see BRYANT, S.H., 86, 586P
- - - see BETTONI, G., 86, 744P
CONTI, A. see BRUNELLESCHI, S., 86, 574P
CONTI, G. see DI CARLO, F., 86, 560P
CONYBEARE, G. see ATTERWILL, C.K., 84, 124P
COOK, P. see CHITRANUKROH, A., 86, 602P
COOK, P.J. & JAMES, I.M. The effect of age on the acute response to diazepam, 84, 135P
COOPER, S.J. & ESTALL, L. Intrinsic actions of Ro15-1788 and CGS 8216: hyperphagia and anorexia-induced in non-deprived rats consuming a palatable diet, 84, 96P
COOPER, S.J. & GILBERT, D.B. The D$_1$ receptor antagonist, SCH 23390, and sultopride, have distinctive effects in a salt preference test, 84, 143P
COOPER, S.J. & JACKSON, A. Hyperphagia induced by K opiate agonists in non-deprived rats: dissociation from a diuretic effect, 84, 75P
COPLAND, A.M. see BALFOUR, D.J.K., 84, 72P; 86, 711P
CORBETT, A.D., GILLAN, M.G.C., KOSTERLITZ, H.W. & PATERSON, S.J. Binding and pharmacological profile of a highly selective ligand for the κ-opioid receptor - U-69, 593, 86, 704P
CORDER, R., LOWRY, P.J., RAMAGE, A.G. & WILKINSON, S.J. Comparison of the haemodynamic actions of neuropeptide Y, angiotensin II and noradrenaline, 85, 231P
CORRADETTI, R. see VANNUCCHI, M.G., 86, 606P
CORSANO, E. see BERNARDINI, C., 86, 781P
CORSINI, A. see OLIVA, D., 86, 805 P
CORUZZI, G. see BERTACCINI, G., 86, 641P
CORUZZI, G., ADAMI, M. & BERTACCINI, G. Regulation of resting acid secretion in the rat isolated fundus, 86, 639P
COSTALL, B. see BARNES, J.C., 86, 695P
- - - see BARNES, N.J.G., 86, 468P, 708P
- - - see BRADBURY, A.J., 85, 348P, 350P; 86, 526P, 685P, 691P
COSTALL, B., DOMENEY, A.M., HUI, SIU-CHUN G., NAYLOR, R.J. & OGLE, C.W. Acute and long-term changes in locomotor activity related to the continuity of dopamine receptor stimulation, 86, 690P
COSTALL, B., DOMENEY, A.M. & NAYLOR, R.J. The amygdala, laterality, and the control of rat locomotor activity, 85, 250P
COSTALL, B., DOMENEY, A.M., FITTON, J. C. & NAYLOR, R.J. Antagonism by lithium of cyclic changes in locomotor activity induced by dopamine infused into rat nucleus accumbens, 85, 354P
COSTALL, B., GUNNING, S.J., NAYLOR, R. J. & SIMPSON, K.H. Antagonism by atropine and glycopyrrolate of metoclopramide-facilitated gastric emptying, 86, 757P
COSTALL, B., NAYLOR, R.J. & TAN, C.W. Dopamine D$_1$ and D$_2$ receptor agonists reduce gastric secretion in the rat, 85, 353P
COTTERELL, D.J. & DUBOCOVICH, M.L. Bay K-8644 increases calcium uptake in the presence of isoproterenol and KCL in rabbit cardiomyocytes, 86, 657P
COURT, J.A. see CANDY, J.M., 84, 61P; 86, 607P
COWAN, A. & HEYMAN, J. Bombesin is a potent antinociceptive agent in mouse writhing and tail flick tests, 86, 485P

COWAN, A., MOSBERG, H.I., PORRECA, F. & ZHU, X.Z. Direct dependence studies in rats with agents selective for different subtypes of opioid receptor, 85, 294P
COX. B. see BLACKBURN, T.P., 85, 381P
- - - see CALLEN, T.S., 86, 750P
COX, H.M., MUNDAY, K.A., PLEVIN, R. & POAT, J.A. A study of bradykinin binding to rat jejunal epithelial cell membranes, 86, 486P
COX, H.M., MUNDAY, K.A., POAT, J.A. & SHARMA, R.P. A novel angiotensin II analogue with high affinity for epithelial ^{125}I-angiotensin II binding sites, 86, 487P
COX, R.T.L. & WALKER, R.J. The inhibition of an acetylcholine-induced calcium current in cell F-1 of Helix aspersa by adenosine, 86, 449P
CRAIG, R.K. see AL-KAZWINI, S.J., 86, 544P, 679P
CREMA, G. see PAROLARO, D., 86, 619P
CREMONESI, P. see AGOZZINO, S., 86, 716P
CRESPI, F., KEANE, P.E. & MORRE, M. Effect of valproate on striatal ascorbic acid, DOPAC and 5-HIAA in rats as measured by voltammetry, 85, 372P
CRISPINO, A. see DI CARLO, F., 86, 560P
CRISTALLI, G. see CANTONI, O., 86, 563P
CRIVELLARI, M.T. see FOLCO, G.C., 86, 645P
CROCI, T., BIANCHETTI, A., CATTANEO, C. & MANARA, L. Morphine or loperamide-induced constipation in mice: comparative antagonism by SR 58002 C and naloxone, 86, 782P
CROME, R., HEARSE, D.J., MAGUIRE, M.E. & MANNING, A.S. Dissociation between reperfusion arrhythmias and increases in ventricular α_1 receptor density in the anaesthetised rat, 86, 498P
CROME, R., HEARSE, D.J. & MANNING, A.S. Reperfusion arrhythmias and time-response relationships: modification by drugs in the anaesthetised rat, 86, 418P
CROMPTON, M.R. see CHEETHAM, S.C., 86, 593P
CROMWELL, O. see MACKAY, J.A., 86, 526P
CROMWELL, O., SHAW, R.J., WALSH, G.M. & KAY, A.B. Inhibition of leukotriene C_4 and B_4 generation by human eosinophils and neutrophils, 86, 427P
CROOK, T., SOUHAMI, R.L. & MCLEAN, A.E.M. DNA cross links in sensitive leukaemia cells exposed to cyclophosphamide activated by rat hepatocytes in vitro, 84, 128P
CROSS, A.J., SKAN, W.J. & SLATER, P. ^{3}H D-aspartic acid labels excitatory amino acid uptake sites in human brain, 86, 686P
- - - Excitatory amino acid binding sites in human cerebellum, 86, 475P
CROW, T.J., FARMERY, S.M., OWEN, F. & POULTER, M. Iodinated somatostatin binding to human brain membranes: a comparison of controls and Alzheimer type dementia patients, 84, 8P
CUNNANE, T.C. see ALLCORN, R.J., 85, 263P
- - - see BEATTIE, D.T., 84, 29P
CUOMO, V. see CAGIANO, R., 86, 789P
CURELLO, S. see GIAMMATTEO, D., 86, 727P
CURLE, P.F., GEDDES, C. & PALOMO, T. The effect of oxypertine on dopamine, DOPAC and HVA in the rat striatum, 84, 197P
CUTHILL, S. see SKETT, P., 86, 555P
CUTLER, M.G. see CHAPMAN, J.B., 86, 540P
CUTLER, M.G., HIGGINS, C.A. & MOORE, M.R. Pharmacological effects of Δ-aminolaevulinic acid and γ-aminobutyric acid in isolated preparations of rabbit jejunum, 86, 680P

D'MELLO, A. see DAVIES, M., 84, 126P
D'MELLO, A. & WIECZOREK, W.J. Effects of calcium removal on response of lung parenchymal strips to KCl, histamine, carbachol or antigen, 84, 151P
DAFFONCHIO, L. see ABBRACCHIO, M.P., 86, 653P
- - - see BERTI, F., 86, 773P
DALTON, D.W., FENIUK, W. & HUMPHREY, P.P.A. An analysis of the cardiovascular effects of 5-hydroxytryptamine in conscious docs-salt hypertensive rats, 86, 595P
- - - The mechanism of the hypotensive action of 5-carboxamidotryptamine in conscious docs-salt hypertensive rats, 86, 737P
DALY, C.J., MCGRATH, J.C., MUIR, A.G. B. & O'BRIEN, J.W. Ca^{++}-dependence of noradrenaline-induced contraction in rat aortic smooth muscle, 86, 723P
DANDONA, P., JEREMY, J.Y. & MIKHAILIDIS, D.P. Mediation of prostacyclin synthesis in the penis by muscarinic receptors, 85, 284P
DASDIA, T. see BOSSA, R., 86, 772P
DAVEY, M.J. see ALABASTER, V.A., 85, 376P

DAVIDSON, J. see BYFORD, A.J., 86, 725P
DAVIES, A.M. & ECCLES, R. The effects of nasal airflow and menthol on the nasal electromyographic activity of the anaesthetised cat, 85, 254P
DAVIES, C.L. & HEAL, D.J. A simplified HPLC method for 3-methoxytyramine: correlation with behavioural activity in rats, 84, 54P
DAVIES, D.S. see BOOBIS, A.R., 84, 138P; 86, 511P
DAVIES, G.J. see KERWIN, R.W., 85, 288P
DAVIES, J.A. see BUTLER, K.D., 86, 556P
DAVIES, J.A., MARSHALL, R.W. & SPARKS, M. A microcomputer system for long-term monitoring and analysis of locomotor activity, 85, 393P
DAVIES, J.M., HENSBY, C.N., LUGINBUHL, B. & WILLIAMS, K.I. Stimulation and inhibition of endothelial-dependent relaxations of rat aortic strips, 85, 343P
DAVIES, M. & D'MELLO, A. The effects of drugs on sexual function, 84, 126P
DAVIES, M. & ROBERTS, M.H.T. The effects of the 5HT 1A ligand, 8-OH-DPAT, applied iontophoretically to rat brainstem neurones, 86, 594P
DAVIES, M., ROBERTS, M.H.T. & WILKINSON, L.S. Effects of intravenous ketanserin, methysergide and MDL 72222 on responses to iontophoretically applied 5-HT in the rat brainstem, 85, 255P
DAVIES, M.W. see KEYSELL, G.R., 86, 513P
DAVIES, P. & ROBERTS, F. Fitting a logistic curve to dose response curves using ALLFIT on an Apple 11E, 84, 175P
DAVIES, S.W. & ROBERTS, P.J. Effects of intracerebro-ventricular kainic acid on acetylcholinesterase-containing neurones in rat hippocampus, 86, 450P
DAVIS, A.S., JENNER, P. & MARSDEN, C.D. Apomorphine induces grooming behaviour in rats pretreated with sulpiride, 86, 434P
- - - Differential induction of climbing behaviour in rats by dopamine agonist drugs, 85, 247P
DAWBARN, D. see KERWIN, R.W., 85, 288P
DE CASTIGLIONE, R. see CESERANI, R., 86, 780P
DE GORI, N. see VACCA, M., 86, 793P
DE JONGE, A. see VAN CHARLDORP, K., 84, 178P
DE LA HUNT, M.N., HILLIER, K., JEWELL, R., PLATT, K. & KARRAN, S.J. Dietary oil modifies duodenal and gastric prostaglandin synthesis in the rat, 86, 428P
DE NUCCI, G. see BAKHLE, Y.S., 84, 38P; 86, 423P
DE SARRO, A. see AMMENDOLA, D., 86, 660P
DE SARRO, G.B., ASCIOTI, C., FROIO, F., LIBRI, V. & NISTICO, G. Locus coeruleus: site of sedation and sleep induced by clonidine, 86, 676P
DEAN, H.G. see BOWMER, C.J., 84, 132P
DEBETTO, P. see BOVA, S., 86, 624P
- - - see FLOREANI, M., 86, 726P
DECORTI, G., BARTOLI KLUGMANN, F., CANDUSSIO, L., BASA, M., MALLARDI, F., GRILL, V., BALDINI, L. Effect of polyethylene glycol 400 on adriamycin induced histamine release, 86, 794P
DEIGHTON, N.M., HAMILTON, C.A., JONES, C.R. & REID, J.L. Acute agonist regulation of α_2-adrenoceptors in vitro in the rabbit, 86, 741P
DEL CARMINE, R. see PREZIOSI, P., 86, 542P
DEL COCO, M. see IORIO, P., 86, 583P
DEL TACCA, M. see BERNARDINI, C., 86, 781P
- - - see SOLDANI, G., 86, 640P
DEL TACCA, M., POLLONI, A., SOLDANI, G., BERNARDINI, C., GIANNETTI, A. & BONIFAZI, V. The influence of pirenzepine on gastrin and somatostatin portal levels in dogs, 86, 638P
DELGADO, C., GARCIA, A., TAMARGO, J. & VALENZUELA, C. Effect of Bay K8644 in guinea-pig atrial and ventricular muscle fibres, 84, 171P
DELGADO, C., TAMARGO, J., TEJERINA, T. & VALENZUELA, C. Effects of 5-hydroxy-propafenone on guinea-pig atrial and ventricular muscle fibres, 86, 499P
DELLA BELLA, D. see SALA, R., 86, 603P
DELLA CORTE, L., SGARAGLI, G.P., TIPTON, K.F. & VALOTI, M. Purification of intestinal peroxidase and its activities towards xenobiotics, 86, 557P
DEMPSTER, J. A set of computer programs for electrophysiological analysis of end plate current characteristics, 85, 390P
- - - see PRIOR, C., 86, 585P
DEMPSTER, J., PRIOR, C., HENDERSON, F. & MARSHALL, I.G. Changes in quantal content produced by endplate channel blocking drugs as assessed by analysis of driving function, 86, 675P

DENNIS, T. & SCATTON, B. Nature of the facilitatory influence of GABA on central noradrenergic transmission, 84, 93P
DENYER, L.H. see COLEMAN, R.A., 86, 803P
DEPOORTERE, H. see ARBILLA, S., 86, 432P
DERVINIS, A. see MUTH, E., 86, 452P
DESTA, B. & SENIOR, J. The effect of streptozotocin-induced diabetes on the blood flow to the reproductive organs, 86, 791P
DETTMAR, P.W. & LORD, J.A.H. Effect of selected α-adrenoceptor agents on responses of rat isolated gastric mucosa to electrical field stimulation, 85, 322P
DETTMAR, P.W. & SMEATON, L.A. The regulation of gastric acid secretion in the rat in vivo; a role for α_2-adrenoceptors? 85, 319P
DETTMAR, P.W., DOWNING, O.A., ROACH, A.G., WILLIAMS, R.J. & WILSON, K.A. Stimulation of fluid transport in rat jejunum by noradrenaline - an attempt to characterise receptors, 86, 519P
DETTMAR, P.W., KELLY, J. & MACDONALD, A. α_1- and α_2-adrenoceptor-mediated effects of noradrenaline in rat gastric fundus, 86, 613P
- - - Effect of UK-14,304 on nerve-induced responses in rat gastric fundus, 86, 491P
DEWHURST, D.G. Sensitivity of catechol-induced sensory myoclonic jerks to valproate and diazepam, 85, 364P
DEWHURST, D.G. & COLLINS, G.G.S. Excitatory effects of catechol on synaptic transmission in the rat olfactory cortex slice, 85, 360P
- - - Inhibitory effects of catechol on synaptic transmission in the rat olfactory cortex slice, 86, 663P
DI CARLO, F., RACCA, S., CRISPINO, A., CONTI, G., GIUBERTONI, M. & PORTALEONE, P. Effect of medroxyprogesterone acetate on cAMP phosphodiesterase activity in rat mammary tumors, 86, 560P
DI CHIARA, G. see IMPERATO, A., 86, 532P
DI GIULIO, A.M., BORELLA, F., PARENTI, M., MANTEGAZZA, P., HONG, J.F., ZANONI, R. & GORIO, A. Peripheral nerve lesions cause peptidergic alterations in the spinal cord, 86, 527P
DI IORIO, P. see CICCARELLI, R., 86, 672P
DI IORIO, P., CICCARELLI, R., LONGHI, O.N. DEL COCO, M. & CACIAGLI, F. Frequency-dependent interactions between adenosine and transmitter releases electrically evoked, from rat brain slices, 86, 583P
DI MONTE, D., GRANT, M.H., JERNSTROM, B. & NORKENSKJOLD, M. Cytotoxicity of menadione and benzo(A)pyrene-3,6-quinone in cultured human fibroblasts, 86, 559P
DI ROCCO, A. see CANEVARI, A., 86, 776P
DI SIMPLICIO, P., IGNESTI, G., PIRISINO, R. & BIANCHI, G.P. Properties of plasma SH groups in experimental inflammation in rat, 86, 777P
DICKINSON, K.E.J. see CARON, M.G., 85, 326P
DICKINSON, K.E.J., MCKERNAN, R.M., MILES, C.M. & SEVER, P.S. Heterogeneity of soluble splenic α_2-adrenoceptors, 86, 492P
DICKINSON, K.E.J., RUDD, R.M., SEVER, P.S. & WINTER, R.J.D. Tissue specific modulation of β-receptor number in chronic hypoxia with an attenuated response to down regulation by salbutamol, 85, 256P
DIGGORY, G.L. see BUCKETT, W.R., 86, 414P
DOBLE, A. see BENAVIDES, J., 86, 440P
DOCHERTY, J.R. Altered cardiovascular responsiveness in the aged rat, 86, 627P
DOCHERTY, J.R. & HYLAND, L. Age-related changes in pre- and post-junctional α-adrenoceptors in human saphenous vein, 84, 144P
- - - An investigation of age-related changes in vascular α-adrenoceptors in the anaesthetised rat, 85, 260P
- - - 5-hydroxytryptamine receptors in the human saphenous vein, 86, 735P
DOCHERTY, J.R. & SAWYER, R. Involvement of vascular α_2-adrenoceptors in blood pressure control in the anaesthetised spontaneously hypertensive rat, 84, 145P
DOCHERTY, J.R. & WARNOCK, P. Effects of α-adrenoceptor antagonists on blood pressure in the spontaneously hypertensive rat, 85, 264P
DODD, M.G. & MACHIN, I. Anti-hypertensive effect of amlodipine, a novel dihydropyridine calcium channel blocker, 85, 335P
- - - Lack of role of angiotensin-II in orthostatic blood pressure control, 86, 488P

DODD, N.J., HUMPHREY, P.P.A., LUMLEY, P. & WESTON, M.J. Effect of the thromboxane receptor blocking drug AH23848 upon thrombocytopenia induced by haemodialysis in the anaesthetised dog, 85, 285P
DODDS, M.G., DOLAMORE, P.G. & LOUTTIT, J.B. The relaxant effects of an atrial peptide and nitroprusside on rat vascular muscle depend on spasmogen concentration, 86, 730P
DOLAMORE, P.G. see DODDS, M.G., 86, 730P
DOLLERY, C.T., HEAVEY, D.J., RICHMOND, R., TAYLOR, G.W. & VIAL, J. Histamine and peptidoleukotriene release from immunologically challenged guinea-pig lung, 85, 277P
DOLPHIN, A.C. & PRESTWICH, S.A. Pertussis toxin reverses adenosine inhibition of glutamate release from cerebellar neurones in culture, 86, 526P
DOLPHIN, C.T. see CALDWELL, J., 85, 208P
DOMENEY, A.M. see BARNES, N.J.G., 86, 468P
- - - see BRADBURY, A.J., 85, 350P; 86, 691P
- - - see COSTALL, B., 85, 354P; 86, 690P
DONALD, F.M.S. A non-adrenergic non-cholinergic (NANC) excitatory response in frog atria, 85, 211P
DONALDSON, J. & HILL, S.J. Alterations in histamine H_1-receptor activity by 1,4-dithiothreitol in guinea-pig ileum, 85, 206P
- - - Histamine-stimulated accumulation of (^{3}H)-inositol phosphates in guinea-pig cerebellum and ileal smooth muscle, 86, 568P
DONG, Y.J. & JONES, R.L. Highly specific action of the prostacyclin mimetic ZK 96480 on smooth muscle preparations, 86, 807P
DONG, Y.J. & WADSWORTH, R.M. Comparison of effect of nifedipine and nisoldipine on the human isolated uterine artery preparation, 85, 379P
DONOGHUE, S. see CHAPPLE, D.J., 85, 308P
DOUGLAS, J.S. see MUTH, E., 86, 452P
DOWLING, E.J., JASANI, M.K., PARKE, D.V., PETERS, R.F. & SYMONS, A.M. Characterisation of ex-vivo luminol-amplified chemiluminescence accompanying the initiation of foot-pad oedema in the Koch model, 84, 79P
- - - Free radicals, lipid peroxidation and prostaglandins during the development and maintenance of foot-pad oedema in the Koch model, 84, 35P
DOWNES, C.P., LEWIS, P.E. & STONE, M.A. A comparison of the binding of [^{3}H]-(+)SKF 10047 and [^{3}H]-PCP in rat brain membranes, 84, 196P
DOWNING, O.A. see DETTMAR, P., 86, 519P
DOWNING, O.A., MARRIOTT, J.F. & WILSON, K.A. Changes in verapamil sensitivity of rat aorta exposed to chronic hypoxia and normoxia, 84, 163P
- - - The use of verapamil to analyse alterations in Ca^{2+} activation of rat aorta during and following an acute hypoxic episode, 86, 504P
DOWNING, O.A., STEIN, W.K. & WILSON, K.A. A diltiazem sensitive component of pressor responses of pithed rats to cirazoline, 86, 717P
DOXEY, J.C., GADIE, B., LANE, A.C., ROACH, A.G., TULLOCH, I.F., VIRDEE, N.K. & WALKER, D.S. Pharmacological profile of aptazapine: a comparison with mianserin and idazoxan, 86, 747P
DRAGO, L. see OLIVA, D., 86, 805P
DRAWBAUGH, R.B. see BROWN, R.F.R., 86, 729P
DREW, G.M. & HILDITCH, A. The effects of (±)3-PPP and its enantiomers at peripheral neuronal dopamine receptors in the cat heart, 86, 617P
DRUMMOND, A.H. see BUSHFIELD, M., 84, 28P
DRUMMOND, A.H., MACINTYRE, D.E., MCNICOL, A. & ROSSI, A. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits agonist- induced phosphoinositide metabolism and Ca^{2+} flux in human platelets, 84, 27P
DUBOCOVICH, M.L. see COTTERELL, D.J., 86, 657P
DUBOCOVICH, M.L. & HENSLER, J.G. Modulation of dopamine release at different frequencies of stimulation from rabbit retina by a D_2 dopamine agonist and melatonin, 85, 240P
DUBOCOVICH, M.L., EELLS, J.T. & HENSLER, J.G. Release of ^{3}H-dopamine from rabbit retina by different depolarizing stimuli: effect of melatonin, 86, 533P
DUBOIS, J.M. see BENOIT, E., 86, 549P, 665P
DUCE, I.R. & SCOTT, R.H. Interactions of dihydro-avermectin B_{1a}, GABA and ibotenic acid on locust (Schistocerca

gregaria) muscle, 86, 431P
DUGGAL, K.N. see BARASI, S., 84, 166P; 85, 352P
DUMONDE, D.C. see BROWN, K.A., 86, 425P
DUNCAN, G.P. see BROWN, C.M., 86, 766P
DUNCKER, D.J., SAXENA, P.R. & VERDOUW, P. D. 5-hydroxytryptamine causes tachycardia in pigs by acting on receptors unrelated to 5-HT_1-, 5-HT_2- or M-type, 86, 596P
DURANT, G.J. see BLAKEMORE, R.C., 86, 570P
DURANT, N.N., LAMBERT, J.J. & PETERS, J.A. The mechanism of action of cholinergic antagonists; chromaffin cells, 86, 609P
DUVAL, N., HICKS, P.E. & LANGER, S.Z. Effects of pirenzepine and MDL 72222 on contractions of the cat nictitating membrane to muscarinic agonists, 86, 764P
DYE, A.D. see BROWN, C.M., 86, 600P

EELLS, J.T. see DUBOCOVICH, M.L., 86, 533P
EBENEZER, I.S. Propranolol pretreatment reverses the depressant effect of arginine-8 vasopressin on the spontaneous activity of rats, 84, 77P
- - - Vasopressin alone produces passive avoidance behaviour in a typical memory experiment, 84, 107P
ECCLES, R. see DAVIES, A.M., 85, 254P
EDEN, R.J. see COATES, W.J., 84, 22P
EDWARDS, D.H., GRIFFITH, T.M., HENDERSON, A.H., LEWIS, M.J. & NEWBY, A.C. Production of endothelium derived relaxant factor is both ATP and calcium dependent, 85, 344P
EDWARDS, D.H., GRIFFITH, T.M., HENDERSON, A.H., LEWIS, M.J. & RYLEY, H.C. Endothelium-dependent relaxation is inhibited by a high molecular weight protein fraction of whole human plasma, 85, 341P
EDWARDS, G. see BRECKENRIDGE, A.M., 86, 405P
EGLEN, R.M. see CLAGUE, R.U., 84, 155P
EGLEN, R.M. & WHITING, R.L. Is the muscarinic receptor present on the vascular endothelium atypical? 84, 13P
EGLEN, R.M., FRASER, S. & WHITING, R.L. Muscarinic receptor subtypes in the ileum, atria and taenia caecum of the guinea-pig, 86, 744P
EGLEN, R.M., MICHEL, A.D. & WHITING, R.L. M1 muscarinic receptor selectivity of McN-A-343 may not be due to receptor heterogeneity, 86, 610P
EGLEN, R.M., PARK, K.C. & WHITING, R.L. Analysis of the muscarinic agonist action of arecaidine propargyl ester, 86, 397P
- - - Analysis of the positive chronotropic action of 5HT on the isolated guinea-pig atria, 86, 658P
EGLEN, R.M., STRACHAN, A.C. & WHITING, R.L. Action of physostigmine on inotropic and chronotropic selectivity of muscarinic agonists, 85, 213P
EL MURADI, E.M.A. & MCCURRIE, J.R. Comparison of dilator activity in rat hepatic portal vein and rat mesenteric arteries, 85, 339P
ELLIOTT, J.M. see BLOOMFIELD, J.G., 85, 217P, 323P; 86, 402P
ELLIS, C.E. see COLES, D.J., 86, 748P
ELSE, E., ROBERTS, F., SPARROW, P. & HAMPSHIRE, A. A genstat program to calculate dose retios from parallel line assays and/or pA_2 values from a Schild plot, 84, 201P
EMERY,S. see CHENERY, R.J., 84, 164P
EMMETT, J.C. see COATES, W.J., 84, 22P
ENGEL, G., HOYER, D., KALKMAN, H. & WICK, M.B. Pharmacological similarity between the 5-HT-D-receptor on the guinea-pig ileum and the 5-HT_2 binding site, 84, 106P
ENGELS, F., OOSTING, R.S. & NIJKAMP, F.P. Modulation of guinea pig tracheal beta-adrenoceptor function by pulmonary macrophages, 86, 604P
ENNIS, C. Comparison of the α_2-adrenoceptors which modulate noradrenaline release in rabbit and rat occipital cortex, 85, 318P
ENGLAND, P.J. & SHAHID, M. Effects of forskolin on cardiac contractile protein phosphorylation, 86, 508P
ENGLAND, P.J., GRISTWOOD, R.W., LEIGH, B.K., OWEN, D.A.A. & REEVES, M.L. Specific inhibition of type III phosphodiesterase activity, comparison with positive inotropic potency, 86, 631P
ENGLISH, T.A.H. see CAMERON, D., 85, 226P
ESPOSITO, E. see ROMANDINI, S., 86, 702P
ESPOSITO, E., BERETTERA, C., ROMANDINI, S. & SAMANIN, R. Nefopam analgesia and cerebral monoamines, 86, 677P
ESTALL, L. see COOPER, S.J., 84, 96P

ETEMADZADEH, E. see AHTEE, L., 84, 11P
EVANS, D.J. see BLOOMFIELD, J.G., 86, 402P
- - - Effect of prolonged treatment of primary afferent C-fibres with maximal doses of kainate, 85, 375P
EVANS, R.H. see BLAKE, J., 86, 396P
EVIS, M.J., KANE, K.A., MOORE, M.R. & PARRATT, J.R. Effects of chronic low level lead treatment and hypertension on the severity of coronary artery ligation induced arrhythmias, 84, 32P

FABRE, M. see BRILEY, M., 84, 127P
FABBRI, L. see BERTI, F., 86, 773P
FAILLI, P. see BACCARO, C., 86, 621P
FAINGOLD, C.L. see CHAPMAN, A.G., 85, 368P
FAINGOLD, C.L., MELDRUM, B.S. & MILLAN, M. H. Blockade of audiogenic seizure susceptibility by focal injection into the inferior colliculus of an excitant amino acid antagonist, 84, 95P
FAN, T.-P.D. & LEWIS, G.P. Mechanism of cyclosporin A-induced inhibition of prostanoid synthesis by macrophages, 84, 46P
FAN, T.-P.D., KALMAR, L. & LEWIS, G.P. Arachidonic acid metabolites in an air-pouch model of acute inflammation in the rat, 84, 33P
FANO, M. see ABBRACCHIO, M.P., 86, 653P
FANTOZZI, R. see BRUNELLESCHI, S., 86, 574P, 575P, 576P
FARMER, P.B. see CALDWELL, J., 84, 24P
FARMERY, S.M. see CROW, T.J., 84, 8P
FARRANT, M. & WEBSTER, R.A. Effects of Ro 15-1788 on caudate-evoked inhibition of neurones in the rat substantia nigra, 84, 183P
FASEHUN, O.A., JENNETT, S.M., MCGRATH, J. C. & UGWU, A.C. What is a suitable O_2 tension for smooth muscle in vitro? 86, 753P
FASSINA, G., CAPARROTTA, L., FROLDI, G. & POJA, R. (-)N^6-phenylisopropyladenosine competitively inhibits bay K8644, calcium agonist, on isolated guinea-pig atria, 86, 584P
FAULKNER, D. see MACLAGAN, J., 86, 608P
FEATHERSTONE, R.L. see CHURCH, M.K., 86, 484P
FEATHERSTONE, R.L. & MORTON, I.K.M. An examination of the mechanisms of the spasmogenic effects of tachykinins on smooth muscle, 84, 142P
- - - The use of functional antagonism in the determination of fundamental parameters for tachykinin-receptor interactions, 84, 141P
FEATHERSTONE, R.L., FOSBRAEY, P. & MORTON, I.K.M. Use of tachykinin antagonists against eledoisin-evoked neurotransmitter release, 86, 489P
FEELY, J. see PATERSON, J.R., 85, 299P
FEELY, M.P., GENT, J.P., HAIGH, J.R.M. & MEHTA, A. A comparison of tolerance to the anticonvulsant effect of clobazam and its N-desmethyl metabolite in mice, 85, 359P
FENIUK, W. see CONNOR, H.E., 85, 222P
FENIUK, W. see DALTON, D.W., 86, 737P
FENIUK, W., HUMPHREY, P.P.A. & HUNT, A. A.E. The haemodynamic profile and mechanism of the hypotensive action of 5-carboxamido-tryptamine in conscious dogs, 85, 310P
FERNANDEZ, A.G. see BOU, J., 85, 210P
FERRANDON, P. see ARMSTRONG, J.M., 85, 328P; 86, 503P, 718P
FERRANNINI, E. see BETTONI, G., 86, 774P
FERRARI, M. see BOVA, S., 86, 720P
FERRARI, R. see GIAMMETTEO, D., 86, 727P
FERRARI, R., RADDINO, R., BONGRANI, S., & SCHIANTARELLI, P. Protective effect of nicardipine against myocardial ischaemia and reperfusion in isolated rabbit hearts, 86, 722P
FERRETTI, V. see BOREA, P.A., 86, 666P
FERRI, S. see SPAMINATO, S., 86, 528P
FERRIE, J. see BROWN, K.A., 86, 425P
FERTI, C. see GROSSONI, M., 86, 628P
FIGLIOMENI, B., FUSCO, M., VANTINI, G. & GORIO, A. Alterations of 5-HT bulbo spinal system induced by 5,7-HT: effects of monosialoganglioside GM_1, 86, 681P
FILE, S.E. see BRILEY, M., 86, 456P
FILE, S.E. & PELLOW, S. Effects of two ligands for peripheral benzodiazepine binding sites on anxiety and stress in rat, 84, 104P
- - - The benzodiazepine receptor antagonist Ro 15-1788 has anxiogenic activity in four animal tests of anxiety, 84, 103P

FILE, S.E. & WILKS, L.J. Behavioural indices of withdrawal following a single dose of sodium phenobarbitone, 86, 457P
FILIPOWICZ, B. see BHASKAR, N.K., 85, 268P
FILIPPELLI, A. see MARMO, E., 86, 626P
FILIPPELLI, W. see MARMO, E., 86, 626P
FINLAYSON, J.R. see CLAGUE, R.U., 84, 154P
FITTON, J.C. see BRIGGS, I., 85, 380P
- - - see COSTALL, B., 85, 354P
FITZGERALD, M.F. & PARENTE, L. The release of paf-acether and lyso-paf from sensitized guinea-pig lungs, 86, 573P
FITZGERALD, M.F., HENDERSON, B., HIGGS, G. A., PARENTE, L. & PETTIPHER, E.R. The levels of PAF and lyso-PAF in the joint fluids of rabbits with antigen-induced arthritis, 86, 422P
FLEMING, W.W. & HAWTHORN, M.H. Does chronic reserpine pretreatment induce supersensitivity to catecholamines in guinea-pig left atria? 86, 437P
FLETCHER, A. & FORSTER, E.A. Monoamine depletion facilitates leptazol-induced tonic seizures, 85, 365P
- - - The use of p-chloroamphetamine-induced behaviour in rodents as an in vivo screen for 5-HT uptake inhibitors, 85, 358P
FLETCHER, C. see BUCKETT, W.R., 86, 466P
FLINT, K.C. see BROSTOFF, J., 85, 205P
FLINT, O.P., ORTON, T.C. & GIRLING, L.R. In vitro inhibition of chondrogenesis in cultured rat embryo limb cells by thalidomide, 84, 122P
FLOREANI, M., SANTI SONCIN, E., SCANFERLATO, R., DEVETTO, P. & CARPENEDO, F. Cardiac effects of 2 methyl,1-4 naftoquinone (menadione), 86, 726P
FLYNN, S.B., GRISTWOOD, R.W., OWEN, D.A.A. & ROTHAUL, A.L. The cardiac electrophysiological effects of methimazole pre-treatment in the rat, 86, 442P
FOLCO, G.C. see NICOSIA, S., 86, 647P
- - - see OLIVA, D., 86, 805P
FOLCO, G.C., GALLI, G., MAGNI, F., VIGANO, T., CRIVELLARI, M.T. & BERTI, F. Modulation of eicosanoid formation in human lung parenchyma, 86, 645P
FOONG, W.C. & GREEN, K.L. Effect of intra-articular yttrium 90 or chlorambucil on an experimental arthritis, 86, 522P
FORD, A.P.D.W. & MARSDEN, C.A. Influence of anaesthetics on striatal dopamine metabolism in vivo, 86, 692P
FORDER, R.A. see CAREY, F., 84, 34P
FOREMAN, J.C., NORRIS, D.B., RISING, T. J. & WEBBER, S.E. Histamine stimulation of adenylate cyclase in guinea pig lung parenchyma homogenates, 84, 48P
FORSTER, E.A. see FLETCHER, A., 85, 358P, 365P
FORTUNE, D.H., IRELAND, S.J. & TYERS, M.B. 5-hydroxytryptamine-induced hyperpolarisations of the rat isolated superior cervical ganglia and vagus nerve, 84, 49P
FOSBRAEY, P. see FEATHERSTONE, R.L., 86, 489P
FOSBRAEY, P., MORTON, I.K.M. & NEWMAN, C.M. The effect of pertussis toxin pretreatment on μ- and κ-opioid modulation of neurotransmitter output, 86, 705P
FOSTER, D. see BYFORD, A.J., 86, 725P
FOSTER, M.R. see BOUTAL, L.E., 86, 802P
FOSTER, R.W. & HOLLINGSWORTH, M. Microcomputer integration of tension development, a versatile aid to concentration-response data collection and analysis, 85, 389P
FOSTER, R.W., SMALL, R.C., TOWART, R. & WESTON, A.H. Effects of the dihydropyridine BAY K8644 on guinea-pig isolated trachealis, 84, 17P
FOULKES, R. see BENNETT, T., 85, 209P
FOZARD, J.R. & KILBINGER, H. 8-OH-DPAT inhibits transmitter release from guinea-pig enteric cholinergic neurones by activating 5-HT_{1A} receptors, 86, 601P
FOZARD, J.R. & MCDERMOTT, I. The cardiovascular response to 8-hydroxy-2-2(di-n-propylamino)-tetralin (8-OH-DPAT) in the rat, 84, 69P
FOZARD, J.R. & MIR, A. Evidence for a centrally mediated cardiovascular response to 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) in the rat, 84, 167P
FOZARD, J.R., GOWER, A.J. & MIR, A.K. Effect of neurochemical lesions on the cardiovascular responses to 8-hydroxy-2-(DI-N-Propylamino)-tetralin (8-OH-DPAT) in rats, 86, 736P
FOZARD, J.R., HUMPHREYS, A., ROUND, A. & WALLIS, D.I. Further studies on the action of MDL 72222 on responses to 5-HT in rabbit nodose and superior cervical ganglia, 85, 309P

FRANCHI-MICHELI, S. see CIUFFI, M., 86, 637P
FRANCONI, F. see BACCARO, C., 86, 621P
- - - see BENNARDINI, F., 86, 623P
- - - see BRYANT, S.H., 86, 586P
FRANKISH, N.H. A low cost system for on-line analysis of cardiovascular data, 86, 762P
FRASER, S. see EGLEN, R.M., 86, 744P
FRENCH, A.M. & HENDERSON, D. Potentiation of the NANC response in rat vas deferens by α_2-adrenoceptor agonists, 86, 510P
FRENCH, A.M., HENDERSON, D.J. & JEFFERSON, G.C. Effects of allozan diabetes on alpha adrenoceptor sensitivity in rat vas deferens, 86, 746P
FRIEND, J. see BLACKBURN, T.P., 85, 382P
FROIO, F. see DE SARRO, G.B., 86, 676P
FROLDI, G. see FASSINA, G., 86, 584P
FRY, J.R. see BALLS, M., 85, 387P
FRY, J.R. & KAMALI, F. Effects of probenecid on paracetamol metabolism and excretion in man, 84, 139P
- - - Inhibition of paracetamol glucuronidation in rat liver microsomes by probenecid, 84, 134P
FRY, J.R. & PATERSON, P. Influence of lipid solubility on the glucuronidation and sulphation of nitrophenols in rat isolated hepatocytes, 84, 133P
FRYER, A.D. see BLABER, L.C., 85, 393P
- - - see MACLAGAN, J., 86, 608P
FUMAGALLI, R. see OLIVA, D., 86, 805P
FURCHGOTT, R.F., JOTHIANANDAN, D., MARTIN, W. & VILLANI, G.M. Depression of contractile responses by spontaneously released EDRF in rat aorta, 86, 565P
FURMAN, B.L. see MCKECHNIE, K., 84, 119P
FURMAN, B.L. & MCMILLAN, M. Does B.pertussis vaccine increase insulin secretion by antagonism of endogenous catecholamines? 84, 12P
FUSCO, M. see FIGLIOMENI, B., 86, 681P

GABL, M. see BONETTI, E.P., 86, 463P
GADIE, B. see BERRIDGE, T.L., 84, 193P
- - - see DOXEY, J.C., 86, 747P
GADIE, B. & TULLOCH, I.F. Comparison of the mydriatic actions of α_1- and α_2-adrenoceptor agonists in the anaesthetized rat, 86, 742P
- - - Proconvulsant action of α_2-adrenoceptor antagonists in mice: possible involvement of α_1-adrenoceptors, 84, 192P
GAIARDI, M. see BABBINI, M., 86, 707P
GALATULAS, I. see ANDREANI, A., 86, 771P
- - - see BOSSA, R., 86, 772P, 779P
GALLI, A. Effects of various enzymatic treatments on glycine-displaceable [^{3}H]strychnine binding to synaptic membranes of rat spinal cord, 86, 682P
- - - see BARTOLINI, A., 86, 547P
GALLI, G. see FOLCO, G.C., 86, 645P
GALLIANI, G. see BARZAGHI, F., 86, 661P
GALLO, V. see ATTERWILL, C.K., 84, 149P
GALLOWAY, D.J., GEORGE, W.D., MCINTYRE, R. & ZEITLIN, I.J. Intestinal kallikrein and carcinogenesis in rat colon: effect of diet and aprotinin, 86, 490P
GALZIN, A.M. see BENKELFAT, C., 85, 215P
GANELLIN, C.R. see BLAKEMORE, R.C., 86, 570P
GARCHA, H.S., KUMAR, R., NORRIS, E.A., REAVILL, C. & STOLERMAN, I.P. Long-term blockade of nicotine cue by chlorisondamine in rats, 85, 245P
GARCIA, A. see DELGADO, C., 84, 171P
GARCIA-SEVILLA, J.A. & ZUBIETA, J.K. Activation and desensitization of presynaptic alpha-2 adrenoceptors after inhibition of neuronal uptake, 86, 580P
GARDINER, D.G. see BURGES, R.A., 85, 281P
GARDINER, S.M. see BENNETT, T., 85, 209P
GARDNER, C. & TWISSELL, D.J. Evaluation of inhibitors of the renin-angiotensin system in the conscious marmoset (callithrix jacchus), 86, 620P
GEDDES, C. see CURLE, P.F., 84, 197P
GEISOW, H.P. see BOUTAL, L.E., 86, 802P
GEMIGNANI, A. see BONANNO, G., 86, 548P
GENT, J.P. see FEELY, M.P., 85, 359P
GEORGE, P. see ARBILLA, S., 86, 432P
GEORGE, W.D. see GALLOWAY, D.J., 86, 490P
GERMANA, G. see AMMENDOLA, D., 86, 660P
GEROLD, M. see BREWSTER, M., 85, 393P
GERSKOWITCH, V.P. see BLACK, J.W., 85, 258P

GESCHER, A., HARPUR, E.S. & PEARSON, P.G. Strain differences in the hepatotoxicity of N-methylformamide in mice, 86, 514P
GESCHER, A., HARPUR, E.S., KESTELL, P. & PEARSON, P.G. Strain differences in the metabolism of N-methylformamide in mice, 86, 515P
GHELANI, A.M. & RADZIWONIK, H. Effect of cimetidine, timoprazole and atropine on pentagastrin-induced gastric acid secretion in the anaesthetised ferret, 85, 346P
- - - Intragastric pH-metry in the anaesthetised ferret: effect of cimetidine, timoprazole and omeprazole, 86, 784P
GHIRARDI, O., MILANO, S., PESCHECHERA, A., RAMACCI, M.T. & ANGELUCCI, L. Learning and brain monoamines in aging rats: effect of chronic treatment with acetyl-L-carnitine, 86, 683P
GIACHETTI, A. see SCHIAVONE, A., 86, 798P
GIACHETTI, D. see MANTOVANI, P., 86, 778P
GIAGNONI, G. see PAROLARO, D., 86, 619P
GIAMMATTEO, D., CECONI, C., CURELLO, S., BOFFA, G., CARGNONI, A. & FERRARI, R. Effect of L-carnitine, acetyl-L-carnitine and L-propionil-carnitine on lipid peroxidation of cardiac mitochondria, 86, 727P
GIANNELLA, E. see BORGHI-CIRRI, M.B., 86, 775P
GIANNETTI, A. see DEL TACCA, M., 86, 638P
GIBSON, A. & MANNING, M. A uterine-type oxytocin receptor in the male mouse anococcygeus, 86, 678P
GIEMBYCZ, M.A. see JONES, C.R., 85, 265P
GIEMBYCZ, M.A. & RODGER, I.W. Is a reduction in tissue cyclic amp responsible for leukotriene D_4-induced tension development in guinea-pig lung parenchyma? 86, 651P
GIGLIO, C. see CANEVARI, A., 86, 776P
GILBERT, D.B. see COOPER, S.J., 84, 143P
GILL, R. see BOWERY, N.G., 85, 238P
GILL, R., IVERSEN, S.D. & THOMAS, S.R. Anxiolytic action of $GABA_A$ and $GABA_B$ agonists, 85, 252P
GILLAN, M.G.C. see CORBETT, A.D., 86, 704P
GILLESPIE, J.S. see BOWMAN, A., 84, 19P
GILLI, G. see BOREA, P.A., 86, 666P
GIOTTI, A. see BACCARO, C., 86, 621P
- - - see BARTOLINI, A., 86, 547P
- - - see BENNARDINI, F., 86, 623P
- - - see BRUNELLESCHI, S., 86, 575P
- - - see BRYANT, S.H., 86, 586P
GIRGIS, S. see BRAIN, S.D., 85, 233P
GIRLING, L.R. see FLINT, O.P., 84, 122P
GIUBERTONI, M. see DI CARLO, F., 86, 560P
GIULIANI, S. see BARTOLINI, A., 86, 547P
GLEN, J.B. see BLACKBURN, T.P., 86, 497P
GOADBY, P. see BARNES, A., 86, 804P
- - - see BYFORD, A.J., 86, 725P
GODFREY, P.P., MCCLUE, S.J., MINCHIN, M.C.W. & YOUNG, M.M. 8-OH-DPAT stimulates inositol phospholipid breakdown in rat brain slices and rabbit platelets, 86, 446P
- - - Ru 24969, a 5-HT_1 agonist, stimulates inositol phospholipid breakdown in rat brain slices, 84, 112P
GONZALEZ, J.P. see BARASI, S., 84, 116P; 85, 352P
- - - see BENSRETI, M.M., 85, 296P
GONZALEZ, J.P. & STOLZ, J.F. Behavioural effects of 5-HT_1 and 5-HT_2 agonists on naloxone-precipitated morphine abstinence, 86, 444P
- - - Functional antagonism between subtypes of 5-hydroxytryptamine receptors on morphine antinociception, 85, 248P
GONZALEZ, J.P., ROONEY, K.F., SEWELL, R.D.E. & SPENCER, P.S.J. Antinociception produced by a stereoisomer of sulpiride combined with a dopamine D-1 agonist, 86, 709P
GOODWIN, G.M. & HEAL, D.J. DSP-4 lesioning abolishes the enhanced monoamine-mediated behaviour following repeated electroconvulsive shock, 84, 53P
GOODWIN, K. see BROWN, C.M., 86, 600P
GORELLI, B. see MANTOVANI, P., 86, 778P
GORI, E. see PAROLARO, D., 86, 619P
GORIO, A. see DI GIULIO, A.M., 86, 527P
- - - see FIGLIOMENI, B., 86, 681P
- - - see TESSARI, F., 86, 622P
GOWER, A.J. see FOZARD, J.R., 86, 736P
GOWER, A.J. & TRICKLEBANK, M.D. Is the analgesic response to footshock a form of passive avoidance

learning? 85, 246P
GROPPETTI, A. see BIELLA, G., 86, 531P
GROSSONI, M., UKMAR, G., FERTI, C., MONGELLI, N. & CESERANI, R. FCE 22509, a stable carboprostacyclin analogue: antiaggregant, cardiovascular and respiratory activity, 86, 628P
GROWCOTT, J.W. see BILLINGHAM, M.E.J., 85, 272P
- - - see BRIGGS, I., 85, 287P
GRABOWSKI, P.S., KITTERINGHAM, N.R., MAGGS, J.L. & PARK, B.K. The formation and elimination of dinitrophenyl-protein conjugates in vivo in the rat and rabbit, 85, 305P
GRAHAM, C.A. see BALFOUR, D.J.K., 86, 591P
GRAHAM, D. & SCOTT, N.C. Effect of reserpine and cocaine on sensitivity of pre- and post-junctional adrenoceptors in rat vas deferens, 86, 758P
GRAHAM, D., HABERT, E. & LANGER, S.Z. Solubilization of the serotonin transporter complex of rat cerebral cortex, 86, 403P
GRAHAM, D., HABERT, E., LANGER, S.Z. & TAHRAOUI, L. Initial characterization of [^{3}H]paroxetine binding in rat cortical membranes, 84, 58P
GRAHAM, W.C. see CAIRNDUFF, B., 86, 525P
GRAHAM, W.C., MEECHAM, K.G. & PITTAWAY, K.M. The antinociceptive effect of cholecystokinin (26-33) in the mouse, 86, 409P
GRAHAME-SMITH, D.G. & O'SHAUGHNESSY, K. M. Evidence that inhibition of brain protein synthesis inhibits striatal dopamine release, 84, 50P
GRANGER, S.E., HOLLINGSWORTH, M. & WESTON, A.H. Calcium antagonist inhibition of responses of rat uterus to calcium, oxytocin and potassium, 85, 282P
GRANT, M.H. see DI MONTE, D., 86, 559P
GRANT, T.L. & MCGRATH, J.C. Influence of angiotensin II on pressor responses to α-adrenoceptor agonists in the pithed rat, 86, 752P
GRANTHAM, C.J. see BAKHLE, Y.S. 84, 203P
GREEN, A.R. see BENNETT, G.W., 86, 455P
GREEN, A.R. & VINCENT, N.D. GABA synthesis rate and release in rat brain following repeated electroconvulsive shock, 86, 541P
GREEN, A.R., HAYES, C., METZ, A., MINCHIN, M.C.W., WILLIAMS, H. & VINCENT, N.D. Decreased GABA synthesis in regions of rat brain following a seizure, 84, 88P
GREEN, A.R., MINCHIN, M.C.W. & VINCENT, N.D. GABA release in rat brain following a seizure, 84, 89P
GREEN, K.L. see FOONG, W.C., 86, 522P
GREEN, K.L. & SAPRA, M. Effect of topical salbutamol on epidermal proliferation, 86, 502P
GREEN, P.G. & KITCHEN, I. Displacement of [^{3}H]alfentanil from plasma protein binding sites by di-isopropylfluorophosphate, 86, 558P
GREEN, S.E., HODGES, H.M. & SUMMERFIELD, A. Effects of chlordiazepoxide and ethanolamine-O-sulphate on discrimination learning and performance in rats, 84, 74P
GREENGRASS, P.M. see ALABASTER, V.A. 85, 376P
GREENWOOD, D.T., KELLY, E., MARSHALL, P.W. & MITCHELL, K. Failure of vilixazine to inhibit tyramine induced pressor responses in the anaesthetised rat, 86, 479P
GREGG, C.N. & OSBORNE, R.H. Evidence for the presence of 5-HT$_2$ receptors on the rat fundic strip preparation, 85, 312P
GREGORY, C.Y., MCNAMEE, P.M., MARKHAM, A. & MORGAN, R.M. The effect of heavy metals on the biosynthesis of prostaglandins D_2, E_2 and F_2 in rabbit kidney, 86, 812P
GRIEVE, K.L., MURPHY, P.C. & SILLITO, A.M. The actions of VIP and ACH on the visual reponses of neurones in the striate cortex, 85, 253P
GRIFANTINI, M. see CANTONI, O., 86, 563P
GRIFFIN, R. see KERWIN, R.W., 85, 288P
GRIFFITH, T.M. see CHAPPELL, S.P., 85, 266P
- - - see COLLINS, P., 85, 279P, 342P
- - - see EDWARDS, D.H., 85, 341P, 344P
GRIFFITHS, E.C. & WIDDOWSON, P.S. Involvement of other neurotransmitters in TRH-induced wet dog shaking, 86, 458P
GRILL, V. see DECORTI, G., 86, 794P
GRISTWOOD, R.W. see BLAKEMORE, R.C., 86, 630P
- - - see CAMERON, D., 85, 226P
- - - see COATES, W.J., 84, 22P
- - - see ENGLAND, P.J., 86, 631P

- - - see FLYNN, S.B., 86, 442P
GRISTWOOD, R.W., OWEN, D.A.A. & REEVES, M. L. Phosphodiesterase in the guinea-pig cardiac ventricle: specific inhibition of type III activity by SK&F 94120, 85, 224P
GUBELLINI, C. see BABBINI, M., 86, 707P
GUERRA, M.C. see CANTELLI FORTI, G., 86, 554P
GUEUDET, C. see BIZIERE, K., 84, 55P; 85, 385P
- - - see BRIET, C., 85, 383P
GUIDOBONO, F., NETTI, C., SIBILIA, V., VILLA, I. & PECILE, A. Calcitonin inhibition of prolactin release induced by serotonergic drugs, 86, 687P
GUNNING, S.J. see BRADBURY, A.J., 86, 738P
- - - see COSTALL, B., 86, 757P
GURDEN, M.F. see BHALLA, P., 86, 438P
GURNEY, A.M., NERBONNE, J.M. & LESTER, H. A. Photodestruction of nifedipine reveals multiple mechanisms of antagonist action, 84, 18P
GUTH, P.H., OREN-WOLMAN, N. & WHITTLE, B. J.R. Vasoconstrictor activity of leukotriene C_4 and epoxy-methano PGH_2 in the rat gastric submucosa, 84, 37P

HABERT, E. see GRAHAM, D., 84, 58P; 86, 403P
HAIGH, C.G., KAFY, A.M.L. & LEWIS, D.A. The action of putrescine on superoxide production from stimulated polymorphonuclear leucocytes, 86, 516P
HAIGH, J.R.M. see FEELY, M.P., 85, 359P
HALL, J.M. & MORTON, I.K.M. Is inhibitory regulation of adenylate cyclase incolved in the action of spasmogens on intestinal smooth muscle? 86, 731P
HALLOT, A. see BIZIERE, K., 84, 198P; 85, 384P
HALLIDAY, J. & IVESON, C.D. Similar effects of acetylcholine and adenosine on cyclic GMP levels in guinea-pig atria, 84, 150P
HAMILTON, C.A. see DEIGHTON, N.M., 86, 741P
HAMILTON, C.A., JONES, C.R. & REID, J.L. Altered peripheral α_2-adrenoceptor responses in rabbits with perinephritis hypertension, 85, 259P
HAMILTON, T.C., WEIR, S.W. & WESTON, A.H. Comparison of the effects of BRL34915 and verapamil on rat portal vein, 86, 443P
HAMPDEN, C.E. see BOOBIS, A.R., 84, 138P
HAMPSHIRE, A. see ELSE, E., 84, 201P
HAND, J.M. see MUTH, E., 86, 452P
HANDLEY, S.L. & SINGH, L. $GABA_A$ agonists potentiate and baclofen antagonises theL-5-HTP head-twitch, 84, 86P
HANDLEY, S.L., MITHANI, S. & SINGH, L. Locus coeruleus lesions do not affect diazepam- or α-adrenergic-modulation of operant conflict, 84, 87P
HARLAND, R. see ATTERWILL, C.K., 84, 124P
- - - see BROWN, M.J., 84, 64P
HARPUR, E.S. see GESCHER, A., 86, 514P. 515P
HART, G.P. see CHAPMAN, A.G., 85, 368P
HART, S.L. & YADAV, N.K. Involvement of acetylcholine and noradrenaline in stress induced antinociception, 86, 662P
HARTLEY, J.E., STEPHENS, R.J. & THOMPSON, A.M. The effects of drugs on the quantity of food consumed by mice under novel and familiar conditions, 84, 82P
HARVEY, A.L. see ANDERSON, A.J., 86, 588P
- - - see JONES, S.V.P., 86, 587P
HAWKEY, C.J. see BHASKAR, N.K., 85, 268P
HAWKSWORTH, G.M. see BARBER, H.E., 84, 120P
HAWORTH, D. see CAREY, F., 85, 271P; 86, 652P, 656P
HAWTHORN, M.H. see FLEMING, W.W., 86, 437P
HAYES, A.G. see SHEEHAN, M.J., 84, 68P; 85, 393P
HAYES, A.G., SHEEHAN, M.J. & TYERS, M. B. Evaluation of and opioid agonists in the guinea-pig paw pressure test, 86, 703P
HAYES, C. see GREEN, A.R., 84, 88P
HEADLEY, P.M. & O'SHAUGHNESSY, C.T., 86, 700P
HEAL, D.J. see DAVIES, C.L., 84, 54P
- - - see GOODWIN, G.M., 84, 53P
HEAL, D.J., METZ, A. & PHILPOT, J. 5,7-dihydroxytryptamine lesioning increases both 5-HT_2-mediated behaviour and cortical 5-HT_2 receptor number in mice, 85, 311P
HEAPY, C.G. see RUSSELL, N.J.W., 84, 180P
HEARSE, D.J. see CROME, R., 86, 418P, 498P
HEAVEY, D.J. see DOLLERY, C.T., 85, 277P

HEIKKILA, R.E. see BARWELL, C.J., 86, 477P
HEILIGERS, J., MYLECHARANE, E.J. & SAXENA, P.R. Mechanism of tachycardia elicited by 5-hydroxytryptamine in the spinal cat, 85, 218P
HEILIGERS, J., MYLECHARANE, E.J., SAXENA, P.R. & TIO, R. Mediation of cat urinary bladder contractions by 5-hydroxytryptamine via the M- and 5-HT_2 type 5-HT receptors, 85, 393P
HELLEWELL, P.G. & WILLIAMS, T.J. Inhibition of allergic inflammation by PAF antagonists in the rabbit, 86, 572P
HENDERSON, A.H. see CHAPPELL, S.P., 85, 266P, 332P
HENDERSON, A.H. see COLLINS, P., 85, 279P, 342P
HENDERSON, A.H. see EDWARDS, D.H., 85, 341P, 344P
HENDERSON, B. see FITZGERALD, M.F., 86, 422P
HENDERSON, B., HIGGS, G.A., JACKSON, K.E. & SALMON, J.A. Eicosanoid production during the development of antigen-induced chronic arthritis, 85, 276P
HENDERSON, D.J. see FRENCH, A.M., 86, 510P, 746P
HENDERSON, F. see DEMPSTER, J., 86, 675P
- - - see PRIOR, C., 86, 585P
HENDRIE, C.A. Naloxone antagonism of the morphine withdrawal syndrome, 84, 51P
HENSBY, C.N. see DAVIES, J.M., 85, 343P
HENSBY, C.N., SEED, M.P. & WILLIAMS, K.I. Effects of oxytocic drugs on prostaglandin synthesis by human pregnant myometrium, 86, 806P
HENSLER, J.G. see DUBOCOVICH, M.L., 85, 240P; 86, 533P
HERDON, H., NAHORSKI, S.R. & STRUPISH, J. Differences between endogenous and radiolabelled catecholamine release from superfused rat brain slices, 84, 170P
HERMAN, A.G. see COENE, M.-C., 85, 267P
HERNANDEZ, A. see BERTI, F., 86, 773P
HERRON, C.E. see COLLINGRIDGE, G.L., 86, 474P
HEWICK, D.S. see ANDREWS, M., 84, 125P
HEYMAN, J. see COWAN, A., 86, 485P
HEYWOOD, B. see BLACKBURN, T.P., 85, 381P
HIBERT, M. & MIDDLEMISS, D.N. Stereoselective antagonism at the 5-HT autoreceptor by the optical isomers of methiothepin, 84, 65P
HICKS, P.E. see CAVERO, I., 84, 16P; 86, 416P, 436P, 612P, 618P
- - - see DUVAL, N., 86, 764P
HICKS, P.E., LANGER, S.Z. & NAJAR, M. Is idazoxan a partial agonist at presynaptic inhibitory α_1-receptors in SHR tail arteries? 84, 67P
HICKS, P.E., LANGER, S.Z. & VIDAL, M. J. α,β-methylene ATP inhibits the vasoconstriction to periarterial field stimulation in SHR, but not WKY tail arteries in vitro, 85, 225P
HIGGINS, A.J. see BENTHAM, J.M., 86, 810P
- - - see BURGES, R.A., 85, 281P
HIGGINS, C.A. see CUTLER, M.G., 86, 680P
HIGGS, G.A. The mechanism of indomethacin-induced airway hyperreactivity, 85, 223P
- - - see FITZGERALD, M.F., 86, 422P
- - - see HENDERSON, B., 85, 276P
HILDITCH, A. see DREW, G.M., 86, 617P
HILEY, C.R. & NICHOLS, A.J. α_1-adrenoceptor reserve and nifedipine sensitivity of noradrenaline pressor responses in rat superior mesenteric arterial bed, 85, 262P
- - - Effects of intravenous and intrasplenic infusions of glucagon on cardiac output and its distribution in the rat, 84, 157P
HILL, S.J. see DONALDSON, J., 85, 206P; 86, 568P
HILL, S.J., MASON, R. & REFFIN, D. Differential effect of chronic antidepressant administration on entrained circadian wheel-running behaviour in the mouse, 85, 357P
HILLIER, K. see AWARA, W., 86, 429P
- - - see DE LA HUNT, M.N., 86, 428P
HINDS, M. see BUCKETT, W.R., 86, 466P
HINSON, J.P. see PORTER, I.D., 86, 507P
HIRST, B.H. see BLOXHAM, C.A., 85, 232P
HOBAN, R.P. see CANDY, J.M., 86, 607P
HODGES, H.M. see GREEN, S.E., 84, 74P
HOKFELT, T., SHARP, T., UNGERSTEDT, U. & ZETTERSTROM, T. Effect of CCK peptides on dopamine release and metabolism in rat striatum in vivo, 84, 7P
HOLDEN-DYE, L., POAT, J.A. & WOODRUFF, G.N. SCH 23390 lose its high affin-

ity for (^{3}H)-piflutixol binding sites in pig solubilised striatal membranes, 86, 634P
HOLGATE, S.T. see BENYON, R.C., 86, 407P
- - - see CHURCH, M.K., 86, 509P
HOLLINGSWORTH, M. see ABEL, M., 85, 331P
- - - see FOSTER, R.W., 85, 389P
- - - see GRANGER, S.E., 85, 282P
HOLMAN, J.J. see AL-KAZWINI, S.J., 86, 544P
HOLMAN, R.B. & WIDDOWSON, P.S. The effects of substance P on endogenous dopamine release from rat corpus striatum in vitro, 86, 412P
HOLMES, S.W. see COLES, D.J., 86, 748P
HOLMES, S.W. & TRIM, J.L. A re-examination of the actions of prostaglandins E_1, $F_{1\alpha}$ and D_2 administered intracerebro-ventricularly to cats, 84, 36P
HOLT, D.J., HUNT, W.B. & WILKINSON, J. The nature of substance P receptors in the rat gastric corpus strip, 85, 292P
HOLZER, P. see BAILEY, S.J., 86, 410P
HONG, J.F. see DI GIULIO, A.M., 86, 527P
HONG, M., JENNER, P. & MARSDEN, C.D. The interaction of amine-depleting drugs with dopamine receptors in rat brain, 84, 129P
HONG, M., JENNER, P., KILPATRICK, G.J. & MARSDEN, C.D. Effects of one month's administration of amine depleting drugs and neuroleptics to rats on striatal dopamine receptor function, 85, 349P
HORTON, R.W. see CHEETHAM, S.C., 86, 593P
HORTON, R.W. & JAZRAWI, S.P. Noradrenergic receptor binding in brain regions of mice susceptible and resistant to audiogenic seizures, 86, 467P
HORTON, R.W., JENNER, P., MARSDEN, C.D., PRESTWICH, S.A. & RUPNIAK, N.M.J. Alterations in cerebral GABA parameters following treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine, 86, 472P
HOULT, J.R.S. see AGBACK, H., 84, 43P
HOULT, J.R.S. & NOURSHARGH, S. Desensitization of human neutrophil cytosolic calcium changes and degranulation to PAF-acether and FMLP, 84, 169P
HOULT, J.R.S. & PEERS, S.H. Effects of ethanol and mepacrine on arachidonate mobilisation in thrombin and A23187-stimulated platelet phospholipids, 84, 153P
HOWELLS, R.E. see BRECKENRIDGE, A.M., 86, 405P
HOWLETT, G.J. & MCCARTHY, P.S. On the role of α_2-adrenoceptor agents in the morphine abstinence syndrome, 85, 293P
HOYER, D. see ENGEL, G., 84, 106P
HRELIA, P. see CANTELLI FORTI, G., 86, 554P
HU, W.Y. & REIFFENSTEIN, R.J. Acute interactions of ethanol and flurazepam, 86, 768P
HUDSON, A.L. see BOWERY, N.G., 85, 234P, 238P
HUDSON, L.P. & REIFFENSTEIN, R.J. Continuous release in vivo of GABA and other amino acids from rat hippocampus into push-pull perfusates, 86, 536P
HUDSPITH, B. see BROSTOFF, J., 85, 205P
HUDSPITH, M. & LITTLETON, J.M. Effects of ethanol in vitro and in vivo on K^+ -stimulated production of inositol phosphates by phospholipase C in rat brain slices, 84, 130P
HUE, D.P., BEALES, D. & MCLEAN, A.E.M. EDTA enters isolated hepatocytes and protects them against paracetamol injury, 84, 121P
HUGGETT, A.C. see BOOBIS, A.R., 84, 138P
HUGHES, B. see ALLAN, G., 86, 616P
HUGHES, C.L. see BILLINGHAM, M.E.J., 85, 272P
HUGHES, J. see LINGFORD-HUGHES, A.R., 85, 290P
HUGHES, P.J. see BENYON, R.C., 86, 407P
- - - see CHAMBERS, S.D., 86, 400P
HUI, SIU-CHUN, G. see COSTALL, B., 86, 690P
HULL, R.A.D. see BLACK, J.W., 85, 258P
HULME, E.C. see BERRIE, C.P., 84, 4P
HUMPHREY, M.J. see BERESFORD, A.P., 85, 333P
- - - see CONNOR, H.E., 85, 222P
- - - see DALTON, D.W., 86, 595P, 737P
- - - see DODD, N.J., 85, 285P
- - - see FENIUK, W., 85, 310P
HUMPHREYS, A. see FOZARD, J.R., 85, 309P
HUNT, A.A.E. see FENIUK, W., 85, 310P
HUNT, W.B. see HOLT, D.J., 85, 292P
HUNTER, J.C. see BROWN, J.R., 86, 696P
HUNTER, S.C. see BLACKBURN, T.P., 86, 497P

HUSSAINI, I. & MOORE, P.K. Fibrinolytic effect of prostanoids in the rat, 86, 813P
HYLAND, L. see DOCHERTY, J.R., 84, 144P; 85, 260P; 86, 735P

IBBA, M. see ABBIATI, G.A., 86, 659P
IBBA, M., ABBIATI, G.A., ANGELICO, P. & TESTA, R. Imipramine enhances the analgesic effect of morphine but not the electroconvulsive shock-induced analgesia in rats, 86, 706P
IBRAHIM, N., BAGUST, J. & KERKUT, G.A. Differences in responses to GABA of spontaneously active cerebral cells in vitro revealed by inter-spike interval analysis, 86, 471P
IGNESTI, G. see DI SIMPLICIO, P., 86, 777P
IMPERATO, A. & DI CHIARA, G. Opposite effects of μ and κopiate agonists on dopamine release in the N.accumbens and in the caudate of freely moving rats, 86, 532P
IRELAND, S.J. see FORTUNE, D.H., 84, 49P
IRVINE, R.F. see POLLOCK, W.K., 86, 655P
IVERSEN, L.L. see ARKLE, S., 86, 701P
- - - see BRISTOW, D.R., 86, 430P
IVERSEN, S.D. see BOWERY, N.G., 85, 238P
- - - see GILL, R., 85, 252P
IVESON, C.D. see HALLIDAY, J., 84, 150P

JACKSON, A. see COOPER, S.J., 84, 75P
JACKSON, H.C. & SEWELL, R.D.E. Action of opioid antagonists on meptazinol- and levorphanol-induced hyperphagia, 86, 712P
- - - -opioid receptors: a role in the control of appetite in non-deprived rats? 85, 297P
- - - Similar actions of a benzodiazepine agonist and contragonist on ingestive behaviour, 84, 97P
- - - Thiorphan and bestatin: effect on food intake? 86, 459P
JACKSON, K.E. see HENDERSON, B., 85, 276P
JAMIESON, A. see BRIGGS, I., 85, 287P
- - - see CALLEN, T.S. 86, 750P
- - - see RUSSELL, N.J.W., 86, 788P
JAMIESON, A., RUSSELL, N.J.W. & RANCE, M. J. An assessment of the neurogenic component in models of inflammation, 86, 787P
JAMES, I. see CHITRANUKROH, A., 86, 602P
JAMES, I.M. see COOK, P.J., 84, 135P
JANSSENS, W.J. & VAN NUETEN, J.M. Amplification by 5-HT of contractions induced with noradrenaline in the isolated kidney of the rat is increased with age, 86, 597P
JASANI, M.K. see DOWLING, E.J., 84, 35P, 79P
JAUREGUI, J.M. see BOU, J., 85, 210P
JAZRAWI, S.P. see HORTON, R.W., 86, 467P
JEEVANJEE, F., LITTLE, H.J., MARTIN, I. L., NICHOLASS, J.M. & NUTT, D.J. Is FG 7142 mediated kindling due to changes in efficacy at the benzodiazepine/GABA receptor complex? 84, 188P
JEEVANJEE, F., LITTLE, H.J., NICHOLASS, J.M. & NUTT, D.J. Is chronic administration of the benzodiazepine receptor ligand FG 7142 anxiogenic? 84, 186P
JEFFERSON, G.C. see FRENCH, A.M., 86, 746P
JENNER, P. see BAKER, M.K., 84, 181P
- - - see BOYCE, S., 86, 632P
- - - see BRADBURY, A.J., 85, 348P, 350P; 86, 526P, 685P, 691P
- - - see DAVIS, A.S., 85, 247P; 86, 434P
- - - see HONG, M., 84, 129P; 85, 349P
- - - see HORTON, R.W., 86, 472P
JENNER, P., KELLY, E. & MARSDEN, C.D. Dopamine receptors on non-dopamine nigral neurons may mediate dopamine agonist-induced changes in locomotor activity, 84, 85P
JENNER, P., KELLY, E., KILPATRICK, G.J., MARSDEN, C.D. & ROSE, S. Behavioural and biochemical consequence of MPTP administration to the common marmoset, 84, 56P
JENNER, P., KILPATRICK, G.J. & MARSDEN, C.D. Solubilisation of dopamine D_2 receptors from human putamen using the zwitterionic detergent CHAPS, 85, 347P
- - - Thermodynamics of ligand interaction with the dopamine D_2 receptor in native membrane and solubilised environments, 85, 241P
JENNER, P., MARSDEN, C.D. & NOMOTO, M. Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset, 86, 710P
JENNER, P., MARSDEN, C.D. & SIMPSON, M. D.C. Lack of effect of ovine prolactin on specific [^{3}H]-spiperone binding sites in male rat striatum, 86, 469P

JENNETT, S.M. see FASEHUN, O.A., 86, 753P
JEREMY, J.Y. see DANDONA, P., 85, 284P
JERNSTROM, B. see DI MONTE, D., 86, 559P
JESSUP, C.L., JESSUP, R., JOHNSON, M. & WAYNE, M. ICI 159995; a novel thromboxane A_2 receptor antagonist, 86, 808P
JESSUP, R. see JESSUP, C.L., 86, 808P
JEWELL, R. see DE LA HUNT, M.N., 86, 428P
JOHNSON, A.M. & LOUDON, J.M. Interaction of benzodiazepine receptor ligands with ethanol in rodents, 85, 236P
JOHNSON, A.M., NELSON, D.R. & THOMAS, D.R. Effect of paroxetine and other 5-hydroxytryptamine uptake inhibitors on central monoamine uptake in vitro and ex vivo, 85, 221P
JOHNSON, I.R., NICHOLS, C.G. & ROUSE, W. Dependence of Q-A interval upon diastolic blood pressure as well as inotropic state, 86, 763P
JOHNSON, M. see JESSUP, C.L., 86, 808P
JOHNSON, M.A. see CAIRNDUFF, B., 86, 525,
JOHNSON, N. McI. see BROSTOFF, J., 85, 205P
JONES, C.R. see DEIGHTON, N.M., 86, 741P
- - - see HAMILTON, C.A., 85, 259P
JONES, C.R., REID, J.L., RODGER, I.W. & GIEMBYCZ, M.A. α_2-adrenoceptor coupling to adenylate cyclase and adrenaline-induced aggregation of human foetal platelets, 85, 265P
JONES, D. see AWARA, W., 86, 429P
JONES, R.L. see ARMSTRONG, R.A., 84, 147P; 86, 643P
- - - see DONG, Y.J., 86, 807P
JONES, R.L., MACINTYRE, D.E., POLLOK, W.K., SHAW, A.M. & WILSON, N.H. An extreme of thromboxane-like activity, 84, 148P
JONES, R.M. see ADAMS, A.P., 85, 327P
JONES, R.S.G. A comparison of the responses of cingulate cortical neurones to substance P and neurokinin A, 85, 230P
JONES, R.S.G. & OLPE, H-R. Adrenergic inhibition of substance P responses in the cingulate cortex: effects of agonists and antagonists, 84, 2P
JONES, S.V.P., HARVEY, A.L. & MARSHALL, I. G. The effects of two erythrina alkaloids on endplate currents, 86, 587P
JONKMAN, F.A.M., MAN, P.W., THOOLEN, M.J. M.C. & VAN ZWIETEN, P.A. Effects of β-adrenoceptor agonist and antagonist on clonidine and α-methyldopa withdrawal syndromes in rats, 84, 195P
JORDAENS, F. see COENE, M.-C., 85, 267P
JORDAN, C.C. see BROWN, J.R., 86, 696P
JOTHIANANDAN, D. see FURCHGOTT, R.F. 86, 565P
JUSZCZAK, R. & STRANGE, P.G. Preparation of anti-haloperidol antibodies, 84, 110P

KAFY, A.M.L. see HAIGH, C.G., 86, 516P
KAGEY-SOBOTKA, A., LICHTENSTEIN, L.M., ORCHARD, M.A. & PROUD, D. Supernatants from stimulated platelets induce histamine release from human basophils, 85, 345P
KALKMAN, H. see ENGEL, G., 84, 106P
KALMAR, L. see FAN, T.-P.D., 84, 33P
KAMALI, F. see FRY, J.R., 84, 134P, 139P
KAN, J.P. see BIZIERE, K., 86, 404P, 417P
KANE, K.A. see COKER, S.J., 84, 30P
- - - see EVIS, M.J., 84, 32P
KARIM, A.R. see BIRCH, N.J., 84, 23P, 78P; 85, 304P
KARRAN, S.J. see DE LA HUNT, M.N., 86, 428P
KATONA, C.L.E. see CHEETHAM, S.C., 86, 593P
KAY, A.B. see CROMWELL, O., 86, 427P
- - - see MACKAY, J.A., 86, 526P
KEANE, P.E. see CRESPI, F., 85, 372P
KEEN, M. see BERRIE, C.P., 84, 4P
KEENAN, A.K., MARTIN, F. & TREACY, M. Irreversible labelling of the TRH receptor in rat pituitary membranes and GH_3 cells, 84, 101P
KEERY, R.J. & LUMLEY, P. AH 6809, a selective antagonist at the human platelet DP-receptor? 85, 286P
KELLAWAY, I.W., SMITH, A., TAYLOR, G. & WOOLFREY, S.G. Absorption from liposomes administered to the rat lung, 85, 300P
KELLY, E. see GREENWOOD, D.T., 86, 479P
- - - see JENNER, P., 84, 56P, 85P
KELLY, E. & NAHORSKI, S.R. Specific inhibition of D_1-mediated cAMP formation by D_2, muscarinic and opiate receptor stimulation in rat striatum, 86, 633P
KELLY, J. see DETTMAR, P.W., 86, 491P, 613P
KELLY, M.E. see BRADBURY, A.J., 85, 348P; 86, 526P, 685P
KEMP, J.A. see BRISTOW, D.R., 86, 430P

KEMP, J.A., MARSHALL, G.R., WONG, E.H.F. & WOODRUFF, G.N. Pharmacological studies on pitrazepin, a $GABA_A$ receptor antagonist, 85, 237P
KENDALL, D.A. see BATTY, I., 84, 108P
KENDALL, D.A. & NAHORSKI, S.R. Dissociation of cuclic GMP formation and inositol phospholipid hydrolysis in rat brain slices, 86, 545P
- - - Effects of dihydropyridine calcium activators and antagonists on potassium-evoked inositol phospholipid hydrolysis in brain, 86, 526P
KENNEDY, I. see BHALLA, P., 86, 438P
- - - see COLEMAN, R.A., 85, 273P
KENNEDY, I. & ROBERTS, F. Comparison of dose-response curves for full and partial agonists, 86, 755P
KENNEDY, I., WHELAN, C.J. & WRIGHT, G. Further studies on the cardiovascular actions of the leukotrienes in the anaesthetised rat, 86, 523P
KENNEDY, J.F. see CALDWELL, J., 86, 512P
KENNY, B.A., MICHEL, A.D. & WHITING, R.L. The effect of dicyclomine and trifluoperazine on muscarinic receptors, 86, 451P
KERKUT, G.A. see IBRAHIM, N., 86, 471P
KERWIN, R.W., DAWBARN, D., DAVIES, G.J., GRIFFIN, R., YACOUB, M. & MASERI, A. Immunohistochemical localisation of neuropeptide Y in single nerve fibres in fresh human heart, 85, 288P
KESTELL, P. see GESCHER, A., 86, 515P
KEYSELL, G.R. & DAVIES, M.W. The effect of pregnancy and lactation on aldrin metabolism in vitro by rat liver, 86, 513P
KHAN, G. see BERTI, C., 86, 668P
KHOYI, M.A. see AKHTAR-KHAVARI, F., 85, 334P, 336P
KICZINSKA, J. see ALI, H., 85, 302P
KILBINGER, H. see FOZARD, J.R., 86, 601P
KILPATRICK, A.T. see ALPS, B.J., 85, 329P; 86, 669P
- - - see BROWN, C.M., 86, 600P
KILPATRICK, G.J. see HONG, M., 85, 349P
KILPATRICK, G.J. see JENNER, P., 84, 56P; 85, 241P, 347P
KILPATRICK, I.C. & STANCLIFFE, D. On the transmitter chemistry of the thalamo-striatal pathway in the rat, 86, 408P
KIRBY, G.C. & MCQUEEN, D.S. Effects of selective 5-hydroxytryptamine agonists on carotid body chemoreceptor discharge in anaesthetized cats, 86, 733P
KIRKMAN, E. & SCOTT, E.M. The effect of captopril on the baroreceptor reflex in the cat, 84, 21P
KITCHEN, I. see BAILEY, C.C., 85, 291P
- - - see GREEN, P.G., 86, 558P
KITTERINGHAM, N.R. see CHRISTIE, G., 86, 799P
- - - see GRABOWSKI, P.S., 85, 305P
KLEVANS, L.R. see BREWSTER, M., 85, 393P
- - - see NATOFF, I.L., 85, 337P
KORSTANJE, C., THOOLEN, M.J.M.C. & VAN ZWIETEN, P.A. α_1-adrenoceptor mediated contraction by B-HT 920 and ST 587 in rat perfused hindquarters, 84, 179P
KOSHIKAWA, N., SMOKCUM, R.W.J. & STEPHENSON, J.D. Association between down-regulation of cortical 5-HT_2 receptors and waning of a related behavioural response, 84, 113P
KOSTERLITZ, H.W. see CORBETT, A.D. 86, 704P
KRUK, Z.L. & STAMFORD, J.A. Nomifensine increases stimulated dopamine release in vivo by an action on the dopamine storage pool: voltammetric evidence, 86, 635P
KRUK, Z.L., MILLAR, J. & STAMFORD, J.A. Voltammetric detection of dopamine released by stimulation of the MFB in the anaesthetised rat, 84, 199P
KUMAR, R. see GARCHA, H.S., 85, 245P

LACEY, G., NEWSOM-DAVIS, J., VINCENT, A., WHITING, P. & WRAY, D. The effect of monoclonal antibodies on the function of mouse acetyl-choline receptor, 85, 214P
LAL, C. & NAYLOR, I.L. Rat testicular capsule - a tissue for myofibroblast drug sensitivity? 86, 517P
LAMB, R.J. & MILLER, A.A. Effect of lamotrigine and some known anticonvulsant drugs on visually-evoked after-discharge in the conscious rat, 86, 765P
LAMB, R.J., LEACH, M.J., MILLER, A. A. & WHEATLEY, P.L. Anticonvulsant profile in mice of lamotrigine, a novel anticonvulsant, 85, 235P
LAMBERT, J.J. see DURANT, N.N., 86, 609P
- - - see OGG, G.D., 84, 161P
LAMBERT, J.J., NOONEY, J.M. & PETERS, J.A. (+)-tubocurarine activates the nicotinic channels of bovine chromaff in cells, 84, 62P

LAMPA, E. see MARMO, E., 86, 626P
LANE, A.C. see BERRIDGE, T.L., 84, 193P
- - - see DOXEY, J.C., 86, 747P
LANGER, S.Z. see ARBILLA, S., 86, 413P, 432P
- - - see BENKELFAT, C., 85, 215P
- - - see CAVERO, I., 84, 16P
- - - see DUVAL, N., 86, 764P
- - - see GRAHAM, D., 84, 58P; 86, 403P
- - - see HICKS, P.E., 84, 67P; 85, 225P
LANGER, S.Z. & SCHOEMAKER, H. [^{3}H]-diltiazem labels a specific recognition site associated with the calcium channel in the rat cerebral cortex, 85, 278P
LANGER, S.Z., SCHOEMAKER, H. & SEGONZAC, A. Comparative studies on [^{3}H]-paroxetine and [^{3}H]-imipramine binding to human platelets, 84, 59P
- - - [^{3}H]-imipramine and [^{3}H]-paroxetine binding to human platelets: clues to a selectivity paradox from temperature studies, 85, 216P
LATTA, G., SCHROR, K. & VERHEGGEN, R. Different roles for platelet-derived thromboxane A_2 (TXA_2) in platelet activation and coronary arterial vasoconstriction, 84, 41P
LATTIMER, N. see MCADAMS, R.P., 86, 494P
LAVEZZO, A. see BIANCHETTI, A., 86, 790P
LAWANG, A. & SAXENA, P.R. Pharmacological comparison between 5-hydroxytryptamine (5-HT) and 5-carboxamide tryptamine (5-CT), 85, 316P
LAWSON, K. & WEETMAN, F. High doses of indanidine release adrenaline from the rat adrenal glands, 85, 386P
- - - The rat isolated inferior tarsal muscle: a new adrenergically innervated preparation, 85, 283P
LAYCOCK, S.M., SMITH, H. & SPICER, B.A. Rat active peritoneal anaphylaxis, 86, 424P
LE FUR, G. see BENAVIDES, J., 86, 440P
LEACH, M.J. see LAMB, R.J., 85, 235P
LEDDA, F. see BRUNELLESCHI, S., 86, 575P
LEE-TSANG-TAN, L. see ALLAN, G., 86, 439P
LEEB-LUNDBERG, L.M.F. see CARON, M.G., 85, 326P
LEES, G.M. see BORNSTEIN, J.C., 86, 724P
LEES, I.W. & PAYNE, A.N. α-adrenoceptor mediated contractile effects of adrenaline in cat airways, 86, 611P
- - - Isometric measurement of cat trachealis muscle tension in situ, 85, 317P
LEFF, P. see BLACK, J.W., 85, 212P, 258P
LEFEVRE-BORG, F. see CAVERO, I., 84, 16P, 31P; 86, 416P, 618P
LEFKOWITZ, R.J. see CARON, M.G., 85, 326P
LEFOURNIER, C. see ARMSTRONG, J.M., 84, 173P
LEIGH, B.K. see ENGLAND, P.J., 86, 631P
LEIGH, P.J. see ARMSTRONG, R.A., 86, 643P
LEIGH, P.J. & MACDERMOT, J. Spare receptors for prostacyclin (epoprostenol) on NCB-20 cells, 84, 203P
LELLI, G. see ANDREANI, A., 86, 771P
LENNARD, M.S. see AL-ASADY, S.A.H., 85, 306P
- - - see BAX, N.D.S., 84, 137P
LEON, A. see CAVICCHIOLI, L., 86, 671P
LESLIE, G.B. see ATTERWILL, C.K., 84, 124P
LESTER, H.A. see GURNEY, A.M., 84, 18P
LEUNG, K.B.P. see BROSTOFF, J., 85, 205P
LEWIS, A.J. see CARLSON, R.P., 86, 521P
- - - see MUTH, E., 86, 452P
LEWIS, D.A. see BEST, R., 86, 520P
- - - see HAIGH, D.A., 86, 516P
LEWIS, G.P. see FAN, T.-P.D., 84, 33P, 46P
LEWIS, M.J. see CHAPPELL, S.P., 85, 266P, 332P
- - - see COLLINS, P., 85, 279P, 342P
- - - see EDWARDS, D.H., 85, 341P, 344P
LEWIS, P.E. see DOWNES, C.P., 84, 196P
LIBERINI, P., MISSALE, C., MEMO, M., PIZZI, M. & SPANO, P.F. D dopamine receptors and the regulation of aldosterone production, 86, 552P
LIBRI, V. see DE SARRO, G.B., 86, 676P
LICHTENSTEIN, L.M. see KAGEY-SOBOTKA, A., 85, 345P
LIGHTON, C. see BENNETT, G.W., 85, 244P; 86, 455P, 673P
LINGFORD-HUGHES, A.R., CLARK, C.R. & HUGHES, J. Cholecystokinin receptor activation in the pancreas: evidence for an involement of protein kinase C, 85, 290P
LINDSAY, R.M. & BATY, J.D. In vitro studies on the acetylation of sulphamethazine by human whole blood, 85, 378P

LINDSAY, R.M., BATY, J.D. & WAUGH, N.R. The effect of added glucose on the in vitro acetylation of sulphamethazine by human whole blood in healthy and diabetic subjects, 86, 797P
LITTLE, H.J. see JEEVANJEE, F., 84, 188P
LITTLE, H.J. & NUTT, D.J. The effects of β-carbolines in infant rats, 86, 464P
LITTLE, H.J., NUTT, D.J. & TAYLOR, S.C. Kindling with FG 7142 and benzodiazepine -GABA receptor function, 84, 187P
LITTLE, H.J., NUTT, D.J., STANFORD, S.C. & TAYLOR, S.C. Adrenoceptor numbers increase after kindling with the benzodiazepine receptor ligand FG 7142, 85, 369P
LITTLE, H.J., STANFORD, S.C. & TAYLOR, S. C. A single dose of the benzodiazepine receptor ligand FG 7142 causes prolonged β-adrenoceptor up-regulation in mouse brain, 86, 769P
LITTLETON, J.M. see HUDSPITH, M., 84, 130P
LIVINGSTON, A. see BOUCHENAFA, O., 86, 518P
- - - see NOLAN, A.M., 86, 462P
LOCK, E.A. The effect of probenecid on N-acetyl-S-(pentachlorobutadienyl)-L-cysteine-induced nephrotoxicity, 84, 203P
LODGE, D. see ARAM, J.A., 86, 538P
LODGE, D., MARTIN, D. & O'SHAUGHNESSY, C. T. Haloperidol and the actions of N-methylaspartate, ketamine and (+) SKF 10,047 on frog spinal cord, 86, 539P
LODOVICI, M. see BRUNELLESCHI, S., 86, 574P
LOESBERG, C., WOUTERSEN-VAN NIJNANTEN, F. M.A. & NIJKAMP, F.P. Dietary effects on guinea-pig bronchial reactivity to histamine, 86, 569P
LOMBARDELLI, G. see ABBRACCHIO, M.P., 86, 582P
LONG, C.J. & STONE, T.W. Adenosine retardation of adrenoceptor resensitisation in the prostatic rat vas deferens, 85, 340P
- - - The release of endothelium-derived relaxant factor is calcium-dependent, 84, 152P
LONG, S.K., O'SHAUGHNESSY, C.T., POAT, J. A. & TURNBULL, M.J. Studies on the effects of cholecystokinin on cyclic AMP efflux from rat striatal slices, 84, 6P
LONGHI, O.N. see CICCARELLI, R., 86, 672P
- - - see DO IORIO, P., 86, 583P
LONGMAN, S.D. The effects of enalapril upon blood pressure, plasma and tissue angiotensin converting anzyme (ACE) in the rat, 86, 751P
LONGSTAFF, A. see ALI, S.M., 86, 470P
LOO, H. see BENKELFAT, C., 85, 215P
LOPEZ-COLOME, A.M. see ANAND, H., 84, 184P
LORD, J.A.H. see DETTMAR, P.W., 85, 322P
LOUDON, J.M. see JOHNSON, A.M., 85, 236P
LOUTTIT, J.B. see DODDS, M.G., 86, 730P
LOWE, K.C. & MCNAUGHTON, D.C. Intravascular fluid composition following blood replacement with fluosol-DA in the rat, 84, 116P
LOWRY, P.J. see CORDER, R., 85, 231P
LUCIANI, S. see BOVA, S., 86, 624P
LUGINBUHL, B. see DAVIES, J.M., 85, 343P
LUMACHI, B. & SCURI, R. Hexaprazol activity on gastric electrical potential fall by asa in rat, 86, 783P
LUMLEY, C.E. & WALKER, S.R. What is the value of animal toxicology studies beyond 6 months? 84, 117P
LUMLEY, P. see DODD, N.J., 85, 285P
- - - see KEERY, R.J., 85, 286P
LUSCOMBE, G.P. see BUCKETT, W.R., 86, 478P, 590P, 713P

MCADAMS, R.P. & WATERFALL, J.F. The effect of cold and restraint on activation of pre- and post-synaptic α-adrenoceptors in the rat, 86, 493P
MCADAMS, R.P., LATTIMER, N., RHODES, K.F. & WATERFALL, J.F. The effect of age on activation of pre- and postsynaptic α-adrenoceptors in the rat, 86, 494P
MCALLISTER-WILLIAMS, R.H. & MITCHELL, R. Benzodiazepines regulate coupling to anion channels in only some $GABA_A$ receptor complexes, 84, 60P
MCARDLE, C.A. see BATES, R.F.L., 86, 809P
MCBAIN, C.J. see BORNSTEIN, J.C., 86, 724P
MCCARTHY, P.S. see BLACKMAN, D.E., 85, 292P

- - - see HOWLETT, G.J., 85, 293P
MCCARTHY, T.M. see AGBACK, H., 84, 43P
MCCLEARY, W.L. see BENSRETI, M.M., 85, 296P
MCCLELLAND, G.R., SEMPLE, J.M., SHORTER, J.H. & WATERFIELD, S. Use of microprocessor technology in a test battery for psychopharmacological volunteer studies, 84, 202P
MCCLUE, S.J. see GODFREY, P.P., 84, 112P; 86, 446P
MCCURRIE, J.R. see EL MURADI, E.M.A., 85, 339P
MACDERMOT, J. see ARMSTRONG, R.A., 86, 643P
- - - see LEIGH, P., 84, 203P
MCDERMOTT, I. see FOZARD, J.R., 84, 69P
MACDONALD, A. see DETTMAR, P.W., 86, 491P; 613P
MACDONALD, A. & MCFRATH, J.C. Effects of cocaine on catecholamine-induced inhibition of nerve-induced responses in rat vas deferens, 86, 566P
MCGIFF, J.C. see CARRARA, M.C., 84, 39P
MCGRATH, J.C. see BULLOCH, J.M., 86, 745P
- - - see DALY, C.J., 86, 723P
- - - see FASEHUN, O.A., 86, 753P
- - - see GRANT, T.L., 86, 752P
- - - see MACDONALD, A., 86, 566P
MACINTYRE, D.E. see BUSHFIELD, M., 84, 28P; 86, 577P
- - - see DRUMMOND, A.H., 84, 27P
- - - see JONES, R.L., 84, 148P
- - - see MCNICOL, A., 86, 546P
MACINTYRE, D.E. & MACMILLAN, L.J.M. Inositol phospholipid hydrolysis and Ca^{2}+ flux in the responses of rat platelets to ADP and thrombin, 84, 25P
- - - Rat platelets and cultured promegakaryoblasts share a common purinoreceptor, 86, 581P
MACINTYRE, D.E. & ROSSI, A.G. Inhibition of agonist-induced Ca^{2+} flux in human neutrophils by tumour promoting phorbol esters, 85, 377P
- - - Phosphoinositide metabolism and cytosolic free Ca^{2+} in leukotriene B_4(LTB_4)-induced activation of human neutrophils, 86, 654P
MACINTYRE, I. see BRAIN, S.D., 85, 233P
MCINTYRE, R. see GALLOWAY, D.J., 86, 490P
MACKAY, J.A., CROMWELL, O. & KAY, A.B. A rapid method for identification of high molecular weight neutrophil chemotactic activity from human lung, 86, 526P
MCKEAN, C.E. see BULLOCK, J.M., 86, 745P
MCKECHNIE, K., FURMAN, B.L. & PARRATT, J.R. Effect of antioxidants on endotoxin shock in conscious, unrestrained rats, 84, 119P
MCKENNIFF, M.G. see BROWN, C.M., 86, 766P
MCKERNAN, R.M. see DICKINSON, K.E.J., 86, 492P
MCKILLOP, C.M., BROCK, J.A.C. & RHODES, C. A comparison of the ability of pyrethroids and the veratrum alkaloids to induce cutaneous sensory effects, 84, 123P
MACLAGAN, J. see BLABER, L.C., 85, 393P
MACLAGAN, J., FRYER, A.D. & FAULKNER, D. Post-ganglionic neuronal muscarinic receptors in transmurally stimulated guinea-pig trachea, 86, 608P
MCLEAN, A.E.M. see CROOK, T., 84, 128P
- - - see HUE, D.P., 84, 121P
MACLEAN, M.R. & UNGAR, A. The interaction of naloxone and captopril on the control of catecholamine release from the adrenal medulla of the dog, 86, 761P
MCLEAN, W.G. see BEAHON, S.J., 84, 81P
MACMILLAN, L.J.M. see MACINTYRE, D.E., 84, 25P; 86, 581P
MCMILLAN, M. see FURMAN, B.L., 84, 12P
MCMILLAN, R.M. see MASTERS, D.J., 84, 45P
MCMILLAN, R.M., MASTERS, D.J. & STERLING, W.W. Modulation of leukotriene B_4 biosynthesis in human leukocytes, 84, 44P
MCNAMEE, P.M. see GREGORY, C.Y., 86, 812P
MCNAMEE, P.M., MARKHAM, A. & SWEETMAN, A.J. Flufenamic acid inhibits prostaglandin F_2, E_2 and D_2 biosynthesis in guinea-pig lung, 86, 811P
- - - Flufenamic acid promotes the uptake of calcium across the human red blood cell plasma membrane, 86, 505P
MCNAUGHTON, D.C. see LOWE, K.C., 84, 116P
MCNICOL, A. see BUSHFIELD, M., 86, 577P
- - - see DRUMMOND, A.H., 84, 27P
MCNICOL, A. & MACINTYRE, D.E. Reversal of agonist-induced phosphoinositide hydrolysis in human platelets by cAMP and 1,2-diacylglycerol, 86, 546P

MCPHERSON, G.A., MOLENAAR, P., MALTA, E. & RAPER, C. Influence of assay buffer on dissociation constants of drugs at subtypes of β-adrenoceptors, 84, 84P
MCQUADE, J. see BOOBIS, A.R., 86, 511P
MCQUEEN, D.S. see KIRBY, G.C., 86, 733P
MCQUEEN, J.K., MARTIN, M.J. & SALAMONE, J. Deoxyglucose uptake in rat cerebral cortex following ibotenic acid lesions of the nucleus basalis magnocellularis, 86, 674P
MCRITCHIE, B. & MINER, W. Dopamine antagonist activity is not a pre-requisite for increasing gastric emptying in the rat with benzamides, 84, 100P
MACCARI, F., PESSOTTO, P., ARSENI, A., RAMACCI, M.T. & ANGELUCCI, L. Exogenous L-carnitine is absorbed by the rat intestine at a dose-dependent wide dose range, 86, 800P
MACHIN, I. see DODD, M.G., 85, 335P; 86, 488P
MADEDDU, L., SCHEER, H., WANKE, E. & MELDOLESI, J. Ion transport activated by latrotoxin and congeners at the pre-synaptic membrane, 86, 564P
MAGGS, J.L. see CHRISTIE, G., 86, 799P
- - - see GRABOWSKI, P.S., 85, 305P
MAGNI, F. see FOLCO, G.C., 86, 645P
MAGUIRE, J.J., MARSHALL, R.W. & WOODRUFF, G.N. A microcomputer method to aid in vitro screening of novel compounds for pharmacological activity, 85, 388P
MAGUIRE, M. see SWART, S.S., 84, 63P
MAGUIRE, M.E. see CROME, R., 86, 498P
MAIDMENT, N.T. & MARSDEN, C.A. Central dopamine metabolism monitored by in vivo voltammetry: effects of acute and chronic neuroleptic administration, 85, 239P
MAIN, I.H.M. & WILSON, G.A.M. Effects of forskolin, an adenylate cyclase activator, on gastric acid secretion in the rat, in vivo and in vitro, 86, 426P
MAJOR, J.S. see CALLEN, T.S., 86, 750P
MALLARDI, F. see DECORTI, G., 86, 794P
MALMBERG-AIELLO, P. see BARTOLINI, A., 86, 547P
MALTA, E. see MCPHERSON, G.A., 84, 84P
MAMBRINI, M. see BRYANT, S.H., 86, 586P
MAN, P.W. see JONKMAN, F.A.M., 84, 195P
MANARA, L. see BIANCHETTI, A., 86, 790P
- - - see CROCI, T., 86, 782P
MANNAIONI, P.F. see BORGHI-CIRRI, M.B., 86, 775P
- - - see BRUNELLESCHI, S., 86, 574P, 576
MANNING, A.S. see CROME, R., 86, 418P, 498P
MANNING, M. see GIBSON, A., 86, 678P
MANOURY, Ph. see CAVERO, I., 84, 31P
MANTEGAZZA, P. see DI GIULIO, A.M., 86, 527P
MANTEGAZZA, P., ROVATI, L.C., SACERDOTE, P. & PANERAI, A.E. Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin, 86, 530P
MANTOVANI, M. see NIADA, R., 86, 625P
MANTOVANI, P., GIACHETTI, D., TADDEI, E. & GORELLI, B. 4-aminopyridine and gastric secretion, 86, 778P
MANZONI, L. see BIANCHETTI, A., 86, 790P
MARCHI, M. see BONANNO, G., 84, 190P
MARKHAM, A. see GREGORY, C.Y., 86, 812P
- - - see MCNAMEE, P.M., 86, 505P, 811P
MARMO, E., ROSSI, F., LAMPA, E., FILIPPELLI, W., BERRINO, L., FILIPPELLI, A., RUSSO, S., MATERA, C. & MATERA, M.G. Participation of opiate peptidergic, gabaergic and prostaglandin: mechanisms in the cardiovascular effects of clonidine, 86, 626P
MARRIOTT, D.B. see BOARDER, M.R., 86, 482P
MARRIOTT, J.F. see DOWNING, O.A., 84, 163P; 86, 504P
MARRS, T.C. see BRIGHT, J.E., 85, 301P; 86, 740P
MARRS, T.C. see BROWN, R.F.R., 86, 729P
MARSDEN, C.A. see BENNETT, G.W., 85, 244P; 86, 455P, 673P
- - - see FORD, A.P.D.W., 86, 692P
- - - see MAIDMENT, N.T., 85, 239P
MARSDEN, C.A. & MARTIN, K.F. In vivo voltammetric evidence that the 5-HT autoreceptor is not of the 5-HT_{1A} sub-type, 86, 445P
- - - RU 24969 decreases 5-HT release in the SCN by acting on 5-HT receptors in the SCN but not the dorsal raphe, 85, 219P
MARSDEN, C.A. & ROUTLEDGE, C. Electrical stimulation of rat C1 neurones increases blood pressure and extracellular hypothalamic adrenaline, 86, 415P

MARSDEN, C.A., MARTIN, K.F. & WEBB, A.J. Diurnal variation in 5-HT_1 receptor function, 86, 398P
MARSDEN, C.D. see BAKER, M.K., 84, 181P
- - - see BOYCE, S., 86, 632P
- - - see BRADBURY, A.J., 85, 348P, 350P; 86, 526P, 685P, 691P
- - - see DAVIS, A., 85, 247P; 86, 434P
- - - see HONG, M., 84, 129P; 85, 349P
- - - see HORTON, R.W., 86, 472P
- - - see JENNER, P., 84, 56P, 85P; 85, 241P, 347P; 86, 469P, 710P
MARSHALL, G.R. see BRISTOW, D.R., 86, 430P
- - - see KEMP, J.A., 85, 237P
MARSHALL, I. see AL-KAZWINI, S.J., 86, 544P, 679P
MARSHALL, I.G. see DEMPSTER, J., 86, 675P
- - - see JONES, S.V.P., 86, 587P
- - - see PRIOR, C., 86, 585P
MARSHALL, P.W. see GREENWOOD, D.T., 86, 479P
MARSHALL, R.W. see DAVIES, J.A., 85, 392P
- - - see MAGUIRE, J., 85, 388P
MARSHALL, R.W. & SPRIGGS, T.L.B. A versatile microcomputer system to automate in vitro pharmacological experiments, 85, 392P
MARTELLI, C. see CAGIANO, R., 86, 789P
MARTELLI, F. see ANTONETTI, F., 86, 714P, 715P
MARTIN, D. see LODGE, D., 86, 539P
MARTIN, F. see KEENAN, A.K., 84, 101P
MARTIN, I.L. see JEEVANJEE, F., 84, 188P
- - - see WUSTEMAN, M., 85, 363P
MARTIN, J., SALAICES, M., TAMARGO, J. & TEJERINA, T. Effects of oxodipine on vascular smooth muscle fibres, 86, 500P
MARTIN, K.F. see MARSDEN, C.A., 85, 219P; 86, 398P, 445P
MARTIN, M.J. see MCQUEEN, J.K., 86, 674P
MARTIN, W. see FURCHGOTT, R.F., 86, 565P
MARTIN, W. & SMITH, J.A. Binding of nitrovasodilators and bovine retractor penis inhibitory factor by haemoglobin and methaemoglobin immobilized on agarose, 86, 567P
MARTINEZ, J. see BRIET, C., 85, 383P
MARTIRE, M. see PREZIOSI, P., 86, 542P
MASERI, A. see KERWIN, R.W., 85, 288P
MASINI, E. see BORGHI-CIRRI, M.B., 86, 775P
- - - see BRUNELLESCHI, S., 86, 574P, 576P
MASON, D.F.J. & MEDBAK, S. The effect of nitroprusside on circulating MET-enkephalin levels in dogs, 86, 411P
MASON, R. Characterisation of 5-HT sensitive neurones in the rat CNS using ionophoresed 8-OH-DPAT and ketanserin, 86, 433P
- - - see BUCKETT, W.R., 86, 466P
- - - see HILL, S.J., 85, 357P
MASON, S.T. β-blockade with propranolol causes resistance to extinction in rats, 84, 76P
MASSINGHAM, R. see BOU, J., 85, 210P
MASSOTTI, M. An eeg study of the inverse benzodiazepine agonists in the rabbit, 86, 688P
MASTERS, D.J. see MCMILLAN, R.M., 84, 44P
MASTERS, D.J., SPRUCE, K.E., VICKERS, V.C. & MCMILLAN, R.M. Measurement of arachidonate metabolism using cyanopropyl mini-columns: effects of cyclo-oxygenase and lipoxygenase inhibitors, 84, 45P
MATERA, C. see MARMO, E., 86, 626P
MATERA, M.G. see MARMO, E., 86, 626P
MATTHEWS, D.M. see CLARK, B.F., 86, 795P
MATUCCI, R. see BENNARDINI, F., 86, 623P
MAURA, G. see BONANNO, G., 86, 548P
MAZEL, P. see CALLINGHAM, B.A., 86, 553P
MAZZEI, T., MINI, E. & PERITI, P. 5-methyltetrahydrofolate (MeTHF) enhances fluoropyrimidine cytotoxicity against human leukemia cells in vitro, 86, 561P
MAZZONI, L., MORLEY, J., PAGE, C.P., SANJAR, S. Prophylactic anti-asthma drugs impair the airway hyper-reactivity that follows exposure to platelet activating factor (PAF), 86, 571P
MEDBAK, S. see MASON, D.F.J., 86, 411P
MEECHAM, K.G. see CAIRNDUFF, B., 86, 525P
- - - see GRAHAM, W.C., 86, 409P
MEHTA, A. see FEELY, M.P., 85, 359P
MEHTA, H. Effect of thyroxine on ventricular adenosine triphosphatase activity in guinea-pigs, 86, 792P

MEGHJI, P. & NEWBY, A.C. Dipyridamole, dilazep and hexobendine inhibit both adenosine uptake into and release from neonatal rat heart cells in culture, 85, 280P
MELDOLESI, J. see MADEDDU, L., 86, 564P
MELDRUM, B.S. see CAVALHEIRO, E.A., 85, 367P
- - - see FAINGOLD, C.L., 84, 95P
MELDRUM, B.S., TURSKI, L. & WATKINS, J.C. Anticonvulsant action of γ-D-glutamyl-amino-methylsulphonic acid in mice, 85, 370P
MELLERUP, E.T. & PLENGE, P. High affinity binding sites for [^{3}H]-imipramine and [^{3}H]-paroxetine in platelet and neuronal membranes, 84, 203P
MEMO, M. see LIBERINI, P., 86, 552P
MEMO, M., CASTELLETTI, A., VALERIO, A., MISSALE, C. & SPANO, P.F. Characterization of neurotensin receptors associated with calcium channels and prolactin release in rat pituitary, 86, 543P
MENYS, V.C. see BUTLER, K.D., 86, 556P
METZ, A. see GREEN, A.R., 84, 88P
- - - see HEAL, D.J., 85, 311P
MERLO PICH, E. see ROMANDINI, S., 86, 702P
MEZZETTI, M. see NICOSIA, S., 86, 647P
MIAN, M. see BRUNELLESCHI, S., 86, 575P
MICHALEK, R. see ARKLE, S., 86, 701P
MICHAUD, J.C. see BIZIERE, K., 84, 198P
MICHEL, A.D. see EGLEN, R.M., 86, 610P
- - - see KENNY, B.A., 86, 451P
MICHEL, A.D. & WHITING, R.L. Agonist affinity for α-adrenoceptors, 86, 495P
- - - Analysis of pharmacological concentration-response curves (CRCs) with a BBC microcomputer, 86, 816P
MICHELETTI, R. see SCHIAVONE, A., 86, 798P
MIDDLEMISS, D.N. β-adrenoceptor antagonists and blockade of the 5-HT autoreceptor in rat frontal cortex, 84, 189P
- - - [^{3}H]-8-OH-DPAT does not bind to the 5-HT autoreceptor in rat striatum, 85, 315P
- - - see HIBERT, M., 84, 65P
MIDDLEMISS, D.N., NEILL, J. & TRICKLEBAMK, M.D. Subtypes of the 5-HT receptor involved in hypothermia and forepaw treading induced by 8-OH-DPAT, 85, 251P
MIHALY, G.W. see BRECKENRIDGE, A.M., 86, 405P
MIKHAILIDIS, D.P. see DANDONA, P., 85, 284P
MILANO, S. see GHIRARDI, O., 86, 683P
MILES, C.M.M. see DICKINSON, K.E.J., 86, 492P
MILLAN, M.H. see FAINGOLD, C.L., 84, 95P
MILLAR, J. see KRUK, Z.L., 84, 199P
MILLER, A.A. see LAMB, R.J., 85, 235P; 86, 765P
MILLER, A.A. & WHEATLEY, P.L. Anticonvulsant action of labotrigine, phenytoin and phenobarbitone on electrically-induced after-discharge, 85, 366P
MILLER, R.C., SCHINI, V., SCHOEFFTER, P. & SPEDDING, M. Modification of the effects of BAY K8644 in rat aorta by the endothelium, 84, 20P
MINCHIN, M.C.W. see GODFREY, P.P., 84, 112P, 446P
- - - see GREEN, A.R., 84, 88P, 89P
MINER, W. see MCRITCHIE, B., 84, 100P
MINI, E. see MAZZEI, T., 86, 561P
MIR, A.K. Cardiovascular responses to nifedipine in combination with β-adrenoceptor antagonists or clonidine in conscious SH rats, 86, 719P
- - - see FOZARD, J.R., 84, 167P; 86, 736P
MIRANDA, G.F., CASSISI, M. & BIANCHETTI, A. The effect of anoretic agents on cafeteria diet-induced hyperphagia and overweight, 86, 689P
MISSALE, C. see LIBERINI, P., 86, 552P
- - - see MEMO, M., 86, 543P
MITCHELL, K. see GREENWOOD, D.T., 86, 479P
MITCHELL, P. see BROWN, F., 84, 185P
MITCHELL, R. see ANDERSON, R.A., 84, 5P
- - - see MCALLISTER-WILLIAMS, R.H., 84, 60P
MITCHELL, R. & OGIER, S.-A. A novel stimulatory action of somatostatin on prolactin secretion, 86, 698P
MITHANI, S. see HANDLEY, S.L., 84, 87P
MITOLO-CHIEPPA, D. see BENOIT, E., 86, 549P, 665P
MITOLO-CHIEPPA, D. see BENOIT, E., 86, 665P
MOHD YUSOFF, Z. Effects of thyroxine on the frequency-force relationship of isolated and paced left atria of guinea-pigs, 86, 501P
MOHLER, H. see BONETTI, E.P., 86, 463P
MOLENAAR, P. see MCPHERSON, G.A., 84, 84P

MOLLOY, A.G. & WADDINGTON, J.L. Mechanism of paradoxical blockade of D_2 agonist induced stereotypy by the enantiomers of the D_1 antagonist SK&F 83566, 85, 242P
- - - Spontaneous orofacial dyskinesia during long-term depot neuroleptic treatment: interactions with age, 84, 71P
MONCADA, S. see BAKHLE, Y.S., 84, 38P; 86, 423P
MONGELLI, N. see GROSSONI, M., 86, 628P
MONS, G. see BIZIERE, K., 86, 417P
MONTORSI, L. see BACCARO, C., 86, 621P
MOORE, M.R. see CUTLER, M.G., 86, 680P
- - - see EVIS, M.J., 84, 32P
MOORE, P.K. see HUSSAINI, I., 86, 813P
MORET, C. see BRILEY, M., 85, 220P
MORETTI, A. see CARFAGNA, N., 86, 670P
MORGAN, R.M. see GREGORY, C.Y., 86, 812P
MORICE, A., SCHACHTER, M. & SEVER, P.S. Characterisation of high-affinity binding sites for vasoactive intestinal peptide (VIP) in human lung, 86, 697P
MORINAN, A. & PARKER, V. Are socially isolated rats anxious? 86, 460P
- - - Evidence for a lack of memory impairment in socially isolated rats, 86, 420P
MORL, C.J. see CAMERON, D., 85, 226P
MORLEY, J. see MAZZONI, L., 86, 571P
MORLEY, M.J. see BRADSHAW, C.M., 85, 356P; 86, 419P
MORONI, F. see BONGIANNI, F., 86, 529P
MORRE, M. see CRESPI, F., 85, 372P
MORRIS, H.R. see BRAIN, S.D., 85, 233P
MORRISON, K.J. & PERTWEE, R.G. A possible link between delta-9-tetrahydrocannabinol and GABA in mice, 86, 684P
MORTON, I.K.M. see FEATHERSTONE, R.L., 84, 141P, 142P; 86, 489P
- - - see FOSBRAEY, P., 86, 705P
- - - see HALL, J.M., 86, 731P
MOSBERG, H.I. see COWAN, A., 85, 294P
MOSER, P.C. & REDFERN, P.H. Behavioural parameters of 5-HT_1 receptor stimulation do not show circadian variation, 86, 461P
- - - The discriminative stimulus properties of 5-HTP are mediated by the 5-HT_1 receptor, 84, 70P
MOUGET-GONIOT, C. see BIZIERE, K., 86, 417P
MUIR, A.G.B. see DALY, C.J., 86, 723P
MUIR, T.C. see ALLCORN, R.J., 85, 263P
- - - see BEATTIE, D.T., 84, 29P
MUNDAY, K.A. see COX, H.M., 86, 486P, 487P
MURPHY, J.J. & RYAN, M.P. The effects of propranolol on ^{86}Rb effluxes in rat thymocytes and human peripheral blood lymphocytes, 84, 26P
MURPHY, P.C. see GRIEVE, K.L., 85, 253P
MUSCHOLL, E. see BOHM, E., 86, 534P
MUSCHOLL, E. & RACKE, K. Release of endogenous dopamine and its metabolites from the neurointermediate lobe of the rat hypophysis in vitro, 84, 3P
MUTH, E., LEWIS, A.J., DERVINIS, A., HAND, J.M., ROTHBERG, K. & DOUGLAS, J.S. A comparison of the muscarinic and histamine H_1 receptor binding activities of thiazinamium chloride and its major metabolites, 86, 452P
MYLECHARANE, E.J. see HEILIGERS, J., 85, 218P, 393P

NACCARI, F. see AMMMENDOLA, D., 86, 660P
NADALINI, V.F. see CANEVARI, A., 86, 776P
NAHORSKI, S.R. see BATTY, I., 84, 108P
- - - see HERDON, H., 84, 170P
- - - see KELLY, E., 86, 633P
- - - see KENDALL, D.A., 86, 526P, 545P
NAHORSKI, S.R. & ROONEY, T.A. Regional differences in agonist and depolarisation-induced inositol phospholipid hydrolysis in rat brain, 86, 667P
NAHORSKI, S.R. & STRUPISH, J. Dopamine D_2 receptors regulate spontaneous and veratrine-evoked release of endogenous dopamine from striatal slices, 84, 109P
NAJAR, M. see HICKS, P.E., 84, 67P
NATOFF, I.L. see BREWSTER, M., 85, 393P
NATOFF, I.L., BREWSTER, M., PATEL, A. T., KLEVANS, L. & WENGER, J. Effect of indomethacin on the antihypertensive and sympathetic inhibitory activities of ACE inhibitors in the rat, 85, 337P
NAYLOR, I.L. see LAL, C., 86, 517P
NAYLOR, R.J. see BARNES, J.C., 86, 695P
- - - see BARNES, N.J.G., 86, 468P, 708P
- - - see BRADBURY, A.J., 85, 348P, 350P; 86, 526P, 685P, 691P, 738P
- - - see COSTALL, B., 85, 250P, 353P, 354P; 86, 690P, 757P

NAYLOR, V.J.H. see BLACKMAN, D.E., 85, 295P
NAVARRA, P.L. see VACCA, M., 86, 793P
NEDERGAARD, O.A. Pre- and post-junctional effects of pinacidil on sympathetic neuroeffector transmission in rabbit blood vessels, 85, 338P
NEILL, J. see MIDDLEMISS, D.N., 85, 251P
NEILSON, D.G. see OGG, G.D., 84, 161P
NELSON, D.R. see JOHNSON, A.M., 85, 221P
NERBONNE, J.M. see GURNEY, A.M., 84, 18P
NETTI, C. see GUIDOBONO, F., 86, 687P
NEWBY, A.C. see EDWARDS, D.H., 85, 344P
- - - see MEGHJI, P., 85, 280P
NEWMAN, C.M. see FOSBRAEY, P., 86, 705P
NEWSOM-DAVIS, J. see LACEY, G., 85, 214P
NIADA, R., PORTA, R., MANTOVANI, M., PESCADOR, R. & PRINO, G. Defibrotide's thrombolytic activity on thrombi of different ages in the rabbit, 86, 625P
NICHOLASS, J.M. see JEEVANJEE, F., 84, 186P, 188P
NICHOLLS, P.J. see ABDUL, R., 85, 371P
- - - see ALI, H., 85, 302P
- - - see ALLEN, E.M., 85, 303P
NICHOLS, A.J. see HILEY, C.R., 84, 157P; 85, 262P
NICHOLS, C.G. see JOHNSON, I.R., 86, 763P
NICHOLSON, J.K. see TULIP, K., 84, 136P
NICOSIA, S. see OLIVA, D., 86, 805P
NICOSIA, S., CIVELLI, M., ROVATI, G.E., OLIVA, D., SAUTEBIN, L., FOLCO, G.C. & MEZZETTI, M. Specific binding of leukotriene C_4 (LTC_4) to membranes from human lung parenchima and bronchi, 86, 647P
NIGLIO, T. see SAGRATELLA, S., 86, 694P
NIJKAMP, F.P. see ENGELS, F., 86, 604P
- - - see LOESBERG, C., 86, 569P
- - - see VAN OOSTERHOUT, A.J.M., 86, 785P
NISTICO, G. see AMMMENDOLA, D., 86, 660P
- - - see DE SARRO, G.B., 86, 676P
NISTRI, A. see BERTI, C., 86, 668P
NISTRI, A. & SIVILITTI, L. Effects of glycine on synaptic transmission in the frog optic tectum in vitro, 86, 537P
NOE, A. see OLIVA, D., 86, 805P
NOLAN, A.M., LIVINGSTON, A. & WATERMAN, A. The use of a thermal stimulus device to assess analgesics in the sheep, 86, 462P
NOMOTO, M. see JENNER, P., 86, 710P
NOONEY, J.M. see LAMBERT, J.J., 84, 62P
NORKENSKJOLD, M. see DI MONTE, D., 86, 559P
NORMAN, S. see BADAWY, A.A.-B, 85, 298P
NORN, S. see CHURCH, M.K., 86, 509P
NORRIS, A.A. see BLACKHAM, A., 86, 786P
NORRIS, D.B. see FOREMAN, J.C., 84, 48P
NORRIS, E.A. see GARCHA, H.S., 85, 245P
NOTARIANNI, L.J. see AIRD, S.A., 86, 796P
NOURSHARGH, S. see HOULT, J.R.S., 84, 169P
NUTT, D.J. see JEEVANJEE, F., 84, 186P, 188P
- - - see LITTLE, H.J., 84, 187P; 85, 369P; 86, 464P
O'BOYLE, K.M. & WADDINGTON, J.L. Binding of [^{3}H]-SCH 23390, a selective D-1 dopamine receptor antagonist in human brain, 86, 435P
- - - Striatal [^{3}H]-spiperone binding after long-term depot neuroleptic treatment: interactions with age, 84, 73P
O'BRIEN, J.W. see DALY, C.J., 86, 723P
O'NEIL, G.S. see ALI, S.M., 86, 470P
O'SHAUGHNESSY, C.T. see HEADLEY, P. M., 86, 700P
- - - see LODGE, D., 86, 539P
- - - see LONG, S.K., 84, 6P
O'SHAUGHNESSY, K.M. see GRAHAME-SMITH, D.G., 84, 50P
OGIER, S.-A. see MITCHELL, R., 86, 698P
OGLE, C.W. see COSTALL, B., 86, 690P
OHIA, S.E. see BOYLE, F.C., 84, 42P; 86, 648P
OLDHAM, A.A. see CALLEN, T.S., 86, 750P
OLDHAM, A.A. & SCOTCHER, K.P. Interactions between angiotensin II, the sympathetic nervous system and blood pressure of the pithed rat, 86, 749P
OLDHAM, H.G. see CHENERY, R.J., 84, 164P
OLIVA, D. see NICOSIA, S., 86, 647P

OLIVA, D., NOE, A., DRAGO, L., CORSINI, A., FUMAGALLI, R., FOLCO, G.C. & NICOSIA, S. 5Z-carbacyclin discriminates between PGI_2-receptors on vascular smooth muscle cells and platelets: agonist/antagonist properties, 86, 805P
OLPE, H-R. see JONES, R.S.G. 84, 2P
OMINI, C. see ABBRACCHIO, M.P., 86, 653P
- - - see BERTI, F., 86, 773P
ONONIWU, I.M. see ADEBANJO, A.O., 85, 243P, 355P
OOSTING, R.S. see ENGELS, F., 86, 604P
ORCHARD, M.A. see KAGEY-SOBOTKA, A., 85, 345P
OREN-WOLMAN, N. see GUTH, P.H., 84, 37P
ORTON, T.C. see FLINT, O.P., 84, 122P
OSBORNE, R.H. Is RU24969 a 5-HT_2 antagonist on the rat fundic strip preparation? 86, 447P
- - - see GREGG, C.N., 85, 312P
OWEN, D.A.A. see BLAKEMORE, R.C., 86, 630P
- - - see CAMERON, D., 85, 226P
- - - see COATES, W.J., 84, 22P
- - - see ENGLAND, P.J., 86, 631P
- - - see FLYNN, S.B., 86, 442P
- - - see GRISTWOOD, R.W., 85, 224P
OWEN, F. see CROW, T.J., 84, 8P

PACIFICI, L., BOTARELLI, M., RAMACCI, M. T. Effect of propionyl-L-carnitine-taurine amide on recovery of cardiac functions as after ischemic hypoxia in rat working heart, 86, 728P
PACIFICO, P. see CANEVARI, A., 86, 776P
PACIOREK, P.M. & SHEPPERSON, N.B. Estimates of the antagonist potency of WY 26392 against various α_2-adrenoceptor agonists in the pithed rat, 85, 321P
- - - Evidence for an indomethacin sensitive α_1-adrenoceptor mediated modulation of responses in the pithed rat heart, 84, 40P
PADRINI, R. see BOVA, S., 86, 720P
PALFREYMAN, M.G. see SLEIGHT, A.J., 86, 480P
PALMI, M. & SGARAGLI, G.P. Hyperthermia induced in rabbits by AMBD and organic calcium antagonists: its reversal by taurine, 86, 693P
PALOMO, T. see CURLE, P.F., 84, 197P
PANERAI, A.E. see MANTEGAZZA, P., 86, 530P
PANKHANIA, J.J. see BAKHLE, Y.S., 85, 275P
PAO, G.J-K. see CHURCH, M.K., 86, 509P
PARENTE, L. see FITZGERALD, M.F., 86, 422P, 573P
PARENTI, M. see BIELLA, G., 86, 531P
- - - see DI GIULIO, A.M., 86, 527P
PARK, B.K. see CHOLERTON, S., 86, 406P
- - - see CHRISTIE, G., 86, 799P
- - - see GRABOWSKI, P.S., 85, 305P
PARK, K.C. see EGLEN, R.M., 86, 397P, 658P
PARKE, D.V. see DOWLING, E.J., 84, 35P, 79P
PARKER, S.J. see CHEETHAM, S.C., 86, 593P
PARKER, V. see MORINAN, A., 86, 420P, 460P
PAROLARO, D., SALA, M., CREMA, G., GIAGNONI, G. & GORI, E. Periaqueductal gray matter as a site of central inhibition of intestinal motility in the rat, 86, 619P
PARRATT, J.R. see COKER, S.J., 84, 30P
- - - see EVIS, M.J., 84, 32P
- - - see MCKECHNIE, K., 84, 119P
PARRATT, J.R. & WAINWRIGHT, C.L. The effects of adenosine on arrhythmias induced by myocardial ischaemia and reperfusion in dogs, 85, 228P
PARSONS, M.E. see BLAKEMORE, R.C., 86, 570P, 630P
PATACCHINI, R. see BARTOLINI, A., 86, 547P
PATEL, A.T. see BREWSTER, M., 85, 393P
- - - see NATOFF, I.L., 85, 337P
PATEL, R. see BEST, R., 86, 520P
PATEL, S. & SLATER, P. Serotonin receptor subtypes in rat basal forebrain and their role in nucleus accumbens-evoked activity, 85, 314P
PATERSON, J.R., STEVENSON, I.H. & FEELY, J. Metabolism of H_2-antagonists by a flavin-containing monooxygenase, 85, 299P
PATERSON, P. see FRY, J.R., 84, 133P
PATERSON, S.J. see CORBETT, A.D., 86, 704P
PATMORE, L. see BROWN, C.M., 86, 766P
- - - see CLARKE, B., 85, 330P; 86, 760P
PATMORE, L. & WHITING, R.L. Measurement of inotropic responses of cultured heart cells using a video

tracking device, 86, 817P
PAYNE, A.N. see LEES, I.W., 85, 317P; 86, 611P
PEARCE, F.L. see BROSTOFF, J., 85, 205P
PEARSON, P.G. see GESCHER, A., 86, 514P, 515P
PECILE, A. see GUIDOBONO, F., 86, 687P
PEDATA, F. see VANNUCCHI, M.G., 86, 606P
PEDDER, E.K. & PRINCE, A.K. Ethylcholine mustard aziridinium: inhibition of rat brain synaptosome choline uptake and choline acetyltransferase, 84, 114P
- - - The reaction of O-acetylethylcholine mustard aziridinium with rat brain choline acetyltransferase, 84, 115P
PEERS, S.H. see HOULT, J.R.S., 84, 153P
PELLEGRINI, D. see BONGIANNI, F., 86, 529P
PELLOW, S. see BRILEY, M. 86, 456P
PELLOW, S. see FILE, S.E., 84, 103P, 104P
PENINGTON, N.J. & REIFFENSTEIN, R.J. Microiontophoetic application of the hallucinogen dom facilitates facial motor neurone excitation, 86, 550P
PEPEU, G. see VANNUCCHI, M.G., 86, 606P
PERIO, A. see BIZIERE, K., 84, 146P
PERITI, P. see MAZZEI, T., 86, 561P
PERREN, M.J. see CONNOR, H.E., 85, 222P
PERRY, R.H. see CANDY, J.M., 84, 90P
PERSICHELLA, M. see BETTONI, G., 86, 774P
PERTWEE, R.G. see MORRISON, K.J., 86, 684P
PESCADOR, R. see NIADA, R., 86, 625P
PESCHECHERA, A. see GHIRARDI, O., 86, 683P
PESSOTTO, P. see MACCARI, F., 86, 800P
PETERS, J.A. see DURANT, N.N., 86, 609P
- - - see LAMBERT, J.J., 84, 62P
PETERS, J.R. see CARON, M.G., 85, 326P
PETERS, R.F. see DOWLING, E.J., 84, 35P, 79P
PETTIPHER, E.R. see FITZGERALD, M.F., 86, 422P
PHILLIPS, J.A. see AGBACK, H., 84, 43P
PHILPOT, J. see HEAL, D.J., 85, 311P
PICERNO, N. see BIANCHETTI, A., 86, 790P
PIERCE, V. & SHEPPERSON, N.B. Comparison of the cardiovascular effects of central and peripheral administration of indoramin in anaesthetised rats, 84, 162P
PIEDIMONTE, G. see CANTONI, O., 86, 563P
PIERI, L., BIRY, P. & WDONWICKI, G. Proconvulsant action of Ro 15-3505, the 7-chloro analogue of Ro 15-1788, on isoniazid convulsions in rats, 86, 592P
PILCHER, C.W.T. see BROWNE, J.L., 86, 483P
PIOVAN, D. see BOVA, S., 86, 720P
PIPER, P.J. see BARNETT, K., 86, 642P
PIPER, J. & STANTON, A.W.B. Leukotrienes C_4 and D_4 decrease intracranial blood flow in the anaesthetised pig, 85, 270P
PIPER, P.J. & STEWART, A.G. Platelet-activating factor induces the release of leukotriene-like material from rat isolated, perfused hearts, 86, 814P
PIRISINO, R. see DI SIMPLICIO, P., 86, 777P
PITTAWAY, K.M. see GRAHAM, W.C., 86, 409P
PIZZI, M. see LIBERINI, P., 86, 552P
PLATT, K. see DE LA HUNT, M.N., 86, 428P
PLENGE, P. see M ELLERUP, E.T., 84, 203P
PLEVIN, R. see COX, H.M., 86, 486P
POAT, J.A. see ARKLE, S., 86, 701P
- - - see COX, H.M., 86, 486P, 487P
- - - see HOLDEN-DYE, L., 86, 634P
- - - see LONG, S.K., 84, 6P
POIRIER, M.F. see BENKELFAT, C., 85, 215P
POJA, R. see FASSINA, G., 86, 584P
POLC, P. Interactions of partial inverse benzodiazepine agonists Ro 15-4513 and FG 7142 with ethanol in rats and cats, 86, 465P
POLI, E. see BERTACCINI, G., 86, 641P
POLLOCK, W.K. see JONES, R.L., 84, 148P
POLLOCK, W.K., IRVINE, R.F., & RINK, T.J. Differential Ca^{2+} sensitivity of arachidonate liberation evoked by collagen and ionomycin in FURA2-loaded human platelets, 86, 655P
POLLONI, A. see DEL TACCA, M., 86, 638P
POYSER, N.L. & RILEY, S.C. Effect of actinomycin on prostaglandin $F_{2\alpha}$ output from the guinea-pig uterus

superfused in vitro, 86, 644P
PORRECA, F. see COWAN, A., 85, 294P
PORTA, R. see NIADA, R., 86, 625P
PORTALEONE, P. see DI CARLO, F., 86, 560P
PORTER, I.D., WHITEHOUSE, B.J., VINSON, G. P. & HINSON, J.P. Effects of increasing potassium ion concentration on steroid secretion from the in situ perfused rat adrenal gland, 86, 507P
PORTER, J.C. see CALLINGHAM, B.A., 86, 553P
PORTER, M. see BORKOWSKI, K.R., 84, 158P
POULTER, M. see CROW, T.J., 84, 8P
PRENTIS, R.A. & WALKER, S.R. Pharmaceutical innovation in the UK (1964-1980), 84, 118P
PRESTWICH, S.A. see DOLPHIN, A.C., 86, 526P
- - - see HORTON, R.W., 86, 472P
PREZIOSI, E. see BENOIT, E., 86, 549P
- - - see VACCA, M., 86, 793P
PREZIOSI, P. & CIABATTONI, G. Isolated and ventilated guinea-pig lung: a method for studying drug interaction with cyclooxygenase and lipoxygenase pathways, 86, 649P
PREZIOSI, P., CERRITO, F., DEL CARMINE, R., CARMIGNANI, M., MARTIRE, M. & VACCA, M. Central norepinephrinergic neurotransmission and adrenocortical activation by hydroxyurea - a new α_2-blocking agent? 86, 542P
PRICE, G.W. see BOWERY, N.G., 85, 234P, 238P
PRINCE, A.K. see PEDDER, E.K., 84, 114P, 115P
PRINO, G. see NIADA, R., 86, 625P
PRIOR, C. see DEMPSTER, J., 86, 675P
PRIOR, C., DEMPSTER, J., HENDERSON, F. & MARSHALL, I.G. Chloramphenicol simultaneously produces endplate ion channel block and slows channel closing rate, 86, 585P
PROSDOCIMI, M. see TESSARI, F., 86, 622P
PROUD, D. see KAGEY-SOBOTKA, A., 85, 345P
PUGLISI, L., CHINETTI, L., ACCOMAZZO, M. R. & SCHATTON, W. Antilipolytic and antiinflammatory action of a new nicotinic acid derivative in tha rat, 86, 646P

QUATTRONE, G. see SQUADRITO, F., 86, 629P
QUINN, M.J. see CONOLAN, S., 86, 399P

RACAGNI, G. see CAGIANO, R., 86, 789P
RACCA, S. see DI CARLO, F., 86, 560P
RACKÉ, K. see BÖHM, E., 86, 534P
- - - see MUSCHOLL, E., 84, 3P
RADDINO, R. see FERRARI, R., 86, 722P
RADZIWONIK, H. see GHELANI, A.M., 85, 346P; 86, 784P
RAITERI, M. see BONANNO, G., 84, 190P; 86, 548P
RAMACCI, M.T. see GHIRARDI, O., 86, 683P
- - - see MACCARI, F., 86, 800P
- - - see PACIFICI, L., 86, 728P
RAMAGE, A.G. Effects of ritanserin and cinanserin on the cardiovascular system of the cat, 86, 598P
- - - see CORDER, R., 85, 231P
RAMAN, V. see ALI, S.M., 86, 470P
RAMBALDI, M. see ANDREANI, A., 86, 771P
RAMPART, M. & WILLIAMS, T.J. Inhibition of PMN-dependent oedema formation in rabbit skin by systemic treatment with catalase and 15-methyl -PGE_1, 85, 274P
RANCE, M.J. see JAMIESON, A., 86, 787P
- - - see RUSSELL, N.J.W., 84, 180P; 86, 788P
- - - see TRAYNOR, J.R., 84, 52P
RANDALL, J.I. see RODGERS, R.J., 84, 105P
RANDO, S. see ANTONELLI, T., 86, 535P
RAPER, C. see MCPHERSON, G.A., 84, 84P
RASMUSSEN, A.C. see BLAKEMORE, R.C., 86, 570P
RAWLINGS, D.A. see BLAKEMORE, R.C., 86, 570P
REAVILL, C. see GARCHA, H.S., 85, 245P
REES, C., ROBERTS, F., BLAKEMORE, R.B., COTTERELL, P. & MARLOW, S. An automated bioassay system using an Apple 11E microcomputer, 84, 200P
REEVES, J.J. & STABLES, R. Antisecretory activity of the prostaglandin endoperoxide analogue, U46619, on the rat isolated gastric mucosa, 86, 524P
REEVES, M.L. see ENGLAND, P.J., 86, 631P
- - - see GRISTWOOD, R.W., 85, 224P
REDFERN, P.H. see MOSER, P., 84, 70P; 86, 461P
- - - see SLEIGHT, A.J., 86, 480P

REFFIN, D. see HILL, S.J., 85, 357P
REGGIANI, A. see SALA, R., 86, 603P
REID, J.L. see DEIGHTON, N.M., 86, 741P
- - - see HAMILTON, C.A., 85, 259P
- - - see JONES, C.R., 85, 265P
REIFFENSTEIN, R.J. see HU, W.Y., 86, 768P
- - - see HUDSON, L.P., 86, 536P
- - - see PENINGTON, N.J., 86, 550P
RENNA, G. see CAGIANO, R., 86, 789P
RENNIE, J.A. see CAPASSO, F., 86, 650P
RENZI, A. see BARTOLINI, A., 86, 547P
RESTELLI, G.V. see ABBIATI, G.A., 86, 659P
REYNOLDS, G.P. see CHEETHAM, S.C., 86, 593P
- - - see WUSTEMAN, M., 85, 363P
REZAEI, E. see AKHTAR-KHAVARI, F., 85, 334P, 336P
RHODES, C. see MCKILLOP, C.M., 84, 123P
RHODES, K.F. see MCADAMS, R.P., 86, 494P
RHODES, K.F. & WATERFALL, J.F. Differences in the sensitivity of regions of the canine saphenous vein to α_1 and α_2-adrenoceptor selective agonists, 86, 496P
RIBEIRO, J.A. & SEBASTIAO, A.M. The effects of forskolin and papaverine on nerve conduction in the presence of tetrodotoxin, 85, 362P
RICHMOND, R. see DOLLERY, C.T., 85, 277P
RILEY, S.C. see POYSER, N.L., 86, 644P
RINK, T.J. see POLLOCK, W.K., 86, 655P
RISING, T.J. see BOTTOMLEY, K.M.K., 84, 47P
- - - see FOREMAN, J.C., 84, 48P
RIVIERE, J.H. see BACK, D.J., 86, 801P
ROACH, A.G. see BERRIDGE, T.L., 84, 193P
- - - see BROADLEY, K.J., 85, 324P; 86, 699P
- - - see DETTMAR, P., 86, 519P
- - - see DOXEY, J.C., 86, 747P
ROACH, A.G. & VIRDEE, N.K. Effects of aptazapine, mianserin and idazoxan on pressor responses to α-agonists, tyramine and 5-HT in pithed rats, 86, 743P
ROBERTS, F. Measuring the dissociation constant of a partial agonist from its interaction with a full agonist, 85, 307P
- - - see DAVIES, P., 84, 175P
- - - see ELSE, E., 84, 201P
- - - see KENNEDY, I., 86, 755P
ROBERTS, L. see BROADLEY, K.J., 85, 320P
ROBERTS, M.H.T. see DAVIES, M., 85, 255P; 86, 594P
ROBERTS, P.J. see ANAND, H., 84, 184P; 86, 473P
- - - see DAVIES, S.W., 86, 450P
ROBERTS, P.J., SCHWARCZ, R. & SHARPE, J.A. Do L-glutamate binding sites on human erythrocyte plasma membranes provide a model for CNS excitatory amino acid receptors? 85, 374
ROBERTSON, D. & SMITH, G.M. The role of products of platelet activation in collagen-induced death in rabbits, 86, 578P
ROBERTSON, M.J. Endothelium-dependent, calcium-induced relaxation of vascular smooth muscle, 86, 506P
RODGER, I.W. see GIEMBYCZ, M.A., 86, 651P
- - - see JONES, C.R., 85, 265P
RODGERS, R.J. & RANDALL, J.I. Strain differences in behaviourally-induced antinociception and morphine analgesia in male mice, 84, 105P
RODIER, D. see BIZIERE, K., 85, 384P
ROMA, A., ARMSTRONG, R.L., JONES, R.L., LEIGH, P.J., MACDERMOT, J. & WILSON, N.H. Novel prostaglandin endoperoxide analogues which block thromboxane receptors and mimic prostacyclin, 86, 643P
ROMANDINI, S. see ESPOSITO, E., 86, 677P
ROMANDINI, S., MERLO PICH, E., ESPOSITO, E. & SAMANIN, R. Is the effect of intracerebroventricular 5,7-dihydroxytryptamine on morphine analgesia time-dependent? 86, 702P
ROMUALDI, P. see SPAMPINATO, S., 86, 528P
ROONEY, K.F. see GONZALEZ, J.P., 86, 709P
ROONEY, T.A. see NAHORSKI, S.R., 86, 667P
ROSE, S. see JENNER, P., 84, 56P
ROSSI, A.G. see DRUMMOND, A.H., 84, 27P
- - - see MACINTYRE, D.E., 85, 377P; 86, 654P
ROSSI, F. see MARMO, E., 86, 626P
ROTHAUL, A.L. see FLYNN, S.B., 86, 442P
ROTHBERG, K. see MUTH, E., 86, 452P
ROTIROTI, D. see AMMMENDOLA, D., 86, 660P
ROUND, A. see FOZARD, J.R., 85, 309P

ROUND, A. & WALLIS, D.I. Selective blockade by ICS 205-930 of 5-HT depolarisations of the rabbit vagal afferent and sympathetic gaglion cells, 86, 734P
ROUNDING, H.P. & TOWART, R. The effect of nifedipine on bronchoconstriction in the guinea-pig in vivo, 84, 15P
ROUSE, W. see JOHNSON, I.R., 86, 763P
ROUTLEDGE, C. see MARSDEN, C.A., 86, 415P
ROUTLEDGE, P.A. see WATT, A.H., 84, 140P
ROVATI, G.E. see NICOSIA, S., 86, 647P
ROVATI, L.C. see MANTEGAZZA, P., 86, 530P
RUCCI, L. see BORGHI-CIRRI, M.B., 86, 775P
RUDD, R.M. see DICKINSON, K.E.J., 85, 256P
RUPNIAK, N.M.J. see HORTON, R.W., 86, 472P
RUSSELL, N.J.W. see CALLEN, T.S., 86, 750P
- - - see JAMIESON, A., 86, 787P
RUSSELL, N.J.W., HEAPY, C.G. & RANCE, M. J. Naloxone induced desensitisation of perivascular nociceptors in the isolated perfused rabbit ear, 84, 180P
RUSSELL, N.J.W., JAMIESON, A., CALLEN, T. S. RANCE, M.J. Peripheral opioid receptors, extravasation, neurogenic inflammation, 86, 788P
RUSSO, S. see MARMO, E., 86, 626P
RUTTERFORD, M.G. see BLOOMFIELD, J.G., 85, 217P, 323P
RYAN, M.P. see MURPHY, J.J., 84, 26P
RYLEY, H.C. see EDWARDS, D.H., 85, 341P

SACERDOTE, P. see MANTEGAZZA, P., 86, 530P
SAGRATELLA, S., NIGLIO, T. & SCOTTI DE CAROLIS, A. An investigation on the anticonvulsant activity of phencyclidine and ketamine in rabbits, 86, 694P
SALA, M. see PAROLARO, D., 86, 619P
SALA, R., CARENZI, A., REGGIANI, A. & DELLA BELLA, D. Effect of the new β_2-agonist broxaterol on receptor-mediated lipolysis and pulmonary surfactant release in isolated cell systems, 86, 603P
SALAICES, M. see MARTIN, J., 86, 500P
SALES, G.D. see CAGIANO, R., 86, 789P
SALMON, J.A. see BAKHLE, Y.S., 84, 38P; 86, 423P
- - - see HENDERSON, B., 85, 276P
SALAMONE, J. see MCQUEEN, J.K., 86, 674P
SAMANIN, R. see ESPOSITO, E., 86, 677P
- - - see ROMANDINI, S., 86, 702P
SANGSTER, S.A. see CALDWELL, J., 84, 24P
SANJAR, S. see MAZZONI, L., 86, 571P
SANTI SONCIN, E. see FLOREANI, M., 86, 726P
SAPRA, M. see GREEN, K.L., 86, 502P
SARRET, M. see AGOZZINO, S., 86, 716P
SASTRY, B.R. Leupeptin does not block the induction of long-lasting potentiation in hippocampal CA_1 neurones, 86, 589P
SAUTEBIN, L. see NICOSIA, S., 86, 647P
SAWYER, R. see DOCHERTY, J.R., 84, 145P
SAXENA, P.R. An interactive computer programme for data management and parametric and nonparametric statistical analysis, 86, 818P
- - - Heart rate responses to selective agonists of 5-hydroxytryptamine$_1$ receptors in the spinal cat, 86, 599P
- - - see DUNCKER, D.J., 86, 596P
- - - see HEILIGERS, J., 85, 218P, 393P
- - - see LAWANG, A., 85, 316P
SCANFERLATO, R. see FLOREANI, M., 86, 726P
SCARPONI, U. see CESERANI, R., 86, 780P
SCATTON, B. see DENNIS, T., 84, 93P
SCHACHTER, M. see MORICE, A., 86, 697P
SCHATTON, W. see PUGLISI, L., 86, 646P
SCHEER, H. see MADEDDU, L., 86, 564P
SCHIANTARELLI, P. see FERRARI, R., 86, 722P
SCHIANTARELLI, P. & BONGRANI, S. Cardiovascular and bronchodilating properties of trapidil, 86, 732P
SCHIAVONE, A., ANGELICI, O., MICHELETTI, R. & GIACHETTI, A. M_1 muscarinic antagonists selectively inhibit vagally-induced acid secretion, 86, 798P
SCHINETTI, M.L. & BERTELLI, A. Effect of anthracyclines on superoxide production and metabolic activity of human neutrophils, 86, 562P
SCHINI, V. see MILLER, R.C., 84, 20P
SCHOEFFTER, P. see MILLER, R.C., 84, 20P

SCHOEMAKER, H. see LANGER, S.Z., 84, 59P; 85, 216P, 278P
SCHROR, K. see LATTA, G., 84, 41P
SCHWARCZ, R. see ROBERTS, P.J., 85, 374P
SCHWARTZMAN, M. see CARRARA, M.C., 84, 39P
SCOTCHER, K.P. see CALLEN, T.S., 86, 750P
- - - see OLDHAM, A.A., 86, 749P
SCOTT, E.M. see KIRKMAN, E., 84, 21P
SCOTT, N.C. see BRADLEY, H.A., 86, 767P
- - - see GRAHAM, D., 86, 758P
SCOTT, R.H. see DUCE, I.R., 86, 431P
SCOTTI DE CAROLIS, A. see SAGRATELLA, S., 86, 694P
SEBASTIAO, A.M. see RIBEIRO, J.A., 85, 362P
SECHTER, D. see BENKELFAT, C., 85, 215P
SEED, M.P. see HENSBY, C.N., 86, 806P
SEGONZAC, A. see LANGER, S.Z., 84, 59P; 85, 216P
SEMPLE, J.M. see MCCLELLAND, G.R., 84, 202P
SENIOR, J. see BARNES, N.J.G., 85, 289P
- - - see DESTA, B., 86, 791P
SESARDIC, D. see BOOBIS, A.R., 86, 511P
SESTILI, P. see CANTONI, O., 86, 563P
SEVER, P.S. see DICKINSON, K.E.J., 85, 256P; 86, 492P
- - - see MORICE, A., 86, 697P
SEWELL, R.D.E. see BARASI, S., 84, 166P; 85, 35P
- - - see BENSRETI, M.M., 85, 296P
- - - see GONZALEZ, J.P., 86, 709P
SEWELL, R.D.E. see JACKSON, H.C., 84, 97P; 85, 297P; 86, 459P, 712P
SGARAGLI, G.P. see DELLA CORTE, L., 86, 557P
- - - see PALMI, M., 86, 693P
SHAHID, M. see ENGLAND, P.J., 86, 508P
SHAND, R.A. see BUTLER, K.D., 86, 556P
SHANKLEY, N.P. see BLACK, J.W., 85, 212P
SHARIF, N.A. Low-affinity substance P receptors modulate TRH-receptor interactions: tissue specificity and effects of other drugs, 84, 66P
SHARMA, R.P. see COX, H.M., 86, 487P
SHARP, T., see HOKFELT, T., 84, 7P
SHARP, T., UNGERSTEDT, U. & ZETTERSTROM, T. Effect of dopamine D-1 receptor selective drugs on dopamine release and metabolism in rat brain in vivo, 84, 191P
SHARPE, J.A. see ROBERTS, P.J., 85, 374P
SHAW, A.M. see JONES, R.L., 84, 148P
SHAW, J.S. Threshold effects: a source of error in pA_2 determinations, 86, 770P
SHAW, L. see AL-ASADY, S.A.H., 85, 306P
SHAW, R.J. see CROMWELL, O., 86, 427P
SHEEHAN, M.J. see HAYES, A.G., 86, 703P
SHEEHAN, M.J. & HAYES, A.G. Opioid receptors in the hamster vas deferens, 85, 393P
SHEEHAN, M.J., HAYES, A.G. & TYERS, M.B. Irreversible block of K receptors in the guinea-pig ileum, 84, 68P
SHELDRICK, R.L.G. see COLEMAN, R.A., 85, 273P; 86, 803P
SHEPPERSON, N.B. see PACIOREK, P.M., 84, 40P; 85, 321P
SHERIDAN, D.J. see BROADLEY, K.J., 84, 194P; 85, 261P, 320P; 86, 759P
SHERIDAN, R.D. see BRADSHAW, C.M., 84, 1P; 86, 395P
SHORTER, J.H. see MCCLELLAND, G.R., 84, 202P
SILBERSTEIN, D.J. see BOWMER, C.J., 84, 132P
SIBILIA, V. see GUIDOBONO, F., 86, 687P
SILLITO, A.M. see GRIEVE, K.L., 85, 253P
SIMMONDS, S.H. & STRANGE, P.G. Effect of D_2 dopamine receptor on inositol phosphokipid metabolism in anterior pituitary, 84, 111P
SIMONATO, M. see ANTONELLI, T., 86, 535P
SIMPSON, K.H. see COSTALL, B., 86, 757P
SIMPSON, M.D.C. see JENNER, P., 86, 469P
SINGH, L. see HANDLEY, S.L., 84, 86P, 87P
SINISCALCHI, A. see BEANI, L., 86, 664P
SIVILOTTI, L. The frog optic tectum in vitro is a useful preparation for studies on the pharmacology of central transmitters, 84, 102P
- - - see NISTRI, A., 86, 537P
SKAN, W.J. see CROSS, A.J., 86, 475P, 686P
SKETT, P. & CUTHILL, S. Influence of vesicle lipid composition of drug metabolism by a reconstituted mixed function oxidase enzyme system, 86, 555P
SKIDMORE, I.F. see BOUTAL, L.E., 86, 802P
SKIDMORE, I.F. & VARDEY, C.J. β-adrenoceptor agonists stimulate the release of 5-HT from rat

serosal mast cells, 86, 448P
SLATER, P. A microcomputer-based image analyser for receptor autoradiography, 85, 391P
- - - Quantitative autoradiography of [^{3}H]dynorphin$_{1-9}$ binding sites in guinea pig brain, 84, 99P
- - - see CROSS, A.J., 86, 475P, 686P
- - - see PATEL, S., 85, 314P
SLATER, R.A. see COATES, W.J., 84, 22P
SLEIGHT, A.J., REDFERN, P.H. & PALFREYMAN, M.G. Pharmacological evidence for the neuronal selectivity of the MAO inhibiting prodrug, MDL 72394, 86, 480P
SMALL, R.C. see FOSTER, R.W., 84, 17P
SMEATON, L.A. see DETTMAT, P.W., 85, 319P
SMITH, A. see KELLAWAY, I.W., 85, 300P
SMITH, C.J. see CANDY, J.M., 84, 61P
SMITH, D.A.S. see BLAKE, J., 86, 396P
SMITH, G. see CAIRNDUFF, B., 86, 525P
SMITH, G.M. see ROBERTSON, D., 86, 578P
SMITH, H. see LAYCOCK, S.M., 86, 424P
SMITH, J.A. see ASKAM, V., 85, 313P
- - - see MARTIN, W., 86, 567P
SMITH, R.L. see CALDWELL, J., 85, 208P
SMOKCUM, R.W.J. see KOSHIKAWA, N., 84, 113P
SNELL, C.R. see BLOXHAM, C.A., 85, 232P
- - - see CANDY, J.M., 86, 551P
SOARES-DA-SILVA, P. see BOWMAN, A., 84, 19P
SOLDANI, G. see DEL TACCA, M., 86, 638P
SOLDANI, G., DEL TACCA, M., BERNARDINI, C. & BARTOLINI, D. Mu and delta but not kappa opioid agonists mediate gastric secretory effects in the dog, 86, 640P
SOUHAMI, R.L. see CROOK, T., 84, 128P
SPAMPINATO, S., CANDELETTI, S., CAVICCHINI, E., ROMUALDI, P., SPERONI, E. & FERRI, S. Characterization of antinociceptive profiles of intrathecal dynorphin and calcitonin-related peptides, 86, 528P
SPANO, P.F. see LIBERINI, P., 86, 552P
- - - see MEMO, M., 86, 543P
SPARKS, M. see DAVIES, J.A., 85, 393P
SPARROW, P. see ELSE, E., 84, 201P
SPEDDING, M. Tissue size is a major factor influencing tissue selectivity studies with nifedipine, 84, 156P
- - - see MILLER, R.C., 84, 20P
SPENCER, P.S.J. see GONZALEZ, J.P., 86, 709P
SPERONI, E. see SPAMPINATO, S., 86, 528P
SPICER, B.A. see LAYCOCK, S.M., 86, 424P
SPRAGGS, C.F. see BUNCE, K.T., 85, 204P
SPRUCE, K.E. see MASTERS, D.J., 84, 45P
SQUADRITO, F., TRIMARCHI, G.R., QUATTRONE, G., BREZENOFF, H.E. & CAPUTI, A.P. Central nervous system (CNS) control of arterial blood pressure in streptozotocin (STZ) diabetic rats, 86, 629P
STABLES, R. see REEVES, J.J., 86, 524P
STAMFORD, J.A. Actions of methylphenidate on neurogenic release and uptake of dopamine in vivo, 84, 9P
- - - see KRUK, Z.L., 84, 199P; 86, 635P
STANCLIFFE, D. see KILPATRICK, I.C. 86, 408P
STANFORD, S.C. see LITTLE, H.J., 85, 369P; 86, 769P
STANTON, A.W.B. see PIPER, P., 85, 270P
STEEL, G. see BOUGHTON-SMITH, N.K., 84, 159P
STEIN, W.K. see DOWNING, O.A., 86, 717P
STENDARDI, I. see BENNARDINI, F., 86, 623P
STEPHENS, D.N. Tolerance to the antipunishment effects of diazepam in mice, 85, 249P
STEPHENS, M.R. see WATT, A.H., 84, 140P
STEPHENS, R.J. see HARTLEY, J.E., 84, 82P
STEPHENSON, J.D. see KOSHIKAWA, N., 84, 113P
STERLING, W.W. see MCMILLAN, R.M., 84, 44P
STEVENSON, I.H. see OGG, G.D., 84, 161P
- - - see PATERSON, J.R., 85, 299P
STEVENSON, M. see ANDREWS, M., 84, 125P
STEWARD, A. see BOTTOMLEY, K.M.K., 84, 47P
STEWART, A.G. see PIPER, P.J., 86, 814P
STOCKTON, J.M. see BERRIE, C.P., 84, 4P
STOLERMAN, I.P. see GARCHA, H.S., 85, 245P
STOLZ, J. see ABDUL, R., 85, 371P
STOLZ, J.F. see GONZALEZ, J.P., 85, 248P; 86, 444P
STONE, M.A. see DOWNES, C.P., 84, 196P
STONE, T.W. see ADDAE, J.I., 84, 91P; 85, 361P
- - - see COLLINS, J.F., 85, 373P
- - - see CONNICK, J.H., 84, 92P
STONE, T.W. see LONG, C.J., 84, 152P; 85, 340P

STOPHER, D.A. see BERESFORD, A.P., 85, 333P
STRACHAN, A.C. see CLAGUE, R.U., 84, 155P
- - - see EGLEN, R.M., 85, 213P
STRACHAN, D.A. see BERRIDGE, T.L., 84, 193P
STRANGE, P.G. see JUSZCZAK, R., 84, 110P
- - - see SIMMONDS, S.H., 84, 111P
STRASSER, R.H. see CARON, M.G., 85, 326P
STRETTLE, R.J. see BATES, R.F.L., 86, 809P
STRUPISH, J. see NAHORSKI, S.R., 84, 109P
SUMMERFIELD, A. see GREEN, S.E., 84, 74P
SUTTON, J.D. see CALDWELL, J., 84, 24P
SWEETMAN, A.J. see MCNAMEE, P.M., 86, 505P, 811P
SWART, S.S., MAGUIRE, M. & BARNETT, D.B. Normal α_2-adrenoceptor coupling in adrenaline insensitive human platelets, 84, 63P
SYMONS, A.M. see DOWLING, E.J., 84, 79P
SZABADI, E. see BRADSHAW, C.M., 84, 1P; 86, 395P, 419P
SZABADI, E. see BRADSHAW, C.M., 85, 356P

TADDEI, E. see MANTOVANI, P., 86, 778P
TAHRAOUI, L. see GRAHAM, D., 84, 58P
TAMARGO, J. see CALLEJA, C., 84, 172P
- - - see DELGADO, C., 84, 171P; 86, 499P
- - - see MARTIN, J., 86, 500P
TAN, C.C.W. see BRADBURY, A.J., 86, 691P, 738P
- - - see COSTALL, B., 85, 353P
TANGANELLI, S. see ANTONELLI, T., 86, 535P
TAVARES, I.A. see CAPASSO, F., 86, 650P
TAYLOR, D.A. see CONOLAN, S., 86, 399P
TAYLOR, E.M. see COATES, W.J., 84, 22P
TAYLOR, G. see KELLAWAY, I.W., 85, 300P
TAYLOR, G.W. see DOLLERY, C.T., 85, 277P
TAYLOR, S.C. see LITTLE, H.J., 84, 187P; 85, 369P; 86, 769P
TAYLOR, S.G. see BULLOCK, G.R., 85, 269P
TEE, L.B.G. see BOOBIS, A.R., 84, 138P
TEJERINA, T. see DELGADO, C., 86, 499P
- - - see MARTIN, J., 86, 500P
TEMPLETON, D. see ADHAM, N., 86, 756P
- - - see ARKLE, S., 86, 701P
TESSARI, F., GORIO, A. & PROSDOCIMI, M. Analysis of endogenous noradrenaline outflow from cardiac sympathetic efferent fibres, 86, 622P
TESTA, R. see ABBIATI, G.A., 86, 659P
- - - see IBBA, M., 86, 706P
THIRY, C. see CAVERO, I., 84, 182P
THOMAS, D.R. see JOHNSON, A.M., 85, 221P
THOMAS, S. see BOWERY, N.G., 85, 238P
THOMAS, P.J. see AL-DAHAN, M., 86, 605P
THOMAS, S.R. see GILL, R., 85, 252P
THOMPSON, A.M. see HARTLEY, J.E., 84, 82P
THOOLEN, M.J.M.C. see JONKMAN, F.A.M. 84, 195P
- - - see KORSTANJE, C., 84, 179P
- - - see VAN CHARLDORP, K., 84, 178P
THULESIUS, O. see ANGELO-KHATTAR, M., 85, 325P
TIMBRELL, J.A. see TULIP, K., 84, 136P
TIMMERMANS, P.B.M.W.M. see BECKERINGH, J.J., 84, 177P
TIO, R. see HEILIGERS, J., 85, 393P
TIPPINS, J.R. see BRAIN, S.D., 85, 233P
TIPTON, K.F. see DELLA CORTE, L., 86, 557P
TORTORELLA, V. see BETTONI, G., 86, 774P
TOTI, D. see CESERANI, R., 86, 780P
TOWART, R. see FOSTER, R.W., 84, 17P
- - - see ROUNDING, H.P., 84, 15P
TRAYNOR, J.R. & RANCE, M.J. Unexpected properties of [^{3}H]-bremazocine binding to rat lumbrosacral spinal cord membranes, 84, 52P
TREACY, M. see KEENAN, A.K., 84, 101P
TERRANOVA, J.P. see BIZIERE, K., 84, 146P
TRICKLEBANK, M.D. see GOWER, A.J., 85, 246P
- - - see MIDDLEMISS, D.N., 85, 251P
TRIM, J.L. see COLES, D.J., 86, 748P
- - - see HOLMES, S.W., 84, 36P
TRIMARCHI, G.R. see SQUADRITO, F., 86, 629P
TROUT, S.J. see BURLEIGH, D.E., 84, 165P
TSANG, R. see CAPASSO, F., 86, 650P
TUCKER, G.T. see AL-ASADY, S.A.H., 85, 306P
- - - see BAX, N.D.S., 84, 137P

TUCKER, J.F. & VON UEXKULL, A. Differential effect of pertussis toxin on the inhibitory actions of adenosine in guinea-pig isolated ileum and trachea, 86, 579P
TULIP, K., NICHOLSON, J.K. & TIMBRELL, J. A. Studies on the metabolism of N-methylformamide, 84, 136P
TULLOCH, I.F. see BERRIDGE, T.L., 84, 193P
- - - see DOXEY, J.C., 86, 747P
- - - see GADIE, B., 84, 192P; 86, 742P
TURNBULL, M.J. see LONG, S.K., 84, 6P
TURSKI, L. see CAVALHEIRO, E.A., 85, 367P
- - - see MELDRUM, B.S., 85, 370P
TWISSELL, D.J. see GARDNER, C.J., 86, 620P
TYERS, M.B. see FORTUNE, D.H., 84, 49P
- - - see HAYES, A.G., 86, 703P
- - - see SHEEHAN, M.J., 84, 68P
TYMKEWYCZ, P.M. see ARMSTRONG, R.A., 84, 147P
- - - see CLARK, B.F., 86, 795P

UGWU, A.C. see FASEHUN, O.A., 86, 753P
UKMAR, G. see GROSSONI, M., 86, 628P
UNGAR, A. see MACLEAN, M.R., 86, 761P
UNGERSTEDT, U. see ARBUTHNOTT, G., 84, 10P
- - - see HOKFELT, T., 84, 7P
- - - see SHARP, T., 84, 191P
UZAN, A. see BENAVIDES, J., 86, 440P

VACCA, M. see PREZIOSI, P., 86, 542P
VACCA, M., NAVARRA, P.L., DE GORI, N. & PREZIOSI, P. Adrenal stimulation or corticosteroid replacement treatments counteract an unique hydroxyurea toxicity in pituitary-ablated rats, 86, 793P
VACCARI, A. Central high affinity binding of ^{3}H-tyramine, 86, 636P
VAGHI, F. see CESERANI, R., 86, 780P
VALENZUELA, C. see DELGADO, C., 84, 171P; 86, 499P
VALERIO, A. see MEMO, M., 86, 543P
VALOTI, M. see DELLA CORTE, L., 86, 557P
VAN CHARLDORP, K., DE JONGE, A., THOOLEN, M.J.M.C., WILFFERT, B. & VAN ZWIETEN, P. A. Selectivity of different muscarinic agonists for receptors in the heart, urinary bladder and sympathetic ganglia in the pithed rat, 84, 178P
VAN HOVE, C., see COENE, M.-C., 85, 267P
VAN NUETEN, J.M. see JANSSENS, W.J., 86, 597P
VAN OOSTERHOUT, A.J.M. & NIJKAMP, F.P. Effect of anterior hypothalamic lesions on anaphylactic contraction and histamine sensitivity of guinea-pig trachea, 86, 785P
VAN WAY, C. see ALLAN, G., 86, 439P
VAN ZWIETEN, P.A. see BECKERINGH, J. J., 84, 177P
- - - see JONKMAN, F.A.M., 84, 195P
- - - see KORSTANJE, C., 84, 179P
- - - see VAN CHARLDORP, K., 84, 178P
VANNUCCHI, M.G., CORRADETTI, R., BARTOLINI, L., PEDATA, F. & PEPEU, G. Chronic caffeine treatment reduces caffeine but not adenosine effects on cortical acetylcholine release, 86, 606P
VANTINI, G. see FIGLIOMENI, B., 86, 681
VARDEY, C.J. see SKIDMORE, I.F., 86, 448P
VERBEUREN, T.J. see COENE, M.-C., 85, 267P
VERDOUW, P.D. see DUNCKER, D.J., 86, 596P
VERHEGGEN, R. see LATTA, G., 84, 41P
VIAL, J. see DOLLERY, C.T., 85, 277P
VICKERS, V.C. see MASTERS, D.J., 84, 45P
VIDAL, M.J. see HICKS, P.E., 85, 225P
VIGANO, T. see FOLCO, G.C., 86, 645P
VILLA, I. see GUIDOBONO, F., 86, 687P
VILLANI, G.M. see FURCHGOTT, R.F., 86, 565P
VINCENT, A. see LACEY, G., 85, 214P
VINCENT, N.D. see GREEN, A.R., 84, 88P, 89P; 86, 541P
VINSON, G.P. see PORTER, I.D., 86, 507P
VIRDEE, N.K. see DOXEY, J.C., 86, 747P
- - - see ROACH, A.G., 86, 743P
VON UEXKULL, A. see TUCKER, J.F., 86, 579P

WADDINGTON, J.L. see MOLLOY, A.G., 84, 71P; 85, 242P
WADDINGTON, J.L. see O'BOYLE, K.M., 84, 73P; 86, 435P
WADSWORTH, R.M. see DONG, Y.J., 85, 379P
WAINWRIGHT, C.L. see PARRATT, J.R., 85, 228P

WALI, F.A. In vitro comparison between the neuromuscular blockade produced by atracurium and tubocurarine in the frog sartorius muscle, 86, 453P
- - - The effect of meptazinol on rat skeletal and smooth muscle, 84, 83P
- - - Verapamil and calcium chelating agents increase the neuromuscular blockade produced by pancuronium in the chick skeletal muscle, 86, 739P
- - - see ADAMS, A.P., 85, 327P
WALKER, D.S. see DOXEY, J.C., 86, 747P
WALKER, K.A. see BARBER, H.E., 84, 120P
WALKER, R. see ARBUTHNOTT, G., 84, 10P
WALKER, R.J. see COX, R.T.L., 86, 449P
WALKER, R.J. & WRIGHT, N.J.D. Action of piretanide on acetylcholine responses of central neurones of Helix aspersa, 86, 454P
WALKER, S.R. see LUMLEY, C.E., 84, 117P
- - - see PRENTIS, R.A., 84, 118P
WALLACE, J.L. see BOUGHTON-SMITH, N.K., 84, 159P
WALLIS, D.I. see FOZARD, J.R., 85, 309P
- - - see ROUND, A., 86, 734P
WALLIS, R.B. see BUTLER, K.D., 86, 556P
WALLWORK, J. see CAMERON, D., 85, 226P
WALSH, G.M. see CROMWELL, O., 86, 427P
WANKE, E. see MADEDDU, L., 86, 564P
WARD, S.A. see BRECKENRIDGE, A.M., 86, 405P
WARDLE, K.A. see ALLCORN, R.J., 85, 263P
WARNOCK, P. see DOCHERTY, J.R., 85, 264P
WARREN, M. see BALLS, M., 85, 387P
WARRINGTON, B.H. see COATES, W.J., 84, 22P
WATERFALL, J.F. see MCADAMS, R.P., 86, 493P, 494P
- - - see RHODES, K.F., 86, 496P
WATERFIELD, S. see MCCLELLAND, G.R., 84, 202P
WATERMAN, A. see NOLAN, A.M., 86, 462P
WATKINS, J.C. see MELDRUM, B.S., 85, 370P
WATLING, K.J. see BRISTOW, D.R., 86, 430P
WATT, A.H., BUSS, D.C., STEPHENS, M.R. & ROUTLEDGE, P.A. Amiodarone reduces plasma warfarin clearance in man, 84, 140P
WAUGH, N.R. see LINDSAY, R.M., 86, 797P
WAYNE, M. see JESSUP, G.L., 86, 808P
WDONWICKI, G. see PIERI, L., 86, 592P
WEBB, A.J. see MARSDEN, C.A., 86, 398P
WEBBER, S.E. see FOREMAN, J.C., 84, 48P
WEBSTER, R.A. see FARRANT, M., 84, 183P
WEETMAN, D.F. see LAWSON, K., 85, 283P, 386P
WEIGHTMAN, D.R. see BLOXHAM, C.A., 85, 232P
WEIR, S.W. see HAMILTON, T.C., 86, 443P
WELBOURN, A.P. see BERRIDGE, T.L., 84, 193P
WENGER, J.J. see NATOFF, I.L., 85, 337P
- - - see BREWSTER, M., 85, 393P
WERMUTH, C.G. see BIZIERE, K., 86, 404P
WESTON, A.H. see BULLOCK, G.R., 85, 269P
- - - see FOSTER, R.W., 84, 17P
- - - see GRANGER, S.E., 85, 282P
- - - see HAMILTON, T.C., 86, 443P
WESTON, M.J. see DODD, N.J., 85, 285P
WHALLEY, E.T. Vascular permeability actions of kinins, 86, 754P
WHEATLEY, P.L. see LAMB, R.J., 85, 235P
- - - see MILLER, A.A., 85, 366P
WHELAN, C.J. see KENNEDY, I., 86, 523P
WHITE, J.P.N. see CANFIELD, S.P., 84, 80P
WHITEHOUSE, B.J. see PORTER, I.D., 86, 507P
WHITFORD, C.A. see BLOXHAM, C.A., 85, 232P
- - - see CANDY, J.M., 86, 551P
WHITING, M.V. see ALLAN, G., 86, 439P
WHITING, P. see LACEY, G., 85, 214P
WHITING, R.L. see BROWN, C.M., 86, 600P, 766P
- - - see CLAGUE, R.U., 84, 154P, 155P
- - - see CLARKE, B., 85, 330P; 86, 760P
- - - see EGLEN, R.M., 84, 13P; 85, 213P; 86, 397P, 610P, 658P, 744P
- - - see KENNY, B.A., 86, 451P
- - - see MICHEL, A.D., 86, 495P, 816P
- - - see PATMORE, L., 86, 817P
WHITTLE, B.J.R. see BOUGHTON-SMITH, N.K., 84, 159P
- - - see GUTH, P.H., 84, 37P
WICK, M.B. see ENGEL, G., 84, 106P
WIDDOWSON, P.S. see GRIFFITHS, E.C., 86, 458P
- - - see HOLMAN, R.B., 86, 412P
WIECZOREK, W.J. see D'MELLO, A., 84, 151P
WILBOURN, B. see BROWN, K.A., 86, 425P

WILFFERT, B. see VAN CHARLDORP, K., 84, 178P
WILKS, L.J. see FILE, S.E., 86, 457P
WILKINSON, J. see HOLT, D.J., 85, 292P
WILKINSON, L.S. see DAVIES, M., 85, 255P
WILKINSON, S.J. see CORDER, R., 85, 231P
WILLIAMS, F.M. see COKER, S.J., 84, 30P
WILLIAMS, H. see GREEN, A.R., 84, 88P
WILLIAMS, K.I. see DAVIES, J.M., 85, 343P
- - - see HENSBY, C.N., 86, 806P
WILLIAMS, R.J. see DETTMAR, P., 86, 519P
WILLIAMS, S.H. see CONSTANTI, A., 86, 394P
WILLIAMS, T.J. see BRAIN, S.D., 85, 233P
- - - see HELLEWELL, P.G., 86, 572P
- - - see RAMPART, M., 85, 274P
WILLIAMSON, K.L. see BROADLEY, K.J., 84, 160P; 85, 261P, 324P; 86, 699P
WILLIAMSON, R. see COLLINGRIDGE, G.L., 86, 474P
WILSON, A.N.A. see BROADLEY, K.J., 84, 176P; 85, 227P; 86, 441P, 721P
WILSON, G.A.M. see MAIN, I.H.M., 86, 426P
WILSON, J.F. see ASKAM, V., 85, 313P
WILSON, K. see DETTMAR, P., 86, 519P
WILSON, K.A. see DOWNING, O.A., 84, 163P; 86, 504P, 717P
WILSON, K.L. see COLES, D.J., 86, 748P
WILSON, N.H. see ARMSTRONG, R.A., 86, 643P
- - - see JONES, R.L., 84, 148P
WINTER, R.J.D. see DICKINSON, K.E.J., 85, 256P
WONG, E.H.F. see BRISTOW, D.R., 86, 430P
- - - see KEMP, J.A., 85, 237P
WOOD, B.E. see BLACKHAM, A., 86, 786P
WOOD, D.A.R. see BATES, R.F.L., 86, 809P
WOOD, M.D. see BLURTON, P., 84, 98P
WOOD, P. see BLACKBURN, T.P., 86, 497P
WOODBURN, M.M.P. see BRADLEY, H.A., 86, 767P
WOODRUFF, G.N. see HOLDEN-DYE, L., 86, 634P
- - - see KEMP, J.A., 85, 237P
- - - see MAGUIRE, J., 85, 388P
WOODS, H.F. see AL-ASADY, S.A.H., 85, 306P
- - - see BAX, N.D.S., 84, 137P
WOODWARD, B. see AVKIRAN, M., 86, 615P
- - - see BENTHAM, J.M., 86, 810P
WOOLFREY, S.G. see KELLAWAY, I.W., 85, 300P
WORCEL, M. see HAMON, G., 84, 168P
WORMS, P. see BIZIERE, K. 84, 55P. 85, 385P; 86, 404P, 417P
- - - see BRIET, C., 85, 383P
WOUTERSEN-VAN NIJNANTEN, F.M.A. see LOESBERG, C., 86, 569P
WRAY, D. see LACEY, G., 85, 214P
WRIGHT, D.M. An agonistic effect of a substance P antagonist, 85, 229P
WRIGHT, G. see KENNEDY, I., 86, 523P
WRIGHT, N.J.D. see WALKER, R.J., 86, 454P
WUSTEMAN, M., REYNOLDS, G.P. & MARTIN, I.L. Flunitrazepam and muscimol binding to post-mortem brain tissue in epilepsy, 85, 363P
WYLLIE, M.G. see BROADHURST, A.M., 86, 614P

YACOUB, M. see KERWIN, R.W., 85, 288P
YADAV, N.K. see HART, S.L., 86, 662P
YATES, M. see CANDY, J.M., 84, 90P
YATES, M.S. see BOWMER, C.J., 84, 131P, 132P
YOUNG, M.M. see GODFREY, P.P., 84, 112P; 86, 446P

ZANONI, R. see DI GIULIO, A.M., 86, 527P
ZARIFIAN, E. see BENKELFAT, C., 85, 215P
ZEITLIN, I.J. see AL-DHAHIR, H.A.R., 86, 481P
- - - see GALLOWAY, D.J., 86, 490P
ZETTERSTROM, T. see HOKFELT, T., 84, 7P
- - - see SHARP, T., 84, 191P
ZHU, X.Z. see COWAN, A., 85, 294P
ZILLETTI, L. see CIUFFI, M., 86, 637P
ZONNEKEYN, L. see COENE, M.-C., 85, 267P
ZUBIETA, J.K. see GARCIA-SEVILLA, J.A. 86, 580P
ZUNINO, F. see BOSSA, R., 86, 772P

SUBJECT INDEX

Absorption, 85, 300P
Abstinence, 85, 294P
Acetyl-L-carnitine, 86, 683P
Acetylation, 85, 378P
Acetylcholine, 84, 150P; 85, 253P; 86, 449P, 454P, 535P, 606P, 668P
Acetylcholine receptors, 85, 214P
Acetylcholine release, 84, 108P; 86, 601P, 663P
Acetylcholinesterase containing neurones, 86, 450P
O-acetylethylcholine mustard, 84, 115P
N-acetylprocainamide ethobromide, 84, 132P
Acetylsalicylate, 86, 531P
Actinomycin D, 86, 644P
Adenosine, 84, 150P, 176P; 85, 227P, 228P, 340P; 86, 400P, 441P, 449P, 563P, 582P, 583P, 606P
Adenosine, endogenous, 86, 721P
Adenosine diphosphate, 84, 25P
Adenosine 3',5'-monophosphate, cyclic, 84, 6P, 28P; 86, 407P, 482P, 546P, 552P, 577P, 651P, 672P
Adenosine receptors, 86, 438P
Adenosine release, 86, 672P
Adenosine transport, 85, 280P
Adenosine triphosphate, 85, 344P
Adenosine triphosphatase, 86, 792P
Adenylate cyclase, 84, 48P; 85, 265P; 86, 426P, 582P, 633P, 700P, 731P, 805P
Adrenal cortex, 86, 507P
Adrenal glands, 85, 386P
Adrenal medulla, 86, 761P
Adrenal stimulation, 86, 542P
Adrenaline, 84, 12P; 85, 324P, 386P; 86, 415P
α-Adrenoceptor activation, 86, 494P
α_1-Adrenoceptor activation, 84, 192P
α_2-Adrenoceptor agents, 85, 293P
Adrenoceptor agonists, 84, 2P
α_1-Adrenoceptor agonists, 84, 160P
α_2-Adrenoceptor agonists, 85, 321P; 86, 781P
β-Adrenoceptor agonists, 84, 195P
α-Adrenoceptor antagonists, 85, 264P, 376P
α_2-Adrenoceptor antagonists, 84, 145P, 192P, 193P; 86, 542P, 781P
β-Adrenoceptor antagonists, 84, 76P, 195P; 85, 251P
β_1-Adrenoceptor antagonists, 84, 31P
β-Adrenoceptor binding, 86, 766P
α-Adrenoceptor blockade, 86, 743P
β-Adrenoceptor desensitization, 86, 653P
β_1-Adrenoceptor partial agonists, 84, 31P
β-Adrenoceptor responses, 86, 648P
β-Adrenoceptor up-regulation, 86, 769P
Adrenoceptors, 85, 261P, 340P, 369P; 86, 627P, 699P, 717P, 769P
α-Adrenoceptors, 84, 87P, 144P, 167P, 177P, 179P, 193P; 85, 260P, 320P, 322P; 86, 493P, 495P, 496P, 510P, 565P, 611P, 613P, 742P, 746P, 752P, 759P
α_1-Adrenoceptors, 84, 40P; 85, 262P; 86, 416P, 498P, 612P
β-Adrenoceptors, 84, 84P, 158P, 161P, 189P, 194P; 85, 256P, 326P; 86, 448P, 603P, 604P
α_2-Adrenoceptors, 84, 14P, 63P, 145P, 154P; 85, 259P, 260P, 265P, 318P, 319P; 86, 413P, 491P, 492P, 580P, 614P, 741P, 745P
α_1-Adrenoceptors, presynaptic, 84, 67P
α_2-Adrenoceptors, presynaptic, 86, 548P
Adrenocortical function, 86, 497P, 711P
Adriamycin, 86, 794P
Affinity, 84, 84P; 86, 770P
After discharge, 85, 366P; 86, 765P
Age, 86, 494P
Aging, 84, 71P, 72P, 135P; 85, 260P; 86, 627P, 683P
Agonist affinity, 86, 495P
AH6809, 85, 273P, 286P; 86, 803P
AH23848, 85, 285P; 86, 802P
Airway hyper-reactivity, 85, 223P; 86, 571P, 773P
Airways, guinea-pig, 86, 604P, 651P
Airways, human, 86, 647P
Aldosterone, 86, 552P
Aldrin, 86, 513P
Alfentanil, 86, 558P
Alfuzosin, 84, 16P; 86, 416P, 612P
Alkylating agents, 86, 771P
Allfit, 84, 175P
Allopurinol, 86, 439P
Alloxan diabetes, 86, 746P
N-allylnormetazine, 86, 539P
Alzheimer type dementia, 84, 7P
Amidarone, 84, 140P

Amiloride, 86, 624P
Amine oxidases, 86, 553P
Amine release, 86, 548P
Amino acid binding sites, 86, 475P
Amino acid receptors, 85, 361P
Amino acid release, 86, 536P
Amino acids, 85, 373P; 86, 475P
Amino acids, excitatory, 84, 91P; 86, 686P
2-Amino-7-phosphonoheptanoic acid, 84, 95P
γ-Aminobutyric acid, 84, 5P, 55P, 93P, 102P; 86, 429P, 431P, 470P, 471P, 472P, 483P, 535P, 541P, 680P, 684P
γ-Aminobutyric acid, release, 84, 89P
γ-Aminobutyric acid, synthesis, 84, 88P
γ-Aminobutyric acid agonists, 84, 86P; 85, 252P; 86, 429P
γ-Aminobutyric acid antagonists, 85, 237P, 252P
γ-Aminobutyric acid binding sites, 85, 234P, 238P; 86, 593P
γ-Aminobutyric acid receptors, 84, 60P; 86, 637P
Aminoglutetimide, 85, 302P
Δ-Aminolaevulinic acid, 86, 680P
Aminophenone, 86, 740P
Aminopyridazine derivatives, 86, 417P
Aminopyridines, 86, 778P
2-Aminothiazoline-4-acetic acid, 86, 430P
Amitriptyline, 86, 673P
Amlodipine, 85, 281P, 333P, 335P
Amnesia, 86, 661P
Amplification, 86, 597P
Amrinone, 86, 720P
Amygdala, 85, 250P
Anaesthetics, 86, 497P, 692P
Analeptic response, 86, 455P
Analgesia, 85, 246P; 86, 462P, 485P, 677P, 702P, 706P
Anaphylaxis, 86, 424P, 573P, 649P, 785P, 804P
Androgen receptor, 84, 127P
Angiotensin II, 86, 487P, 488P, 794P, 752P
Angiotensin-converting enzyme, 86, 750P, 751P
Angiotensin converting enzyme inhibitors, 85, 337P; 86, 748P
Anion channels, 84, 60P
Anion secretion, 85, 204P
Anococcygeus muscle, 85, 388P
Anococcygeus muscle, mouse, 86, 678P
Anococcygeus muscle, rat, 86, 470P
Anoretic agents, 86, 689P
Antagonist affinities, 86, 744P
Anterior pituitary, 84, 111P
Anthracyclines, 86, 562P, 772P
Anti-aggregatory drugs, 86, 628P, 802P
Anti-asthma drugs, 86, 571P
Anticholinergics, 86, 757P
Anticoagulants, 86, 406P
Anticonvulsants, 85, 235P, 359P, 364P, 366P, 371P, 384P; 86, 474P, 659P, 765P
Antidepressants, 85, 244P, 357P; 86, 580P
Antigen-induced arthritis, 86, 422P
Antihaloperidol antibody, 84, 110P
Antihypertensives, 85, 335P, 337P
Anti-idiotype, 84, 110P
Anti-inflammatory drugs, 86, 425P, 505P
Antinociception, 84, 105P, 166P; 85, 248P, 352P; 86, 409P, 662P, 709P
Antinociceptive tests, 86, 703P
Antioxidants, 84, 119P
Antisecretory effects, 86, 780P
Antitumour activity, 86, 771P
Antiulcer effects, 86, 780P
Anxiety, 84, 104P, 186P; 85, 249P; 86, 456P, 460P, 713P
Anxiogenic agents, 84, 82P, 103P
Anxiolytic agents, 84, 82P, 146P; 85, 252P
Aorta, guinea-pig, 86, 720P
Aorta, rabbit, 84, 19P; 85, 266P, 342P, 343P
Aorta, rat, 84, 152P, 163P, 173P; 85, 269P; 86, 504P, 723P
Apomorphine, 86, 434P
Appetite, 85, 296P
Aptazapine, 86, 743P, 747P
Archachatina marginata, 85, 243P, 355P
Arachidonic acid, 84, 33P, 147P; 86, 569P, 650P, 655P, 785P
Arachidonic acid metabolism, 84, 38P, 39P, 45P; 86, 653P
Aracaidine propargyl ester, 86, 397P
L-arginine methylester, 86, 621P, 716P
Argenine vasopressin, 84, 77P; 85, 270P
Arrhythmias, 84, 30P, 32P; 85, 228P; 86, 615P, 716P, 810P
Arterial peptide, 86, 730P
Arthritis, 84, 120P; 85, 276P; 86, 422P, 522P
Ascorbic acid, 85, 372P
D-aspartic acid, 84, 92P
Aspirin, 85, 208P; 86, 802P
Assay buffers, 84, 84P
Atacurium, 86, 453P
Atria, guinea-pig, 84, 47P, 176P; 85, 227P; 86, 437P, 501P, 658P
Atria, rat, 84, 160P, 85, 324P; 86, 699P
Atrial muscle, guinea-pig, 85, 258P; 86, 499P

Atropine, 85, 284P; 86, 776P
Audiogenic seizures, 85, 368P; 86, 467P
Automated bioassay, 84, 200P
Automation, 85, 392P
Autoradiography, 84, 99P; 85, 391P
Autoreceptors, 84, 5P, 189P
Avian species, 86, 660P
Aviodance, 85, 246P

Baclofen, 85, 234P
Baroreceptor reflex, 84, 21P
Basophils, human, 85, 345P; 86, 407P
Bay K 8644, 84, 17P, 20P, 171P; 86, 584P, 657P, 718P
BBC computer software, 86, 525P
Beclamide, 85, 371P
Behaviour, 85, 311P; 86, 444P, 479P, 525P, 540P
Behaviour, dopamine mediated, 84, 54P
Behaviour, monamine-mediated, 84, 53P
Benextramine, 84, 13P
Benzamides, 84, 100P
Benzodiazepine agonist, 84, 97P
Benzodiazepine antagonists, 86, 592P
Benzodiazepine binding sites, 86, 593P
Benzodiazepine contragonist, 84, 97P
Benzodiazepine receptor, 84, 186P, 187P, 188P
Benzodiazepine receptor ligands, 85, 236P, 369P
Benzodiazepines, 84, 60P, 104P; 85, 249P; 86, 440P, 472P, 688P
Benzyl acetate, 85, 207P; 86, 512P
Bestatin, 86, 459P
B-HT 920, 84, 184P
B-HT 958, 84, 64P
Bicuculline, 86, 471P, 547P
Bile acids, 86, 481P
Binding, 86, 636P, 647P
Binding sites, 84, 98P; 85, 374P; 86, 551P
Biosynthesis, 84, 44P
Blood, human, 85, 378P; 86, 797P
Blood flow, 84, 157P; 86, 791P
Blood pressure, 84, 145P; 85, 222P, 264P, 310P; 86, 415P, 436P, 598P, 629P, 717P, 745P, 751P, 762P, 763P
BM 13,177, 84, 41P
Body temperature, 85, 296P
Bombesin, 86, 485P
Bradykinin, 86, 485P
Brain asymmetry, 86, 713P
Brainstem neurones, rat, 86, 594P
Breast cancer, 86, 560P
(^{3}H)-bremazocine, 84, 52P
BRL 34915, 86, 443P
Bromocriptine, 86, 632P
Bronchial muscle, 86, 484P
Bronchoconstriction, 84, 15P; 86, 611P
Bronchodilation, 86, 732P
Buprenorphine, 85, 295P
2-t-Butyl-4-methoxyphenol, 86, 557P

C-fibres, 85, 375P
Caffeine, 86, 606P
Calcitonin, 86, 528P, 809P
Calcitonin gene-related peptide, 85, 233P; 86, 544P, 679P
Calcium, 84, 25P, 27P, 142P, 151P, 163P, 169P; 85, 330P, 344P; 86, 505P, 506P, 564P, 639P, 641P, 654P, 655P, 723P, 725P
Calcium antagonism, 85, 289P; 86, 584P
Calcium antagonists, 84, 16P, 17P, 18P, 20P, 29P, 156P, 163P, 156P, 173P, 177P; 85, 281P, 282P, 331P; 86, 503P, 575P, 641P, 693P, 717P, 724P, 772P
^{45}Calcium, 85, 334P, 336P
Calcium channels, 85, 278P; 86, 543P, 545P, 667P
Calcium chelating agents, 86, 739P
Calcium entry blocker, 85, 329P
Calcium entry facilitator, 86, 718P
Calcium flux, 85, 279P, 342P, 377P
Calcium influx, 84, 171P
Calcium ionophore A23187, 86, 400P
Calcium uptake, 86, 440P, 657P
Calmodulin, 86, 760P
Capsaicin, 86, 787P
Captopril, 84, 21P; 86, 761P
Carbachol, 84, 151P, 155P; 85, 257P
Carbacyclin, 86, 805P
Carbamazepine, 85, 384P
β-Carbolines, 86, 464P, 666P, 769P
Carboprostacyclin derivative, 86, 628P
5-Carboxamidotryptamine, 85, 222P, 310P, 316P; 86, 737P
Carcinogenesis, 86, 490P
Cardiac cell cultures, 86, 817P
Cardiac contractility, 86, 726P
Cardiac functions, 86, 728P
Cardiac mitochondria, 86, 727P
Cardiac output, 84, 157P
Cardiac tissue, guinea-pig, 86, 441P
Cardioaccelerator nerves, 84, 182P
Cardiomyocytes, 86, 657P
Cardiorespiratory activity, 86, 628P
Cardiovascular actions, 86, 523P, 595P, 618P, 620P, 627P, 719P, 732P
Cardiovascular regulation, 84, 162P
Cardiovascular system, rat, 84, 69P, 167P, 178P; 86, 736P
Carnitines, 86, 727P, 728P, 800P
Carotid body chemoreceptors, 86, 733P
Catalase, 85, 274P
Catechol, 85, 360P, 364P; 86, 663P
Catecholamine release, 84, 169P
Catecholamines, 86, 566P, 615P
Caudate-putamen, 86, 408P

Cell cultures, 86, 563P, 715P, 766P
Central nervous system, 84, 7P, 191P; 86, 551P, 583P, 619P, 629P
Cerebellum, rat, 85, 351P; 86, 473P
Cerebral cortex, 84, 58P, 94P; 85, 361P; 86, 395P, 403P, 471P
CGS 8216, 84, 96P
Channel closing rate, 86, 585P
Chemotaxis, 85, 274P; 86, 520P
Chemotherapy, 86, 561P
Chlorambucil, 86, 522P
Chloramphenicols, 86, 585P, 675P
Chlordiazepoxide, 84, 74P; 86, 767P
Chloride channel, 86, 586P, 774P
Chlorisondamine, 85, 245P
p-Chloroamphetamine, 85, 358P
N-2-chloroethyl-N-ethyl-2-bromobenzylamine, 85, 356P; 86, 419P, 736P
Cholecystokinin, 84, 6P; 85, 383P; 86, 409P, 530P
Cholecystokinin antagonists, 85, 383P
Cholecystokinin receptor, 85, 290P
Cholesterol, 85, 266P
(^{3}H)-choline, 84, 165P
Choline acetyltransferase, 84, 114P, 115P
Choline uptake, 84, 114P, 115P
Cholinergic antagonists, 86, 609P
Cholinergic mechanisms, 86, 660P
Cholinesterase, 85, 213P
Chondrogenesis, 84, 122P
Chromaffin cells, 84, 62P; 86, 609P
Chronotropic responses, positive, 86, 658P
Cicloprolol, 84, 31P
Cimetidine, 84, 164P
Cingulate cortical neurones, 85, 230P
Circadiam rhythms, 85, 357P; 86, 398P, 461P
CL 28A, 84, 43P
Climbing behaviour, 85, 247P
Clobazam, 85, 359P
Clonidine, 84, 13P, 195P; 86, 548P, 625P, 676P
^{3}H-clonidine binding, 86, 518P
CM 40907, 85, 384P
CM 57373, 86, 689P
CM 57755, 86, 790P
Cocaine, 86, 566P
Cold, 86, 493P
Collagen, 86, 578P
Colon, human, 86, 481P, 650P
Colon, marmoset, 86, 696P
Colon, rat, 84, 159P, 650P
Computer analysis, 86, 762P
Computer systems, 85, 308P
Concentration-response curve, 86, 816P
Conflict, 85, 252P
Constipation, 86, 782P
Contractions, 85, 317P, 325P; 86, 501P
Convulsions, 84, 88P, 89P
Coronary artery, dog, 86, 438P, 506P
Coronary artery occlusion, 84, 30P
Coronary vasospasm, 84, 41P
Cortex, rabbit, 85, 318P
Cortex, rat, 85, 318P; 86, 537P
Cortical cells, 84, 2P
Cortical neurones, 84, 1P
Corticosterone, 84, 72P, 507P
Corticosterone acetate, 85, 209P
Covalent binding, 86, 514P, 515P
Creatine, 84, 131P
Crosslinking, 84, 101P
Crowding stress, 86, 483P
Cushing's disease, 86, 402P
Cyanide, 85, 301P; 86, 740P
Cyclo-oxygenase, 86, 642P, 647P
Cyclo-oxygenase inhibition, 84, 42P, 45P
Cyclophosphamide, 84, 128P
Cyclosporin A, 84, 46P
Cytochrome P450, 84, 39P; 85, 387P; 86, 511P, 513P
Cytoprotection, 84, 159P; 85, 268P, 272P
Cytotoxicity, 86, 559P
Cutaneous sensory effects, 84, 123P

Damage, 86, 802P
Data analysis, 86, 816P
Dazoxiben, 84, 41P
DBA/2 mice, 86, 467P
DDT see 1,1,1-trichloro-2,2-bis-p (chlorophenyl) ethane
Deaza-analogues, 86, 563P
Defibrotide, 86, 625P
Dementia, 84, 7P
Demethylation, 86, 477P
Denervation, 86, 756P
Denzimol, 86, 659P
Deoxycormycin, 86, 441P
Deoxyglucose, 86, 674P
Dependence, 85, 294P
Depolarization, 84, 108P; 86, 564P
Depression, 85, 215P; 86, 590P, 593P, 713P
Desensitization, 84, 91P
Desipramine, 86, 615P
Dexamethasone, 85, 387P
Diabetes, 86, 629P, 746P, 791P, 795P, 797P
Diabetic serum, 84, 81P
Diacylglycerol, 86, 546P
Diazepam, 84, 87P, 135P; 86, 711P, 776P
Diazepam dependence, 84, 72P
Diclofenac sodium, 85, 325P
Dicyclomine, 86, 451P

Diet, 86, 490P, 568P
Dietary fats, 86, 428P
Digitonin, 86, 403P
Digoxin, 84, 125P
Dihydro-β-erythoidine, 86, 587P
Dihydroavermectin B_{1A}, 86, 431P
Dihydropyridine, 84, 17P, 20P; 85, 281P, 333P
3,4-Dihydroxyphenylacetic acid, 85, 372P; 86, 632P
L-dihydroxyphenylalanine rotations, 86, 480P
5,7-Dihydroxytryptamine, 85, 311P; 86, 673P
Dilazep, 85, 280P
Diltiazem, 84, 16P; 85, 331P
[^{3}H]-diltiazem, 85, 278P
4-Dimethylaminophenol, 85, 301P
Dinitrofluorobenzene, 85, 305P; 86, 799P
Dipyridamole, 85, 280P; 86, 441P
Discriminative stimulus, 84, 70P; 86, 707P
Dissociation constants, 85, 307P
1,4-Dithiothreitol, 85, 206P
Diuretics, 84, 75P; 85, 382P; 86, 748P
DNA cross links, 84, 128P
DNA synthesis, 85, 351P
Dopamine, 84, 85P, 197P; 85, 239P, 329P, 383P, 385P; 86, 458P, 468P, 532P, 533P, 534P, 552P, 582P, 635P, 636P, 685P, 692P, 700P, 709P, 710P
Dopamine agonists, 84, 166P; 85, 240P, 247P, 352P, 353P; 86, 436P, 690P
Dopamine antagonists, 84, 100P, 103P
Dopamine autoreceptor agonists, 84, 184P
Dopamine depletion, 84, 11P
Dopamine infusion, 86, 695P
Dopamine metabolism, 86, 670P
Dopamine metabolites, 84, 3P
Dopamine neurones, 84, 56P
Dopamine receptor, supersensitivity, 86, 671P
Dopamine receptors, 84, 64P, 73P, 129P, 191P; 85, 241P, 242P, 346P, 349P; 86, 434P, 469P, 617P, 633P, 634P
Dopamine D_1 receptors, 86, 435P
Dopamine D_2 receptors, 84, 109P, 110P, 111P; 86, 618P
Dopamine release, 84, 3P, 7P, 9P, 10P, 50P, 109P, 181P, 189P, 191P, 199P; 85, 240P; 86, 412P
Dopamine uptake, 84, 9P
Dopaminergic function, 84, 55P
Dopaminomimetics, 86, 404P
Dorsal root potentials, 85, 380P
Dose-response curves, 86, 755P
Dothiepin, 86, 466P
Doxazosin, 85, 376P
Doxorubicin, 86, 714P, 715P
Driving function, 86, 675P
Drug discrimination, 84, 74P
Drug effects, 84, 126P
Drug metabolism, 84, 24P, 136P, 138P, 139P; 86, 555P, 790P
Drug-protein conjugates, 86, 799P
DSP4 see N-2-chloroethyl-N-ethyl-2-bromobenzylamine
Duodenal contractility, 86, 641P
Duodenum, guinea-pig, 85, 204P
Duodenum, rat, 84, 80P
Dynorphin, 84, 99P; 85, 294P; 86, 528P

Ear, rabbit perfused, 84, 180P
Eicosanoid production, 85, 276P
Eicosanoid release, 84, 38P; 86, 423P
Eicosanoids, 85, 271P; 86, 429P
Electrical stimulation, 84, 181P; 86, 622P
Electroconvulsive shock, 84, 53P; 85, 235P; 86, 541P, 544P, 706P
Electroencephalograph, 86, 669P, 688P
Electromyographic activity, 85, 254P
Electrophysiology, 86, 442P
Elesoisin, 86, 489P
Elevated X-maze, 86, 591P, 711P
Embryo, rat, 84, 122P
Enalapril, 86, 751P
Endothelium, 84, 13P, 20P, 152P; 85, 269P, 342P; 86, 425P, 506P
Endothelium-dependent relaxant factor, 85, 266P, 267P, 341P, 343P, 344P; 86, 565P
Endothelium-dependent relaxation, 84, 19P
Endotoxin shock, 84, 119P
Endplate current, 85, 390P; 86, 585P
Enkephalin, D-Ala^2-$MePhe^4$, $Gl-ol^5$, 85, 294P, 297P
Enkephalin, Met-, 86, 411P, 527P
Enzymatic systems, 86, 726P
Enzymatic treatments, 86, 682P
Enzyme inhibition, 84, 137P
Eosiniphils, 86, 426P
EP_1-receptors, 85, 273P
Epilepsy, 84, 95P; 85, 363P, 367P, 370P
Epithelial membranes, 86, 486P, 487P
Ergolines, 86, 670P
Erythrocytes, 85, 374P
β-Erythroidine, 86, 587P
Errors, 86, 770P
Ethanol, 84, 153P; 85, 236P; 86, 768P
Ethanol antagonism, 86, 463P, 465P
Ethanol tolerance, 84, 130P
Ethanolamine-O-sulphate, 84, 74P
Ethylcholine mustard, 84, 114P
Etomidate, 86, 549P
Eugenol, 84, 24P

Evoked potentials, 84, 91P
Excitatory amino acid receptors, 84, 184P
Excitatory amino acids, 85, 367P, 368P, 370P; 86, 408P
Excitatory transmission, 85, 360P
Exploratory activity, 86, 456P
Extinction, 84, 76P
Extravasation, 86, 788P

FAB fragments, 84, 125P
FAD-monooxygenase, 85, 299P
Fatty acids, 86, 428P
Feedback, 84, 109P
Fenfluramine, 85, 381P; 86, 689P
Fenildopam, 86, 436P
Ferret, 85, 346P; 86, 784P
FG 7142, 84, 186P, 187P, 188P
Fibrin deposition, 86, 556P
Fibrinolysis, 86, 813P
Fibroblasts, human, 86, 559P
Field potentials, 86, 394P, 538P
Field stimulation, 86, 738P
Flufenamic acid, 86, 811P
Fluid transport, 86, 519P
Flunitraxepam, 85, 363P
Fluoropyrimidine, 86, 561P
Fluosol-DA, 84, 116P
Flurazepam, 86, 768P
Food consumption, 84, 82P; 86, 459P
Food deprivation, 86, 707P
Foot-pad oedema, 84, 35P
Forskolin, 85, 362P; 86, 426P; 508P
Free radicals, 84, 35P, 79P
Funaltrexamine, 84, 68P
Functional antagonism, 84, 141P
Fundus, 85, 312P; 86, 447P

Gallamine, 85, 327P
Ganglion cells, rabbit, 86, 734P
Ganglionic transmission, 85, 209P
Gastric acid, 86, 570P
Gastric anti-secretory agents, 85, 346P; 86, 784P
Gastric emptying, 84, 100P; 86, 757P
Gastric fundus, rat, 86, 491P, 613P
Gastric microcirculation, 84, 37P
Gastric mucosa, 85, 268P, 322P; 86, 524P
Gastric potential difference, 86, 783P
Gastric protection, 86, 783P
Gastric secretion, 85, 319P, 353P; 86, 426P, 524P, 639P, 640P, 778P, 781P, 798P, 815P
Gastric ulceration, 86, 421P
Gastrin, 86, 638P
Gastrointestinal smooth muscle, 86, 807P
GENSTAT program, 84, 201P
Gerbils, 86, 540P
Glucagon, 84, 157
Glucuronidation, 84, 133P, 134P, 164P
Glutamate, 84, 181P; 85, 374P
Glutamic acid dicarboxylase, 86, 472P
Glutathione, 86, 799P
Glycine, 86, 536P, 695P
Glycine receptor, 86, 682P
GM_1 ganglioside, 86, 671P
Grooming, 86, 434P
Growth hormone, 86, 698P
Guanosine 3',5'-monophosphate, cyclic, 84, 150P, 184P; 86, 545P, 546P
Guanosine monophosphate, 8-bromo cyclic, 85, 279P

Haemodynamics, 84, 174P; 85, 231P
Haemorrhagic shock, 86, 439P
Haemoglobin, 86, 565P, 567P
Haemoglobin-oxygen, 86, 616P
Hallucinogens, 86, 550P
Haloperidol, 86, 539P, 671P, 789P
Head-twitch, 84, 86P
Heart, dog perfused, 86, 616P
Heart, frog, 85, 211P
Heart, guinea-pig, 86, 721P, 792P
Heart, rabbit perfused, 86, 544P
Heart, rat, 84, 40P; 85, 328P; 86, 503P, 544P, 715P, 718P, 814P
Heart rate, 86, 599P, 762P
Heavy metals, 86, 812P
Helix aspersa, 86, 449P, 454P
Hepatic drug metabolism, inhibition, 86, 801P
Hepatic injury, 86, 602P
Hepatocytes, 84, 121P
Hepatotoxicity, 84, 138P; 86, 514P
Hexaprazol, 86, 783P
Hexobendine, 85, 280P
High pressure liguid chromatography, 84, 54P; 85, 277P
Hindlimb, rat perfused, 84, 179P
Hippocampal neurones, rat, 86, 589P
Hippocampus, rat, 85, 238P; 86, 450P, 474P, 536P
Histamine, 84, 47P, 151P, 176P; 85, 205P, 206P, 257P; 86, 484P, 509P, 517P, 568P, 569P, 574P, 775P, 785P, 794P
Histamine H_2 agonists, 84, 47P
Histamine antagonists, 86, 570P
Histamine H_2 antagonists, 85, 299P; 86, 639P, 779P, 780P, 790P
Histamine H_1 receptors, 85, 206P; 86, 452P
Histamine release, 85, 345P
Hordenine, 86, 476P
Hydralazine, 85, 269P
8-Hydroxy-2-(di-n-propylamino)tetralin, 84, 69P, 167P; 85, 215P, 315P; 86,

433P, 445P, 446P, 594P, 601P, 736P
6-Hydroxydopamine, 85, 334P; 86, 736P
5-Hydroxyindolacetic acid, 85, 372P
3-(3-Hydroxyphenyl-N-n-propylpiperidine, 84, 167P; 86, 617P, 710P
5-Hydroxypropafenone, 86, 499P
5-Hydroxytryptamine, 84, 49P, 57P, 65P, 90P, 189P; 85, 218P, 309P, 316P; 86, 401P, 433P, 460P, 531P, 594P, 596P, 597P, 658P, 664P, 681P, 687P, 702P, 733P, 734P, 738P
(^{3}H)-5-hydroxytryptamine, 84, 98P
5-Hydroxytryptamine agonists, selective, 86, 733P
5-Hydroxytryptamine antagonists, 86, 550P, 598P
5-Hydroxytryptamine$_2$ antagonists, 86, 447P
5-Hydroxytryptamine autoreceptor, 84, 65P, 315P, 445P, 446P
5-Hydroxytryptamine$_2$ binding site, 84, 106P; 85, 311P
5-Hydroxytryptamine depolarizations, 86, 734P
5-Hydroxytryptamine receptor blockade, 86, 743P
5-Hydroxytryptamine receptors, 84, 69P, 167P; 85, 219P, 248P, 314P; 86, 44P, 595P, 737P
5-Hydroxytryptamine$_1$ receptors, 84, 58P, 70P; 86, 398P, 401P, 461P, 599P
5-Hydroxytryptamine$_{1A}$-receptors, 86, 601P
5-Hydroxytryptamine$_2$ receptors, 84, 113P; 85, 311P, 312P, 381P
5-Hydroxytryptamine-D-receptor, 84, 106P
5-Hydroxytryptamine release, 86, 400P, 413P, 448P
5-Hydroxytryptamine transporter complex, 86, 403P
5-Hydroxytryptamine uptake, 84, 58P; 85, 215P; 86, 600P
5-Hydroxytryptamine uptake inhibition, 85, 221P, 358P
5-Hydroxytryptophan, 84, 69P
Hydroxyurea, 86, 542P, 793P
Hyperactivity, 86, 544P
Hypercholesterolaemia, 85, 267P
Hyperphagia, 84, 75P, 96P; 86, 712P
Hyperpolarization, 84, 49P
Hypertension, 84, 32P, 39P; 85, 264P; 86, 488P, 595P, 625P, 719P
Hyperthermia, 85, 381P
Hypnotic drugs, 84, 146P, 198P; 86, 431P
Hypophysectomy, 86, 793P
Hypoplasia, type II cell, 86, 729P
Hypotension, 84, 64P; 86, 411P, 737P
Hypothalamus, 86, 785P
Hypothalamus, rat, 84, 169P
Hypothermia, 85, 251P; 86, 684P
Hypoxia, 85, 256P; 86, 504P, 621P, 623P

Ibotenic acid, 86, 431P, 674P
ICI 159995, 86, 808P
ICS 205-930, 86, 734P
Idazoxan, 84, 67P
Ileum, guinea-pig, 84, 106P; 86, 579P, 601P, 705P, 724P
Ileum, marmoset, 86, 696P
Image analysis, 85, 391P
Imidazo-pyridine, 86, 432P
Imiloxan, 84, 154P
Imipramine, 84, 57P, 59P, 90P; 86, 600P, 706P
^{3}H -imipramine binding, 85, 215P, 216P, 217P, 220P
In vitro pharmacology, 85, 392P
In vitro screening, 85, 388P
In vivo voltammetry, 85, 219P
Indanidine, 85, 386P
Indomethacin, 85, 223P, 272P, 325P, 337P
Indoramin, 84, 162P
Induction, 85, 387P
Inferior colliculus, 84, 95P
Inflammation, 84, 33P, 79P; 85, 233P, 271P; 86, 572P, 646P, 652P, 656P, 750P, 754P, 777P, 786P, 787P, 788P
Infusion, 86, 690P, 708P
Ingestive behaviour, 84, 97P
Inhibitory factor, 84, 19P; 567P
Inhibitory junction potentials, 86, 724P
Inhibitory neurotransmission, 86, 431P
Injury, 86, 556P
Inositol phosphates, 84, 130P; 86, 410P, 568P, 607P
Inositol phospholipids, 84, 25P, 108P, 111P, 112P; 86, 545P, 667P
Inotropic effects, 84, 22P; 85, 258P; 86, 631P, 760P, 763P, 817P
Insulin secretion, 84, 12P
Integration, 85, 389P
Intestinal absorption, 86, 800P
Intestinal motility, 86, 619P
Intestinal smooth muscle, 86, 731P
Intestine, rat, 86, 553P, 577P
Intracerbral dialysis, 86, 415P
Intravascular fluid, 84, 116P
Intralaminal thalamus, 86, 408P
Inverse agonists, 86, 688P
Ion channel block, 86, 585P, 587P
Ionic currents, 86, 549P, 665P
Ischaemias, 85, 22P, 329P; 86, 669P, 716P, 722P, 810P
Ischaemic hypoxia, 86, 728P
Isolation, 86, 420P, 460P

Isoprenaline, 84, 158P, 176P; 86, 701P, 721P
D-isopropylfluorophosphate, 86, 558P

Jejunum, guinea-pig, 84, 23P, 78P
Jejunum, rabbit, 86, 680P
Jejunum, rat, 86, 485P, 519P

Kainic acid, 85, 370P, 375P; 86, 450P
Kainic acid binding, 86, 473P
Kallikrein, 86, 481P, 490P
Kelocyanor, 85, 301P
Ketamine, 86, 665P, 694P
Ketanserin, 85, 255P, 312P; 86, 399P, 433P, 771P
Ketocaine derivatives, 86, 771P
Kidney, rat, 86, 597P
Kidney, rabbit, 86, 812P
Kinins, 86, 754P
Kindling, 84, 186P, 187P, 188P; 85, 369P
Kynurenines, 84, 92P

Lamotrigine, 85, 235P, 366P; 86, 765P
Laterality, 85, 250P
α-Latrotoxin receptors, 86, 564P
Lead, 84, 32P; 85, 291P
Leptazol, 85, 365P
Leucocytes, 84, 44P; 86, 424P, 425P, 520P
Leukaemia, 84, 128P
Leukotriene B_4, 84, 34P, 43P; 86, 521P
Leukotriene C_4, 85, 270P; 86, 647P
Leukotriene D_4, 85, 270P; 86, 651P
Leukotrienes, 84, 37P; 85, 277P; 86, 427P, 642P, 649P, 652P, 656P, 814P
Leukotrienes, cat, 86, 523P
Leupeptin, 86, 589P
Levorphanol, 86, 712P
Ligand binding, 86, 451P, 495P, 605P, 697P, 704P, 741P
Lignocaine, 84, 137P; 85, 306P
Lipid peroxidation, 86, 714P, 727P
Lipid solubility, 84, 133P
Lipolysis, 86, 603P, 646P
Lipophilicity, 86, 554P
Liposomes, 85, 300P
Lipoxygenase inhibitors, 84, 45P; 86, 427P
Lithium, 84, 23P, 78P, 304P, 354P
Liver, mouse, 86, 477P
Locomotor activity, 85, 250P, 314P; 85, 354P, 357P; 86, 468P, 690P
Locus coeruleus, 84, 87P, 93P; 86, 676P
Locust, 86, 431P
Logistic curves, 84, 175P
Luminal alkalinisation, 84, 80P
Lung, guinea-pig, 84, 38P, 48P; 86, 423P, 573P, 642P, 649P, 811P
Lung, human, 86, 642P, 645P, 697P, 766P
Lung parenchymal strips, 86, 653P

LY 171555, 84, 1P
Lymphocytes, human, 84, 26P; 86, 429P
Lyso-platelet activating factor, 86, 422P

Macrophages, 84, 46P; 86, 604P
Marmoset, 84, 56P
Mast cells, 86, 509P, 775P
Mast cells, human, 85, 205P
Mast cells, rat, 86, 400P, 407P, 448P, 574P, 576P
Mathematical treatment, 86, 755P
McN-A-343, 86, 610P
MDL 72222, 85, 255P, 309P, 764P
Medroxyprogesterone, 86, 560P
Megakaryoblasts, 86, 581P
Melanophore, 85, 313P
Melatonin, 85, 240P, 313P; 86, 533P
Membrane lipids, 86, 555P
Memory, 84, 107P; 85, 246P; 86, 420P
Menadione, 86, 726P
Menthol, 85, 254P
Mepacrine, 84, 153P
Meptazinol, 84, 83P; 85, 296P; 86, 712P
Mepyramine, 86, 568P
Mesentery, perfused rat, 86, 544P
Metabolism, 85, 299P; 86, 515P
Methaemoglobin, 85, 302P; 86, 740P
Methiothepin, 84, 65P
3-Methoxy-4-dihydroxyphenylethyleneglycol assay, 86, 414P
3-Methoxytyramine, 84, 54P
N-methyl-D-aspartate, 85, 361P; 86, 474P
N-methyl-D-aspartate antagonists, 86, 538P
N-Methyl-D-aspartate receptor, 85, 373P
1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine, 84, 56P; 85, 348P, 477P; 86, 477P, 685P, 708P, 710P
1-Methyl-4-phenylpyridine, 85, 350P
1-Methyl-4-phenylpyridine neurotoxicity, 86, 691P
α-Methyl-p-tyrosine, 84, 11P
α,β-methylene adenosine triphosphate, 85, 225P, 263P
N-methylformamide, 84, 136P; 86, 514P, 515P
Methylphenidate, 84, 9P
5-Methyltetrahydrofolate, 86, 561P
Methyltransferase inhibitors, 86, 407P
^{3}H-methyltrienolone, 84, 127P
Methysergide, 85, 255P
Metoclopramide, 85, 210P; 86, 738P, 757P
Midazolam, 85, 245P
^{3}H-mibolerone, 84, 127P
Microelectrophoresis, 86, 395P
Microcomputers, 85, 388P, 389P, 390P,

391P, 392P; 86, 525P, 816P, 818P, 819P
Microprocessors, 84, 202P
Mitochondiral function, 86, 722P
Mitogen-induced proliferation, 86, 429P
Molecular graphics, 86, 819P
Monoamine depletors, 84, 129P
Monoamine oxidase, 86, 417P
Monoamine oxidase inhibitors, 85, 348P; 86, 404P, 478P, 479P
Monoamine oxidase specificity, 86, 476P
Monoamines, 85, 365P, 371P; 86, 677P, 683P
Monoclonal antibodies, 85, 214P; 86, 511P
Morphine, 84, 11P, 105P; 85, 248P, 298P; 86, 530P, 702P, 706P, 707P, 767P
Morphine abstinance, 85, 293P; 86, 444P
Morphine tolerance, 86, 530P
Morphine withdrawal, 84, 51P; 86, 528P, 535P
Motoneurones, 86, 396P
Motor activity, 84, 77P, 85P; 86, 710P
Mucus, 84, 80P
Muscarinic acetylcholine antagonists, 85, 212P
Muscarinic acetylcholine receptor subtypes, 85, 213P; 86, 610P, 798P
Muscarinic acetylcholine receptors, 84, 4P, 13P, 178P, 190P; 85, 213P; 86, 395P, 397P, 451P, 452P, 605P, 607P, 608P, 633P, 667P, 744P, 764P
Muscimol, 85, 363P
Mydriasis, 86, 742P
Myenteric plexus, guinea-pig, 86, 637P
Myocardial function, 86, 616P, 621P, 630P
Myocardial ischaemia, 86, 578P, 759P
Myocardium, 85, 332P
Myoclonic jerks, 85, 364P
Myofibroblast, 86, 516P

Naloxone, 84, 51P, 180P; 86, 485P, 534P, 761P
Narcotic agonists, 86, 782P
Nefopam, 86, 677P
Neophobia, 86, 420P
Neostriatum, rat, 84, 10P
Nerve conduction, 85, 362P
Nervous tissue, cultured, 86, 672P
Neuroblasoma, 86, 482P
Neurogenic control, 85, 204P
Neurogenic inflammation, 86, 787P, 788P
Neurointermediate lobe, rat, 84, 3P, 5P; 86, 534P
Neurokinin A, 85, 230P
Neuroleptic drugs, 84, 71P, 73P; 85, 239P, 349P; 86, 471P
Neuromuscular blockade, 85, 327P
Neuromuscular junction, 85, 214P, 587P, 588P
Neuromuscular transmission, 86, 779P
Neuronal inhibition, 84, 183P
Neuronal tissue, 84, 49P
Neuropeptide Y, 85, 231P, 288P
Neuropeptides, 84, 7P; 86, 787P
Neurotensin, 86, 543P, 619P
Neurotoxicity, 85, 348P, 350P; 86, 685P
Neurotransmitters, 84, 61P; 86, 489P
Neutrophils, 84, 169P; 85, 377P; 86, 562P, 575P, 576P, 654P, 786P
Nicardipine, 84, 174P; 85, 328P, 329P; 86, 503P, 602P, 722P
Nicergoline, 84, 30P
Nicotine, 85, 245P; 86, 396P, 591P
Nicotinic acetylcholine receptors, 84, 62P
Nicotinic acid derivatives, 86, 646P
Nifedipine, 84, 15P, 18P, 156P; 85, 331P, 379P; 86, 719P
Nigrostriatal neurones marmoset, 86, 708P, 710P
Nigrostriatal system, 85, 350P
Nimodipine, 86, 528P
Nisoldipine, 85, 379P
^{3}H-nitrendipine binding, 86, 623P
Nitroheterocyclic compounds, 86, 554P
Nitrophenols, 84, 133P
Nitroprusside, 86, 730P
Nitrovasodilators, 86, 567P
Nociception, 84, 180P; 86, 483P, 528P
Node of Ranvier, 86, 549P, 665P
Nodose ganglion, 85, 309P
Nomifensine, 84, 10P; 86, 635P
Non-adrenergic non cholinergic nerves, 85, 211P, 292P
Non-steroidal anti-inflammatory drugs, 86, 520P
Nonparametric analysis, 86, 818P
Noradrenaline, 85, 356P; 86, 466P, 519P, 547P, 613P, 622P, 662P, 699P, 723P, 753P
Noradrenaline release, 84, 57P; 85, 263P, 317P; 86, 400P
Noradrenaline turnover, 84, 93P
Noradrenaline uptake, 86, 747P
Noradrenergic binding, 86, 467P
Noradrenergic drugs, 86, 414P
Noradrenergic lesions, 84, 53P
Nose, cat, 85, 254P
Novel receptor, 86, 596P
Nucleus accumbens, marmoset, 86, 468P
Nucleus accumbens, rat, 85, 354P; 86, 695P
Nucleus basalis, 86, 674P

Oedema, 85, 233P, 274P; 86, 572P
Oestrogen, 85, 323P
Olfactory cortex, rat, 85, 360P; 86, 663P

On-line analysis, 85, 308P
Operant behaviour, 85, 356P; 86, 419P
Opioid agonists, 84, 75P; 86, 532P, 703P
Opioid antagonists, 86, 712P
κ-opioid binding site, 84, 52P, 86, 704P
Opioid peptides, 86, 482P
Opioid receptor subtypes, 84, 68P, 99P; 85, 295P, 296P; 86, 640P
Opioid receptors, 85, 294P
Opioid receptors, peripheral, 86, 788P
Opioids, 85, 380P; 86, 531P, 700P, 705P
Optic tectum, frog, 84, 102P; 86, 537P, 668P
Oral dyskinesias, 84, 71P
Orgotein, 86, 714P, 715P
Orthostatic blood pressure control, 86, 488P
Ovalbumin, 86, 423P
Ovariectomy, 84, 42P
Oxidases, 86, 555P
Oxodipine, 86, 500P
Oxygen, 86, 753P
Oxygen consumption, 86, 772P
Oxygen radicals, 86, 576P
Oxypertine, 84, 129P, 197P
Oxytocin, 85, 289P, 806P
Oxytocin, 86, 806P

pA2, 84, 201P
Pain, 85, 271P
Pancuronium, 85, 327P
Papaverine, 85, 362P
Papilary muscle, 85, 330P
Paracetamol, 84, 121P, 134P, 138P; 86, 574P, 602P
Parametric analysis, 86, 818P
Paraquat, 86, 729P
Parasympathetic nerves, pulmonary, 86, 608P
Paroxetine, 85, 221P; 86, 403P
Paroxetine binding, 85, 216P
Parkinson's disease, 86, 632P
Parotid slices, 86, 756P
Paroxetine, 84, 58P, 59P
Partial agonists, 85, 307P; 86. 770P
Passive avoidance behaviour, 84, 107P; 86, 661P
Patch clamp, 86, 609P
d-Pencillamine, 86, 795P
Penicillamine disulphide, 86, 796P
Penicillin, 86, 694P
Penis, rat, 85, 284P
Pentobarbitone, 85, 303P
Pergolide, 86, 632P
Perinephritis hypertension, 85, 259P
Peripheral nerve lesions, 86, 527P
Peripheral nervous system, 85, 293P; 86, 617P
Peroxidase, 86, 557P
Peroxidation, 84, 79P
Pertussis vaccine, 84, 12P
Pertussis toxin, 86, 579P, 705P
Pharmaceutical innovation, 84, 118P
Pharmacokinetics, 84, 132P; 85, 333P; 86, 554P, 796P
Phenobarbitone withdrawal, 86, 457P
Phencyclidine, 84, 196P; 86, 694P
Phenylephrine, 85, 258P; 85, 261P; 324P
α-Phenylethylamine, 86, 413P
(-)N^6-phenylisopropyladenosine, 86, 584P
Phenylpiperazine, 86, 590P
8-Phenyltheophylline, 84, 131P
pH-metry, 86, 784P
Phorbol ester, 85, 377P
Phosphate, 86, 725P
Phosphate metabolism, 85, 328P
Phosphatidylinositol, 84, 61P; 86, 607P
Phosphodiesterase, 85, 224P; 86, 560P, 630P, 631P
Phosphoinositides, 84, 27P, 112P; 86, 654P
Phospholipase C, 84, 130P, 153P
Phospholipids, 86, 810P
Photodestruction, 84, 18P
Picrotoxin, 86, 547P
Pifluthixol, 86, 634P
Pinacidil, 85, 338P
Pineal gland, rat, 85, 326P
Pirenzepine, 84, 4P; 86, 394P, 638P, 764P
Piretanide, 86, 454P
Pithed rabbits, 86, 745P
Pithed rats, 86, 744P, 745P, 749P
Pitrazepin, 85, 237P
Pituritary cell line, 86, 440P
Plasma binding, 86, 558P
Plasma SH groups, 86, 777P
Platelet activating factor, 84, 169P; 86, 422P; 86, 571P, 573P, 814P
Platelet activating factor antagonists, 86, 572P
Platelet aggregation, 84, 147P, 148P; 86, 741P
Platelets, 84, 59P; 85, 265P; 86, 577P
Platelets, human, 84, 28P, 63P; 85, 215P, 286P, 345P; 86, 402P, 546P, 643P, 655P, 802P
Platelets, rabbit, 86, 556P
Platelets, rabbit, 86, 578P
Platelets, rat, 86, 581P
Polyethylene glycol 400, 86, 794P
Polymerisation, 84, 81P
Polymorphonuclear leucocytes, 86, 516P
PolyrI.rC, 85, 208P
Portal vein, rat, 86, 443P
Post junctional actions, 86, 679P

Post mortem human brain tissue, 85, 363P; 86, 593P
Potassium, 84, 61P; 86, 507P
Potassium chloride, 85, 282P, 334P, 336P
Potassium facilitiation, 86, 607P
Potassium release, 86, 756P
Potassium transport, 84, 26P
Prazosin, 84, 160P
^{3}H-Prazosin binding, 86, 518P
Potassium, 86, 507P
Potassium chloride, 85, 334P, 336P
Pregnancy, 85, 217P, 323P, 513P, 806P
Pressor responses, 86, 399P, 479P
Primates, 86, 620P
Probenecid, 84, 134P
Proconvulsant action, 84, 192P; 86, 592P
Prodrug, 86, 480P
Proenkephalin, 85, 291P
Progesterone, 85, 323P
Prolactin, 86, 469P, 543P, 660P, 686P, 698P
Propafenone, 84, 172P
Propofol, 86, 497P
Propranol, 84, 26P, 76P, 137P, 139P, 161P, 195P; 85, 305P
Propranolol glycol, 84, 161P
Prostacyclin, 85, 284P; 86, 643P, 795P, 802P, 805P, 813P
Prostacyclin analogues, 86, 807P
Prostaglandin D_2, 85, 286P; 86, 773P
Prostaglandin E_1, 15-methyl, 85, 274P
Prostaglandin E_1, 6-oxo-, 86, 813P
Prostaglandin E_2, 85, 257P
Prostaglandin F_2, 86, 644P, 815P
Prostaglandin 15-hydroxydehydrogenase, 84, 43P
Prostaglandin inactivation, 85, 275P
Prostaglandin synthetase, 84, 43P
Prostaglandin synthesis, 85, 275P
Prostaglandins, 84, 35P, 36P, 37P, 159P; 86, 421P, 428P, 645P, 652P, 656P, 806P, 810P, 812P
Prostanoid antagonists, 85, 273P
Prostanoid receptors, 86, 803P
Prostanoid synthesis, 84, 46P
Protein binding, 86, 803P
Protein conjugates, 85, 305P
Protein kinase C, 85, 290P
Protein synthesis, 84, 50P
Protein phosphorylation, 86, 508P
Psoriasis, 86, 502P
Psychopharmacological studies, 84, 202P
Pulmonary fibrosis, 86, 729P
Pulmonary smooth muscle, 86, 808P
Purines, 85, 340P
Purinoceptors, 86, 579P, 581P
Purkinje fibres, 84, 172P
Putamen, human, 85, 346P
Putrescine, 86, 516P
Pyrethroids, 84, 123P
Pyrimethamine pamoate, 86, 405P

Q-A interval, 86, 763P
Quantal content, 86, 675P
Quaternarization, 85, 296P
Quinoline derivatives, 86, 801P
Quinolinic acid, 84, 92P; 85, 373P
Quinones, 86, 559P
Quinpirole, 86, 618P

Radioimmunoassay, 84, 34P; 85, 277P, 313P
Radioligand binding, 84, 98P, 196P
Ranitidine, 84, 164P
Raphe nucleus, human, 84, 90P
Raphe nucleus, rat, 86, 691P
Rauwolscine, 86, 614P
Receptor binding, 84, 188P; 86, 402P
Receptor numbers, 84, 194P
Receptor occupation, 86, 755P
Receptor sensitivity, 86, 757P
Receptor solubilization, 85, 346P
Receptors, 85, 391P
Red blood cells, human, 86, 505P
Reflex milk-ejection, 85, 229P
Regeneration, 86, 681P
Regional sensitivity, 86, 496P
Relaxant factor, 84, 152P
Reoxygenation, 85, 332P; 86, 621P
Reperfusion, 86, 759P
Reperfusion arrythmias, 86, 418P, 498P
Reperfusion damage, 85, 332P
Reperfusion injury, 86, 439P
Reserpine, 86, 437P, 757P
Resistance vessels, 85, 339P
Restraint, 86, 493P
Retina, chick, 84, 184P
Retina, rabbit, 86, 533P
Retractor penis, 85, 243P, 355P
Ro 15-1788, 84, 95P, 103P, 183P
Ro 15-3505, 86, 592P
Ro 15-4513, 86, 463P, 465P
RX 821002, 84, 192P
RU 24969, 84, 112P; 86, 398P, 447P
Ryanodine, 85, 330P

Salbutamol, 85, 256P, 331P; 86, 502P
Salicylate, 85, 272P
Salivary amylase, 86, 701P
Salmon calcitonin, 86, 686P
Salt preference, 84, 143P
Saphenouse vein, dog, 86, 496P
Saphenous vein, human, 86, 734P
Sartorius muscle, frog, 86, 453P
SCH 23390, 84, 143P; 86, 434P, 435P, 634P
Schild plot, 84, 201P
Scopolamine, 86, 661P
Secretagogues, 86, 650P

Sedatives, 86, 768P
Seizures, 84, 187P; 85, 365P; 86, 540P
Selectivity, 85, 376P; 86, 610P
Serum, 84, 149P
Serum bovine albumin SH group, 86, 777P
Sex steroids, 86, 605P
Sexual function, 84, 126P
SH depleting agents, 86, 777P
SH rats, 84, 158P
Sheep, 86, 462P
SK&F 83566, 85, 242P
SK&F 93574, 86, 570P
SK&F 94120, 84, 22P; 85, 224P, 226P; 86, 630P, 631P
Skeletal muscle, 86, 774P
Skeletal muscle, chick, 86, 739P
Skeletal muscle, rat, 84, 83P; 86, 586P
SKF 10047, 84, 196P; 86, 539P
SKF 38393, 84, 1P; 86, 434P
Skin, 86, 502P
Skinner box, 86, 683P
Sleep, 86, 676P
Small intestine, guinea-pigs, 86, 410P
Smooth muscle, guinea-pig, 84, 142P
Smooth muscle, rabbit, 84, 156P
Smooth muscle, rat, 84, 83P; 86, 753P
Smooth muscle contractions, 86, 624P
Sodium, 86, 600P
Sodium/calcium exchange, 86, 624P, 720P
Sodium pump, 85, 351P
Sodium uptake, 84, 149P
Sodium urate, 86, 521P
Solubilization, 84, 4P, 101P; 86, 403P
Somatostatin, 84, 7P; 86, 638P
Somatostatin analogues, 86, 698P
Somatostatin receptors, 85, 232P; 86, 551P
Spasmogens, 84, 179P; 86, 731P
Specificity, 85, 287P
Spinal cat, 86, 599P
Spinal cord, 86, 527P; 681P
Spinal cord, frog, 86, 539P
Spinal cord, rat, 84, 52P; 85, 229P, 380P; 86, 396P
Spinal cord, sheep, 86, 518P
Spiperone, 86, 469P, 614P
Spleen, human and rabbit, 86, 492P
Spontaneous behaviour, 86, 532P
SR 41378, 84, 146P, 198P
SR 58002 C, 86, 782P
SR 95191, 86, 404P
Stereochemistry, 86, 666P
Stereospecificity, 86, 774P
Stereotyped behaviour, 85, 242P; 86, 434P
Stimulus generalization, 85, 295P
Strain differences, 84, 105P
Streptozotocin-induced diabetes, 86, 629P
Stress, 84, 72P, 104P
Striatum, 84, 181P; 86, 632P
Striatum, guinea-pig, 86, 664P
Striatum, mice, 85, 385P
Striatum, rat, 84, 6P, 55P, 169P, 197P; 85, 291P; 86, 412P
Structure-activity relationships, 86, 666P
Strychnine, 86, 537P, 682P
Subpallidum, 85, 314P
Subsensitivity, 86, 466P
Substance P, 84, 2P, 165P; 85, 230P; 86, 410P, 412P, 484P, 527P, 701P
Substance P $_{6-11}$, 85, 287P
Substance P antagonists, 85, 229P, 292P
Substance P receptors, 84, 66P; 85, 292P
Substantia nigra, rat, 84, 85P, 183P; 85, 367P
Suicide victims, 86, 593P
Sulphamethazine, 85, 378P; 86, 797P
Sulphation, 84, 133P
Sulpiride, 86, 434P
Sulpiride isomers, 86, 709P
Sultopride, 84, 143P
Superior cervical ganglion, 85, 309P
Superior mesenteric arterial bed, 85, 262P
Superoxide, 86, 516P, 562P
Supersensitivity, 84, 194P, 320P; 86, 437P
Superyldicholine, 84, 155P
Suprachiasmatic nucleus, rat, 85, 219P; 86, 445P, 446P
Surfactant release, 86, 603P
Sustained release, 86, 405P
Sympathetic nerve activity, preganglionic, 86, 598P
Sympathetic nervous system, 86, 748P
Synaptic transmission, 86, 589P, 663P, 668P
Synaptosomes, superfused, 84, 190P
Synovitis, 86, 521P

Tachykinin antagonists, 86, 410P, 489P
Tachikinin receptors, 84, 141P; 85, 287P; 86, 696P
Tachykinins, 84, 142P
Tachyphylaxis, 86, 436P
Taenia, guinea-pig, 84, 165P, 173P
Tail arteries, rat, 84, 67P; 85, 225P
Tardive diskinesia, 86, 472P
Tarsal muscle, rat, 85, 283P
Taurine, 86, 586P
Testicular capsule, rat, 86, 516P
Tetrabenazine, 84, 129P
Tetracosactrin, 86, 793P
12-O-Tetradecanoyl-phorbol-13-acetate, 84, 27P

Δ-9-Tetrahydrocannabinol, 86, 684P
Thalidomide, 84, 122P
Theophylline, 84, 120P
Thermoregulation, 85, 296P; 86, 693P
Thiazinamium chloride, 86, 452P
Thiorphan, 86, 459P
Thrombin, 84, 25P
Thrombolysis, 86, 625P
Thromboxane A_2, 84, 41P; 86, 808P
Thromboxane analogues, 84, 148P
Thromboxane receptor agonists, 84, 184P
Thromboxane receptor antagonists, 84, 147P; 85, 285P; 86, 643P, 804P
Thromboxane synthesis, 85, 268P
Thromboxanes, 84, 37P
Thrombus evolution, experimental, 86, 625P
Thymocytes, 84, 26P
Thyroid, rat, 86, 442P
Thyroid hormone, 84, 149P
Thyrotropin releasing hormone, 86, 458P, 673P
Thyrotropin releasing hormone analogue, 86, 544P
Thyrotropin-releasing hormone-induced behaviour, 85, 244P
Thyrotropin-releasing hormone receptors, 84, 66P, 101P
Thyroxine, 86, 501P, 792P
Tifluadom, 84, 68P; 85, 382P
TN-1, 86, 508P
α-Tochopherol, 84, 119P
Tolerance, 85, 249P, 359P; 86, 530P, 637P, 659P
Toxicity, 86, 768P
Toxicology, 84, 117P; 86, 406P
Toxins, 86, 588P
Trachea, cat, 86, 611P
Trachea, guinea-pig, 85, 257P; 86, 579P, 608P
Trachealis, cat, 85, 317P
Transduction, 86, 577P
Transmitter release, 84, 29P; 85, 338P; 86, 583P, 588P
Transport, 84, 23P, 78P
Trapidil, 86, 732P
Trazodine, 86, 590P
Tri-iodothyronine, 84, 124P
1,1,1-trichloro-2,2-bis(p-chlorophenyl) ethane-induced behaviour, 86, 47ΕP
Trifluoperazine, 86, 451P, 760P
Triton X-100, 85, 210P
Tryptamine derivatives, 86, 399P
L-tryptophan, 84, 94P
Tryptophan pyrrolase, 85, 298P
Tubocurarine, 84, 62P; 86, 453P
Tubulin, 84, 81P
Turning, 85, 385P
Tyramine, 86, 479P, 636P
U46619, 86, 524P
U-69,593, 86, 704P
UK-14, 304, 86, 491P
Ulcers, gastric, 86, 421P, 809P
Ultrasonic vocalization, 86, 789P
Uptake sites, 86, 686P
Ureter, sheep, 85, 325P
Urethra, rabbit, 86, 612P
Urinary bladder, rabbit and dog, 86, 416P
Uterine artery, human, 85, 379P
Uterus, rat, 84, 42P; 85, 282P, 289P, 331P; 86, 644P, 648P, 791P

Vagotomy, 86, 778P
Valproate, 85, 372P; 86, 540P
Vas deferens, guinea-pig, 84, 29P
Vas deferens, human, 86, 776P
Vas deferens, mouse, 86, 679P
Vas deferens, rat, 85, 336P, 340P; 86, 510P, 566P, 580P, 746P, 757P
Vascular muscle, rat, 85, 339P
Vascular permeability, 86, 754P
Vascular resistance, peripheral, 85, 231P
Vascular smooth muscle, 86, 808P
Vascular smooth muscles, rat, 86, 500P, 752P
Vasoactive intestinal peptide, 85, 253P, 697P
Vasoconstriction, 84, 177P
Vasoconstriction, cerebral, 85, 270P
Vasodilators, 84, 20P, 22P; 85, 338P, 339P
Vasodilation, 86, 730P
Vasopressin, 84, 107P
Venticle, human, 85, 226P
Ventricular muscle, 85, 227P; 86, 499P
Ventral tegmental nucleus, 86, 691P
Verapamil, 85, 326P; 86, 443P, 470P, 504P, 528P, 739P
Veratrum alkaloids, 84, 123P
Video tracking, 86, 817P
Vidian nerve, 86, 775P
Viloxazine, 86, 479P
Visual cortex, 85, 253P
Vitamin K_1, 86, 406P
Voltammetry, 84, 9P, 199P; 86, 635P, 692P
Volunteer studies, 84, 202P

Warfarin, 84, 140P
Wet dog shakes, 84, 113P; 86, 458P
Withdrawal syndrome, 84, 51P
Wy 26392, 85, 321P

Xylazine, 86, 510P

Yttrium 90, 86, 522P
Yohimbine, 86, 734P
^{3}H -yohimbine binding, 85, 323P

Zolpidem, 86, 432P